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In recent years, there has been a massive surge in the scale of Counterfeit 
Pharmaceuticals in Nigeria. It violates the Intellectual Property Rights (IPR) standard 
adopted by the World Trade Organisation-Trade Related aspect of the Intellectual 
Property Right (WTO-TRIP) Agreement. The effect of the WTO-TRIPS strict protection 
of Intellectual Property Rights creates problems for developing countries. It has 
provoked counterfeit pharmaceutical activities worldwide, and which is prevalent in 
Nigeria. 
This thesis is an in-depth study of the concept and state of 'counterfeit 
pharmaceuticals' and its application within the WTO-TRIPS framework as transposed 
in Nigeria. The aim is to ascertain, by way of the theoretical and qualitative 
methodology, the viability of the WTO-TRIPS agreement for addressing the scourge 
of counterfeit pharmaceuticals in Nigeria. The concept of counterfeit drugs will be 
explored, and its parameters defined as a premise for challenging the viability of the 
WTO-TRIPS and the Nigerian Counterfeit regulatory framework. The justification for 
this research is because the  issue of counterfeit is topical and important for developing 
countries especially in light of the legal, social, development and health implications 
of counterfeit. Using Nigeria as a case study will set a standard for other developing 
and LDC’s.  
In fulfilling this study's objective, the thesis notes that Nigeria is a member of the World 
Trade Organisation and its predecessor, the General Agreement on Trade and Tariff, 
since its independence in 1960. Nigeria is bound by all WTO trade policies, including 
the standards mandated by the WTO-TRIPS agreement. The historical analysis of the 
WTO is relevant to set a standard for testing how viable its rules and policies are in 
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tackling counterfeit. Nigerian history will be discussed, particularly regarding its legal 
policies on Intellectual Property to assess if the wholesome adoption of WTO-TRIPS 
rules can curb the surge in counterfeit pharmaceuticals. In that section, the laws of the 
foremost Nigerian organization for the regulation and control of drugs will be analysed 
to provide a contextual background to the problem of counterfeit. It will determine if its 
approach to confronting the counterfeit crisis is adequate and within the stated 
requirement of WTO-TRIPS. 
Finally, a comparative analysis of the WTO-TRIPS and the Nigerian legal policies on 
IP will be tested to determine the shortcomings and possible reforms to its policy. This 
study will shed more light on the theoretical perspective of the suitability of the legal 
regime of the WTO-TRIPS to the regulation of counterfeit drug surge. Lastly, the thesis 
will make recommendations on reducing the prevalence of counterfeit drugs without 
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1.1 Statement of the problem in the Nigerian Drug System 
 
Nigeria is a member of the World Trade Organisation (WTO) since its inception in 
1995. It has been a Member of the General Agreement on Trade and Tariff (GATT) 
since its independence in 1960. Although the WTO Agreements adopts a single-
undertaking system, where membership in one agreement means membership in all 
WTO Multilateral agreements, Nigeria gained membership status in the WTO 
agreement by signing on to the Marrakesh Agreement1. Under the WTO trade 
liberalisation policy, Nigeria had significantly opened its market compared to other 
developing countries and implement the WTO Agreement2, including the Trade-
related aspect of intellectual property rights (TRIPS).  
Although the Trade-Related aspect of Intellectual Property Right agreement (TRIPS) 
had as part of its policy the intent to inhibit the problem of counterfeit, while still 
protecting IP in the international trade system, reports have shown that counterfeit 
drugs exist regardless of measures put in place by both state and international 
authorities. To gauge the perversity of counterfeit, data from the Pharmaceutical 
Society Institute indicates that the incidents of counterfeit have increased by 102% 
from 2016 to 20183. Also, the PSI counterfeit seizure reports that over 844 counterfeit 
 
1The WTO Marrakesh Agreement 1994, Available www.wto.org/English/res_booksp-
_e/agrmntseries1_wto-agree-e.htm  Accessed (December 14, 2015) 
2 World Trade Organisation Summary Sheet on Nigeria Available 
https://www.wto.org/english/tratop_e/tpr_e/s247_sum_e.pdf   Accessed (03 May 2021) 
3 OECD -Trade in counterfeit Medicine Available https://www.oecd-ilibrary.org/sites/fe58fe07-
en/index.html?itemId=/content/component/fe58fe07-en Accessed (03 May 2021) 
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incidents4  despite consolidated efforts from various international organisations.  As 
the name implies, counterfeit Pharmaceutical is 'a drug which is deliberately and 
fraudulently mislabelled regarding identity and source '5resulting in high morbidity, 
mortality, and damage to public health structure6. Also, a 'counterfeit drug' can be 
regarded as 'any drug or medical product, which is not what it purports to be, coloured, 
coated, or polished. The damage it creates is far greater than the therapeutic value' it 
purports to resolve7. It can increase the progression of diseases and compromise the 
health and safety of patients and eventually death. The perversity of counterfeit has 
destabilized the slated intention of the Nigerian constitution, which is to guarantee the 
right to health for all its citizens. Therefore, it can be said to undermine Nigerians' right 
to quality medicine needed for the treatment of diseases8.  
The problem of counterfeit drugs is equally severe in other parts of Africa, following a 
recent study organized by the World Health Organisation (WHO). Sample data 
collated from state governments and police seizures of counterfeit drugs in Africa 
provided evidence, and it estimates that 42% of all counterfeit medicines reported from 
2013 and 2017 originated in Africa9. Whereas the PWC believes the proportion of 
counterfeit pharmaceuticals in some African countries could be as high as 70%, this 
supports the claim of counterfeit perversity in Africa10. The problem of counterfeit is 
multidimensional and requires a strong legal solution to reduce its prevalence given 
 
4 PSI Incident Trend Available https://www.psi-inc.org/incident-trends  Accessed (03 May 2021) 
5 WHO Guidelines for the development of measures to combat counterfeit drugs 
6 Robert Cockburn and others' The Global Threat of Counterfeit Drugs: and Why Government Must 
Communicate the Dangers, (2005) Vol. 2 (4) PLoS Medicine e100  
7 Section 12 of the Nigerian counterfeit and fake Drugs (Miscellaneous provision) Act, Cap C34, Laws 
of the federal republic of Nigeria (LFN)2004 
8 The Constitution of Nigeria 1999, CAP 23 LFN 
9 BBC NEWS, Counterfeit Drugs May Kill You or cause Superbugs' September 2013 
Available http://www.bbc.co.uk/news/health-24270737Accessed (May 16, 2016) 
10BBC NEWS, Fake Drugs: How Bad is Africa’s Counterfeit Medicine problem? Available 
http://www.bbc.com/news/world-africa-51122898 Accessed (October 05,2020) 
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the above-mentioned issues. Resolving counterfeit is a pertinent issue especially in 
Nigeria and other developing and LDC’S. 
  
Consumption of Counterfeit drugs has resulted in over 700,000 deaths in Africa 
annually, with most of the drugs originating from China, India, Mexico, and Brazil11. 
An example is discovering a lethal amount of melanin in a baby formula with little or 
no active ingredient12. The Nigerian Government is inundated with providing essential 
medicine and proper health facilities for its citizens regardless of counterfeit medicine 
prevalence. Counterfeit drugs and other public health issues significantly affect 
people's health in Nigeria. Although Nigeria has made a tremendous effort to reduce 
the scale and impact of counterfeit drugs, it remains largely unresolved13.  
The economic implication of counterfeit is multifaceted: counterfeit stifles economic 
growth of countries; It can reduce financial incentives; technological know-how and 
can decrease product value in Pharmaceuticals14. Consequently, the economic effect 
of counterfeit pharmaceuticals can lead to a massive loss in legitimate drugs sale. As 
Peter Bloch, Ronald Bush, and Leland Campbell point out, a high percentage of 
legitimate goods producers face damages to brand reputation due to counterfeit15. 
Hence, in a bid to save the brand name, producers fail to inform consumers of the 
potential existence and consequence of counterfeit pharmaceuticals, which has 
further increased counterfeit growth.   
 
11 Jeremy M. Wilson and Roy Fenoff, 'The Health and Economic Effect of Counterfeit Pharmaceuticals 
in Africa(2011) A-CAPPP Backgrounder, Available http://a-
capp.msu.edu/sites/default/files/files/africabackgroundfinal.pdfAccessed (April 25, 2016) 
12 Elizabeth Gasiorowski Denis' Crackdown on Counterfeiting' International Standard Organisation 
(Jan 2014), Available http://www.iso.org/iso/news.htm?refid=ref1809 Accessed (March 30, 2016)   
13 M Ohuabunwa, 'Health care Delivery in Nigeria, Past Present and the Future' (2002) Vol.31 
Nigerian Journal of Pharmacy pp15, 
14 IBID Ohuabunwa 
15 Bloch, Peter H., Ronald F. Bush, and Leland Campbell, (1993) "Consumer 'Accomplices' in Product 
Counterfeiting: A Demand-Side Investigation," Journal of Consumer Marketing,10:4, 27-36 
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The plague of counterfeit pharmaceuticals, especially in Nigeria, is now regarded as 
a global phenomenon with far-reaching consequences. For example, counterfeit 
consumption led to the death of 2,500 children in the Niger Republic from vaccines 
donated by the Nigerian Government16. Besides, the death of 109 children was 
reported in southern Nigeria, following counterfeit paracetamol consumption. The drug 
was found to contain toxic ethylene glycol solvent instead of propylene glycol17. 
Factors attributed to counterfeit Pharmaceutical prevalence include inadequate drug 
supply, high rate of infectious diseases such as malaria, HIV, Tuberculosis, and 
tropical diseases. Other factors include the irrational use of drugs, low database, and 
ineffective alliance between government agencies and other professional bodies 
responsible for controlling pharmaceuticals. It is imperative to examine Nigeria's drug 
situation, starting from the pharmaceutical market18. 
The Nigerian pharmaceutical market is estimated to be worth more than US$ 600 
million as of 2009, and it is expected to grow significantly at around 12 % yearly to 
reach US$ 717 million by 201919. Despite the Nigerian Government's best efforts to 
promote pharmaceuticals' domestic production, Nigeria remains mostly dependent on 
imported pharmaceutical products. According to Okoli, out of the 130 existing 
Pharmaceutical companies in Nigeria, only 60 is in active manufacturing. Even though 
the installed capacity is estimated to produce 50% to 70% of the total drug needed in 
 
16 New York Times -Fighting Fake Drugs Available 
https://www.nytimes.com/2006/12/12/opinion/12tue4.html   Access (03 May 2021) 
17 Dora Akunyili, 'Fake and Counterfeit Drugs in the Health Sector: The Role of Medical Doctors,' 
(2004) Vol.2 No.2 Annals of Ibadan Postgraduate Medicine PP 19 
18 Harvey E Bale' Consumption and Trade in off –Patented Medicine, Commission on Macroeconomics 
and Health', Available www.icrier.org/pdf/bale65.pdf Accessed (April 25 2016), see also Roger Bate, 
Making a Kill: The Deadly Implication of the Counterfeit Drug Trade ( Washington Dc, AEI Press, 2008)  
19 Pharmaceutical sector profile: Nigeria, Global UNIDO Project, Available www.unido.org Accessed 
September 13, 2020) 
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Nigeria, pharmaceutical companies' capacity utilization is below 30%20 this means 
much-needed drugs will not be unavailable. It will enable counterfeit drug suppliers to 
take advantage of this loophole to supply drugs in high demand such as drugs for 
blood pressure, antimalarials, HIV Aids medication and, antibiotics knowing the need 
is high.  
The delivery of drugs in Nigeria is nearly chaotic; drugs are sold everywhere at a 
fraction of its actual price21: from sale in open markets, kiosks, patent medicine stores, 
unregistered wholesalers, which is distributed by illegal pharmaceutical 
manufacturers. There is no proper mechanism to regulate the inflow of drugs in the 
health sector in Nigeria. It is common to see a public display of medicines in the market 
and motor parks without proper consideration of the weather condition that enables 
the breakdown of the drug's active ingredient 22. From the facts stated above, it is 
evident that Nigeria's pharmaceutical distribution system is poorly organized and 
mismanaged. The situation is so dire that counterfeiters are so skilled in making 
counterfeit medicine look authentic23. 
The seriousness and impact of the problem are reflected in a 2018 Lancet study, which 
ranked Nigeria health care quality 142nd out of 195 countries24, which is extremely 
 
20 S Okoli, 'Pharma Industry in Distress,' (2000) Vol22 Pharma news Issue 3 pp 1  
21 The Berkeley MDP- How to Combat Counterfeit Drugs in Nigeria, Available 
https://mdp.berkeley.edu/how-to-combat-counterfeit-drugs-in-nigeria/ Accessed(October 05, 2020)  
22 Adelusi Adeluyi, 'Drug Distribution: Challenges and Effects on the Nigerian society', Keynote speaker 
at the Annual National Conference of the Pharmaceutical Society of Nigeria, November 2000  
23 BBC News, 'Solving the Problem of Fake Drugs in Nigeria 
Available' https://www.bbc.co.uk/news/av/business-47640706/solving-the-problem-of-fake-drugs-in-
nigeria Accessed (June 18, 2020) 
24 Fullman N and others (2018). 'Measuring performance on the Healthcare Access and Quality Index 
for 195 countries and territories and selected subnational locations: a systematic analysis from the 
Global Burden of Disease Study 2016391(10136) The Lancet, 2236 
GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare 
Access and Quality Index for 195 countries and territories and selected subnational locations: a 




low compared to other countries, underpins the enormity of the problem. The mortality 
rate at birth for an average Nigerian is estimated at 46 years for males, 47 years for 
females, compared to Ghana and South Africa, whose life expectancy is estimated to 
be about 55 and 50 years25. It is a frequent occurrence from a country where infectious 
diseases, malaria, diarrhoea, river blindness, tuberculosis, and ultimately HIV, are part 
of its citizens' everyday lives. Unfortunately, counterfeit drugs and a lack of essential 
medicine such as Antimalarial and HIV drugs have exacerbated the prevalence of 
counterfeit. A recent review of the chemical components of some Antimalarial drugs 
confirms that over 36% of the medicines tested failed the chemical analysis26.  
Another problem attributed to the growth of counterfeit Pharmaceuticals is the 
existence of weak intellectual property laws in Nigeria. Intellectual Property protects 
the right of manufacturers by providing absolute protection for knowledge and creation. 
It gives a manufacturer monopoly right over an invention to the exclusion of all others. 
A manufacturer relies on this right to protect marketable intellectual inventions, given 
the high research and development (R&D). In this light, IP is a justification for the 
economic exploitation of Pharmaceutical products. However, this absolute right gives 
rise to counterfeiting, which is an infringement of IP. Thus, counterfeiting amounts to 
theft, for it misleads the consumers and can damage manufacturers' goodwill.  
 
The WTO–TRIPS framework created a more robust patent protection regime by 
restricting statutory monopoly to an inventor to enjoy the right to its invention solely. 
This protection regarding pharmaceuticals implies that it enabled pharmaceutical 
 
25WHO Mortality Fact Sheet 2006   
26 WHO, 'Malaria rapid Diagnostic test performance 





companies to manipulate the price and supply of medicines, inadvertently making 
them inaccessible and extremely expensive to the public, especially in developing 
countries. The limitation is the protection between IPR and the quest to have access 
to medicine, over and above the safety of IPR, introduced the element of counterfeit 
pharmaceuticals into Nigeria. It has become a topical issue as much as access to 
medicine issues. In response to the problems raised about counterfeiting, the 
proposed chapters aim to evaluate the definition, implication, and counterfeit evidence 
by considering the established framework's contextual scope for regulating counterfeit. 
It will provide an opportunity to clarify the link between IP and counterfeit concerning 
Pharmaceutical. The outcome of this study will highlight the current state of counterfeit 
pharmaceuticals in Nigeria. Analysis from this research will inform policymakers if the 
WTO-TRIPS framework can effectively mitigate the scourge of counterfeit 
Pharmaceuticals. 
  
THE STRUCTURE OF THE THESIS 
The thesis is divided into six main chapters. Chapter one will present an overview of 
the General Agreement on Trade and Tariff/World Trade Organisation (GATT/WTO) 
Intellectual Property (IP) framework and counterfeit issues in the Nigerian drug 
system. The Origin of IP concerns in the early GATT system and its transition through 
the WTO framework under the TRIPS agreement is discussed. The chapter illustrates 
in detail the many problems of counterfeit medicines in Africa generally and specifically 
in Nigeria. It also highlighted other international bodies with responsibility in the IP 
area and how the development question is associated with drug access and IP 
protection. The purpose is to create a premise invariably for questioning the viability 
of the WTO/TRIPS framework for counterfeit regulation. Chapter two explores the 
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concept and state of counterfeit pharmaceuticals in international trade to derive a 
workable interpretation that forms a framework for analysing the WTO/TRIPS and 
Nigeria drug regulatory systems. It will also provide a legal analysis of the debate 
concerning counterfeit, fake, and substandard medicine whilst still discussing the 
substantive nature of counterfeit.  
 Chapter three analyses the WTO/ TRIPS agreement and brings out its objects and 
core principles and the aspects of TRIPS provision about counterfeit pharmaceuticals. 
It also presents other international cooperative regimes for access to medicines such 
as the WHO, WIPO, and their role concerning TRIPS implementation and counterfeit 
drugs. Chapter four will expound on Nigeria’s IP legal and institutional framework for 
implementing WTO/TRIPS and counterfeit regulation. It sets a precedent to analyse 
counterfeit and the implication of the TRIPS agreement transposed in Nigeria's legal 
system and the relative effect of the wholesome transfer of laws into the Nigerian legal 
system.  
Chapter five pulls the research together in critical evaluation of the TRIPS standards 
and Nigerian counterfeit regulation to ascertain the TRIPS' effectiveness concerning 
counterfeit drugs' conceptual and theoretical framework parameters. It will identify 
synergies and discrepancies and propose legal and policy reforms on both the 
Nigerian domestic regime and WTO global system to ensure effective redress to the 
problem of counterfeit pharmaceuticals. Lastly, Chapter 6 will consolidate all the 













Chapter 1- GATT/WTO 
Intellectual Property Framework, Nigerian Economy, and 
Counterfeit Drugs: An Overview 
 
‘The evil of fake drugs is worse than the combined scourge of malaria, HIV/Aids, 




This chapter presents an overview of the General Agreement on Trade and 
Tariff/World Trade Organisation (GATT/WTO) IP framework and counterfeit issues in 
Nigeria. The Origin of IP concerns in the early GATT system and its transition through 
the WTO framework under the TRIPS agreement is mapped out. The chapter 
illustrates in detail the many problems of counterfeit medicines in Africa generally and 
specifically in Nigeria. It also highlights other international bodies with responsibility in 
the IP area and how the development question is associated with drug and IP 
protection. The purpose is to create a premise invariably for questioning the viability 
of the WTO-TRIPS framework for counterfeit regulation. 
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1.2 THE STRUCTURE OF THE GATT/WTO, IP, AND THE ISSUE OF 
COUNTERFEIT’ 
 
The GATT agreement is the source of the WTO framework. The GATT Agreement 
entered into force in 1948, signed by 23 nations in Geneva on October 30, 1947. The 
formation of GATT 27 is motivated by two significant events. The first was the great 
depression that shook the global economy after the 1st World War and the embrace 
of protectionism by developed countries, which failed to reciprocate trade concession, 
especially with developing countries. The second event was the economic pressure 
from the United States (US) after the 2nd World War. It necessitated creating a unified 
multilateral organization (GATT) to protect the trade interest of member countries. 
Although the GATT did not address intellectual property in its formative years, the US 
still linked this to its trade activities by imposing sanctions against states with weak 
intellectual property laws28. It has necessitated creating a unified multilateral 
organization to defend member countries trade interests, thus forming an international 
organization to regulate free trade. The rationale behind this is to understand the 
theoretical underpinning for the inclusion of IP in international trade.  The GATT 
provides trade in goods between nations,29 to ensure openness, fairness, and non-
discrimination. To achieve these objectives, the GATT's drafters acknowledged that a 
total reduction of tariffs is impossible. Thus, the agreement endorsed much greater 
transparency on tariffs as a form of protection against trade barriers. The GATT's 
 
27 The GATT Years/ From Havana to Marrakesh, Available  
https://www.wto.org/English/thewto_e/whatis_e/tif_e/fact4_e.htmAccessed (January 6, 2016) From 
1948 GATT agreement provided the rules for the regulation of international trade. Its original goal was 
to establish a third institution to regulate the international economic corporation's trade aspect, joining 
the World Bank and International Monetary fund. GATT recorded the highest growth rate in 
international trade, and it aimed to correct the legacy of protectionist measures, which was a norm 
from the early 1930s 
28 Bagwell, K., & Staiger, R. W. (1999). An economic theory of GATT. Vol. 89, No 1 American 
Economic Review, pp.215-248. 
29 Ralph Ossa, 'New Trade" Theory of GATT/WTO Negotiations,' (2011) Vol. 119, No. 1 Journal of 
Political Economy, pp.122-152. 
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primary focus is liberalizing trade by controlling the government's actions to create a 
competitive market economy.  
Over time, new issues arose within GATT, which GATT failed to respond to, thus 
undermining its credibility and effectiveness. The issue includes trade-in service, 
intellectual property, and dispute settlement30, which by the early 1980s, became 
relevant to world trade realities. Global trade had expanded far beyond GATT's scope: 
for example, it now recognises the importance of Intellectual Property in cross-border 
technology transfer, research and development, especially pharmaceutical products.31 
This emerging trend on the role of intellectual property (and other regulatory gaps) 
convinced GATT members of the need to re-design the multilateral trading system. 
Thus, when the Uruguay Round of Trade Talks was launched in 1986, intellectual 
property was a significant addition to the negotiating agenda culminating in the 
adoption of the TRIPS Agreement. How did the GATT members manage to extend its 
horizons to include what was seemingly a non-trade matter? How did an issue area 
under the control of the World Intellectual Property Organisation (WIPO) end up on 
the Uruguay round of trade talks? 
The text of the GATT provided for the regulation of IPR within its framework. The first 
provision is found in Article XII (3)(C), which states that states should not apply 
restrictions that will prevent the importation of commercial samples or prevent 
compliance with patent, trademark, copyright, or similar procedures for it is possible 
to adopt measures which will expand trade rather than restrict international trade32. 
Also, Article XI (6) permits contracting parties to cooperate, prevent the use of trade 
 
30 John. H. Jackson, 'GATT and the Future of International Trade Institutions, (1992) Vol.18 Issue 1 
Brooklyn Journal of International law', 11-30, GATT is regarded as the most binding agreement 
relating to trade, yet GATT cannot be recognized as a treaty.   
31 Maria Nelson, Michelle Vizurraga, and David Chang, 'Counterfeit Pharmaceuticals: A worldwide 
Problem,' (2006) Vol. 96 Trademark Representative, 1068 -1100. 
32 Article XII (3)(C)   
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names in such a manner that is inconsistent with its identity, and be detrimental to 
such geographical indication in the contracting party33.  The second provision on 
Intellectual Property Rights is provided for in Article XX (d). This article allows for the 
use of necessary measures to secure compliance with rules and laws that are not 
contradictory to GATT agreement provisions. This includes those relating to the 
protection of patent, trademark, and copyright34. Equally, Article XVIII (10) of GATT 
further states that restrictions cannot be applied to prevent commercial samples 
importation or prevent compliance with patent, trademark, copyright, or similar 
procedures35.  
By interpreting the IPR provision of GATT, it is evident that the GATT framework 
regarded IPR as a condition to accessing free trade. The reality is that GATT cannot 
be said to be protecting ‘the right’ to intellectual property. Instead, it is protecting the 
right to trade. Moreover, if GATT intended to make IPR an international trade standard, 
it would have made annexes provisions instead of inserting scant indications of 
Intellectual Property protection within its framework. The motive for the inclusion of 
IPR within later GATT trade talks stemmed from intense lobbying by the United States, 
the EU, and Japan. The aim here was to provide more robust protection of intellectual 
property by linking it to global trade policy. The protection of IPR was first raised in 
1978 during the Tokyo Round of trade talks sub-group ‘Customs Matter’. The US 
appealed for the support of other developed countries to negotiate international rules 
to prevent commercial counterfeit. It is aimed at finding solutions by creating rules and 
procedures for the prevention of counterfeit in international trade. The contracting 
parties discussed matters informally until it was raised formally in the preliminary 
 
33 Article XI (6) GATT  
34 Article XX (D) GATT  
35 Article XVIII (10) GATT  
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negotiation of GATT ministerial meetings. Some of the contracting parties challenged 
the WIPO's competence in regulating the affairs of IP, given its shortcoming in 
handling the breach of IP, which resulted in the introduction of counterfeit goods into 
the world trading system. WIPO's apparent failure instigated the need to have a 
Universal organisation within the GATT framework instead of having two different 
organisations for the same purpose.   
Further actions within GATT was reached in 1983, after due consideration from the 
Director-General of WIPO. After findings on specific provisions relating to the 
organisation’s experience with the implementation of counterfeit measures in the 
WIPO framework, to serve as a guide for the contracting parties of GATT. The 
contracting parties agreed that an expert group would be opened to all contracting 
parties who had the right to intellectual property. To clarify the legal and institutional 
aspect of IP in the multilateral trade negotiation of GATT.36 
Another reason for the inclusion of IP within GATT is the effect of counterfeiting on IP. 
Counterfeit goods are fake items, usually of lower quality and standard as opposed to 
the original item. It is generally sold at a lower price to attract buyers. However, the 
commercial implication of counterfeit's can be exemplified as the practice of affixing 
false trademark on products and passing it off as the original. The implication of 
consuming counterfeit products can lead to death or outright dissatisfaction37. 
Moreover, the firm whose goods or drugs are counterfeited will lose revenue, and the 
 
36Multilateral Trade Negotiation, the Uruguay Round –Work Undertaken in GATT Concerning Trade –
Related Aspect of Intellectual property Rights, including Trade in Counterfeit Goods 
MTN.GNG/NG11/W/4 6 May 1987  
Available http://www.wto.org/gatt_docs/english/sulpdf/92020093.pdfAccessed( 20 January 2016 )  
37 Gary Bamossy and Debra L. Scammon, ‘Product Counterfeiting: Consumers and Manufacturers 
Beware in NA- Advances in consumer Research Vol.12 (ED) Elizabeth C. Hirchman and Morris B. 
Holbrook, Provo, UT: Association for consumer Research 1985, p.334. 
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goodwill of the company may be adversely affected. Hence this necessitated the need 
for the protection of IP as counterfeiting became a vital issue in the 1970s and 1980s38.  
Developed countries canvassed for the adoption of the IP principle under the Uruguay 
Round to protect the creativity of multilateral companies in the course of international 
trade. However, developing countries opposed the notion of transferring IP to the 
GATT framework, claiming that IP falls under the scope of intangible goods, within 
WIPO's jurisdiction, and GATT ought to recognise WIPO status as a multilateral 
organisation capable of protecting IP.  
Nevertheless, the subject of IP is included in the WTO's multilateral trading system, 
as part of the conditions for succeeding GATT39. It is formed to promote international 
economic growth by establishing legally binding rules to govern trade amongst states. 
Thus, efforts are made through a series of multilateral negotiations known as trade 
rounds’, to establish a new multilateral agreement that incorporates trade and IP in 
one forum. After a series of negotiating difficulties, the Uruguay Round was concluded 
in 1994 in Marrakesh, Morocco. This Uruguay Round further liberalised trade and 
established a permanent structure to manage international trade procedures. It is 
regarded as the most extensive of all rounds of trade talks resulting in the creation of 
the WTO.40 
 
38Wertheimer, Albert I. "The irony of drug product selection." American journal of public health Vol 70 
Issue 5 (1980), pp.473-473. 
39 The issues include the divide in textiles and clothing, and some of the newer issues debated in the 
WTO, for example the developing countries have organized themselves into alliances such as the 
African Group and the Least-Developed Countries Group. In many others, the developing countries do 
not share common interests and may find themselves on opposite sides of a negotiation. A number of 
different coalitions among different groups of developing countries have emerged for this reason. The 
differences can be found in subjects of immense importance to developing countries, such as 
agriculture. 
40 The Tokyo Round during the seventies was the first major attempt to tackle trade barriers that do 
not take the form of tariffs, and to improve the system. The eighth, the Uruguay Round of 1986-94, 
was the last and most extensive of all.  
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The WTO is an international organisation formed to promote and regulate global trade 
in goods, trade in services, intellectual property, and it has a viable dispute settlement 
mechanism41. It provides a framework used by states to implement trade regulations. 
Part of the WTO’s function includes administering and implementing multilateral and 
plurilateral trade agreements under its umbrella42. It provides a forum to monitor 
member country trade policy and cooperate with other international organizations 
involved in global trade and economic policymaking. The WTO is seen to be an 
extension of GATT even though its scope is broader.43 
Ministerial representatives from different member states regulate the activities of the 
WTO. It holds a ministerial conference every two years where trade matters are 
discussed, and decisions are reached. It has an organizational structure which, at the 
top, is the Ministerial Conference and followed in authority by the General Council. 
The General Council comprises representatives of member states whose primary duty 
is to ensure the WTO’s day-to-day running. The General Council directs the Dispute 
Settlement Body (DSB), which oversees trade disputes among states. For instance, 
the WTO uses trade measures to enforce compliance from its members in developing 
and developed, through the DSB which is regarded as a ‘forum of last resort’15. It is 
principally unique for it adds security and predictability to the World trading system by 
preventing member states from taking unilateral actions against each other outside 
the WTO framework.  
 
41Agreement Establishing the WTO-Wold Trade Organisation (January 1 1995), 
www.wto.org/english/res_e/booksp_e/agrmntseries1_wto_agree_e.htm, (December 14, 2015).   
42 Richard Blackhurst, ‘The WTO and Global Economy’ (1997) Vol.20 World Economy pp.527-544.  
43 Note that the WTO is a permanent organisation whereas the application of GATT agreement is just 
on a provisional basis. Frederick M. Abbott, ‘Distributed Governance at the WTO-WIPO: An Evolving 
Model for Open-Architecture Integrated Governance’, (2000) Vol 3 issue 1, Journal of International 




The WTO introduced a robust standard for the protection and enforcement of IP by 
creating the WTO-TRIPS agreement. The TRIPS agreement protects member states 
IP rights and issues penalties for failure to adhere to WTO IP Law44. It utilizes different 
enforcement procedures. Such as civil, administrative, provisional and border 
measures to protect IP45. TRIPS IP framework includes protection for copyright in 
respect of the right of performance, producer of phonograms, sound recording and 
broadcasting organizations46. Protection of trademarks, geographical indications, 
service marks47, industrial designs48, patents, designs and integrated circuits49. Also, 
within the TRIPS agreement spectrum is the provision for a minimum standard to 
measure IP. It proffered meanings to IP rights, the scope of IP, exception, and 
obligation in the context of the Paris Convention, Berne Convention, and the Rome 
Treaty50. Given the stated fact that one of the directives of TRIPS Agreement is to 
enhance freedom of IP cue from WTO goal of ‘freedom of trade’ to strengthen 
economic growth51. The TRIPS agreement works concurrently with the WTO 
objective; thus, it can be said to create a balanced system for trade and IP regulation.  
However, trade and IP cannot exist simultaneously with counterfeit. Counterfeit stifles 
economic growth and development, to the point that it diminishes ideas, inventive 
 
44Frederick M. Abbott, ‘Distributed Governance at the WTO-WIPO’, supra pg 66.   
45‘ World Trade Organisation, overview’ : TRIPS Agreement (1 January 1995) at 
www.wto.org/english/traptop_e/trips_e/intel2_e.htm,(December 19 2013).  
46 ‘Agreement on Trade-Related Aspect of Intellectual Property Right’ (January 1 1995), supra article 
9-14 . 
47 TRIPS Agreement, Supra, Article 15-24.  
48 TRIPS Agreement supra Article 25.  
49 TRIPS Agreement supra article 27 and 35.  
50 TRIPS Agreement supra article 1(3).  
51  Ruth L. Okediji ‘WIPO-WTO Relations and the future of global IP norms ‘, supra 14.  
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steps, reduces the transfer of technology52 between developed and developing 
countries. The term counterfeit within the framework of the TRIPS agreement is 
defined as ‘the use of a trademark or mark like trademark without the permission of 
the rights holder’ 53. Scholars believe that the provisions of this definition risk 
prioritizing IP over other salient issues, including public health, even though protecting 
IP is essential in fostering innovation and generating breakthrough solutions, 
especially in the pharmaceutical sector.  
Pharmaceutical research and development depend on firm patent protection, not just 
for the product, but for the process for which a pharmaceuticals product is 
manufactured. The International Federation on Pharmaceutical Manufacturer 
Associations (IFPMA) argued that “patents have nothing to do with counterfeiting and 
counterfeiting has nothing to do with patents’’54. This statement is absurd and 
contradictory because patent rights in pharmaceuticals create a strong incentive to 
develop medicines. However, the prohibitive cost of patented medicine is a driver for 
counterfeit. Cost is a key driver of IP and IP restricts access to much-needed medicine. 
Thus a correlation can be made between cost, IP and Counterfeit. The subject of 
pharmaceutical patent protection within the WTO-TRIPS is very contentious for both 
scholars and international organisations, especially in response to the WTO-TRIPS 
Agreement’s viability in addressing the scourge of counterfeit pharmaceuticals within 
its framework of binding principles. 
 
 
52 Peter K Yu,’ Toward a Nonzero-Sum Approach to Resolving Global Intellectual Property Disputes: 
What We Can Learn from Mediators, Business Strategies, And International Relations Theorist,’ (2002) 
Vol 70 University Of Cincinnati Law Review pp.569-650. 
53 WTO-TRIPS (1994)Availablehttps://www.wto.org/english/docs_e/legal_e/27-trips_05_e.htm  
54 International Federation of Pharmaceutical Manufacturers Association – IFPMA ‘10 principles of 





1.3. INTERNATIONAL ORGANISATIONS AND DRUG ACCESS ISSUES 
 
WIPO plays an essential role in developing IP and the connection between trade and 
IP. The first stage relates to the Paris Convention for the Protection of Industrial 
Property in 1883, and the Berne Convention for the Protection of Literary and Artistic 
Work (1886).55 These agreements have been revised several times to fit new 
circumstances like technological development and the public's growing health care 
demands. The first phase of WIPO’s growth is its creation in 1967. This organisation 
had the sole responsibility for the administration and control of matters relating to IP 
internationally.56 WIPO limits the powers of other United Nations agencies such as the 
United Nations Development Programme (UNDP), United Nations Industrial 
Development Organisation (UNIDO), and the United Nations Conference on Trade 
and Development (UNCTAD), thus harnessing its authority in IP57. WIPO administers 
23 treaties that deal with the procedural standards of different types of IP58.  IP rights 
protected under WIPO consist of trademarks and copyright. It covers artistic works, 
photographs, architectural design, music, distinctive signs, industrial designs, trade 
secrets and new plant varieties.  
 
55 Supra Ray August,’ International Business Law text case ,Ch. 9B.  
56World Intellectual Property Organisation WIPO (1967) Available 
http://www.wipo.int/portal/en/index.htmlAccessed ( 8 January 2016).  
57 Ruth L. Okediji ,’WIPO-WTO Relations and the Future of Global IP Norms’, Netherlands Yearbook 
of International Law  2009, pp.69-125. 
58 ‘WIPO-Administered Treaties’ ,at www.wipo.int/treaties/en/( 10 December 2015). 
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WIPO's function can be summarised to encompass the promotion of IP development 
internationally and the harmonization of national legislation in different countries to 
facilitate the transfer and growth of technology. It also offers legal assistance to 
developing states in IP; it shares information regarding the protection of IP and 
provides education on IP rules and procedures.59 One view suggests that member 
states to WIPO never accepted the jurisdiction provided by the treaty.60 Similarly, 
changes in International law due to technological advancement made the traditional 
rulemaking system of WIPO inadequate as a multilateral treaty.61 Furthermore, it is 
said to lack both the capability to provide for the growing trend of intellectual property 
protection and the strict consensus present within the WTO-TRIPS framework.62 
Therefore, due to the incessant demands made by the developed countries during the 
Uruguay round, primarily as a result of the apparent incapability of WIPO as a 
regulating body in the area of intellectual property protection, resulted63  in the 





59 Convention establishing the world intellectual property organization (signed at Stockholm on July,  
60 Yoshifumi Fukunaga,’ Enforcing TRIPS: Challenges of Adjudicating Minimum Standard Agreements’ 
(2008) Vol 23 Berkeley Technology Law Journal 867 
61 Edward Kwakwa, ’Some Comments On Rulemaking At The World Intellectual Property Organisation’,   
(2002), Vol 12 Issue 1Duke Journal Of Comparative And International Law 179 
Abbott Frederick M, ‘Future of the Multilateral Trading System in the Context of TRIPS’, The Article, 
Hastings  
(1997) Vol.20, Issue 3 International and Comparative Law Review, PP 661  
63Frederick M. Abbott, ‘Distributed Governance at the WTO-WIPO,’  2000, vol. 3, Issue 1Journal of 
International Economic Law, 63 
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1.4 WTO-TRIPS PROTECTION, DRUGS ACCESS AND THE DEVELOPMENT 
QUESTION 
 
The WTO-TRIPS Agreement is based on the mandate of developing a legal framework 
to effectively regulate the protection of IPRs on a global level through balancing the 
views of two opposing groups. The developed countries (i.e. the IPR advocates and 
protectionism promoters), and the developing countries (i.e. the IPR antagonist and 
free trade promoters)64 One of the primary requisites of the WTO-TRIPs is to avoid 
unilateral retaliation in trade, consequently, prompting the need for a world body that 
would foster global protection of IPR and technological enhancement in developing 
countries65. The merit of the TRIPS agreement is it allows for more robust patent 
protection, which confers limited statutory monopoly to an inventor to enjoy the right 
to its invention solely. This protection of pharmaceuticals enables an investor to control 
a patented pharmaceutical product’s price and supply. In so doing, making them 
inaccessible and extremely expensive to treat diseases, especially in developing 
countries like Nigeria.   
 
On the other hand, TRIPS opponents argue that restrictive patents will unduly increase 
the cost of pharmaceuticals in developing countries66. These countries have 
expressed their dissatisfaction with the TRIPS agreement in how it has been 
 
64Xavier Seuba, 'Free Trade of Pharmaceutical Products: The Limits of Intellectual Property 
Enforcement at the Border' (2010) ICTSD Programme on IPRs and Sustainable Development, Issue 
Paper No. 27, 9 www.ictsd.org/download/2011/.../free-trade-of-phamaceutical-products.p.  Accessed 
(4 April 2015). 
65Carlos M. Correa Intellectual property rights, the WTO and developing countries, the TRIPS policy 
Option 2000 (Zed books: London).   
66The World Bank-‘ Developing Available’ http://data.worldbank.org/about/country-and-lending-groups  
Accessed (19  January 2016). 
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implemented and interpreted67 as it increases protection more than what was 
negotiated during the trade rounds. In reiterating the importance of IP, Secretary-
General Kofi Annan stated that ‘Intellectual property protection is the key to bringing 
forward new medicines, vaccines and diagnostics urgently needed for the health of 
the world's poorest people’68. A significant number of developed and developing 
countries have improved their protection level for intellectual property rights in the past 
two decades, and industry encourages this positive trend for innovation and patient 
access to new medicines. However, the application of IP to developing countries has 
some limitations as highlighted with empirical evidence when UNCTAD noted 'that 
some elements such as patent regime will adversely affect the pursuit of sustainable 
development strategies by raising the prices of essential drugs to levels that are too 
high for the poor to afford’69. One of the Sustainable development goals for developing 
countries is to support research and the development of universal access to affordable 
medicine. Maybe the term affordable is unclear, affordability with patent is 
unaffordable in Developing Countries. In clear terms, patent protection does not 
advance the developmental strategy of developing countries neither does it reduce the 
incident or scale of counterfeit rather the scale of counterfeit is on the rise. 
Counterfeit pharmaceuticals' growth is attributed to the high cost of medicine (IPR), 
poverty, easy supply chain, free trade, advanced technology, and ineffective legislative 
mechanism. However, the resultant effect from the use of counterfeit pharmaceuticals 
motivates this study. Counterfeit leads to an untimely death, therapeutic failure or 
 
67 Peter K. Yu, ‘The Objective and Principles of the TRIPS Agreement’, (2009) Vol. 46 Houston Law 
Review, pp.980-1046.    
68 United Nations United Nation Secretary general to lead fight against HIV/AIDS (2001), Available 
https://www.un.org/press/en/2001/sg2070.doc.htm Accessed (01 June 2021) 
69 UNCTAD, ‘Intellectual property right: implications for development’, Policy discussion paper  -




adverse severe effect or reactions. Counterfeit pharmaceuticals' threat is increasing 
as the World Health Organisation (WHO) estimated that fake pharmaceutical sales 
would reach $75 billion globally by 201670.  
So far, the research has presented an overview of the GATT/WTO IP framework. It 
has examined the issues and adverse effects of counterfeit in the Nigerian drug 
economy. It has also introduced IP concerns in the early GATT system and its 
transition through the WTO and the TRIPS agreement. The chapter illustrated in detail 
the many problems of counterfeit medicines in Africa, and specifically in Nigeria. It also 
highlighted other international bodies with responsibility in the IP area and how the 
development question is associated with drug access and IP protection. The chapter 
has established the premise for questioning the viability of the WTO-TRIPS framework 
for counterfeit regulation and will, in chapter two, seek to develop the analytical 
framework from the concept of counterfeit pharmaceuticals through which to test the 
WTO-TRIPS and consequently, the implementation of TRIPS in Nigeria. IPR seems a 
plaudible justification for the increase in counterfeit drugs because price is a key 
stimulant for counterfeiting, and price increase in pharmaceuticals stems from IPR. 
IPR is a product of the WTO/TRIPS agreement to regulate creative knowledge. 




1.5 AIMS, RESEARCH QUESTIONS AND OBJECTIVES 
 
 
70 World Health Organisation –‘World Malaria Day , The Growing Threat from Counterfeit 
Medicines’(2016)  
Available http://www.who.int/bulletin/volumes/88/4/10-20410/en Accessed (25 April 2016). 
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The thesis aims to address the viability of the WTO-TRIPs agreement to address the 
scourge of counterfeit pharmaceuticals in  Nigeria. It is premised on the investigation 
of the following research questions:  
I. Is the WTO-TRIPS agreement an adequate framework for addressing 
counterfeit drugs in Nigeria?  
II. What type of legal rights and procedural laws are adopted by the WTO-
TRIPS Agreement that can be relied on for the regulation of 
counterfeiting in Nigeria?  
III. What is the role of other international organisations in counterfeit drug 
regulation?  
IV. What are the IPR deficiencies in the Nigerian standards and regulatory 
system for IPR that account for the issue of counterfeit?   
V. Is the 'counterfeit' pharmaceuticals issue in Nigeria a legal problem 
demanding legal solution through the WTO-TRIPS or a conceptual and 
definitional problem?  
1.5.1 Research Objectives  
1) To  provide a contextual background to the problem of counterfeit  
Pharmaceuticals in poor African states, especially in Nigeria.  
2) To establish the theoretical, normative, and legal meaning and scope of 
application of the concept of 'counterfeit' pharmaceuticals.   
3) To analyse the WTO-TRIPS agreement concerning the theoretical, 
normative, and legal parameters of counterfeit pharmaceuticals.  
4) To examine the legal and regulatory framework of the Nigerian drugs 
system connected with the implementation of the WTO-TRIPS standards   
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5) To reveal the role of international standards bodies that facilitate access to 
medicines in developing countries in counterfeit pharmaceuticals   
6) To discuss the relationship between the Nigerian-TRIPS drug control 






In determining the appropriate methodology for this thesis, research was conducted 
on different methodologies concerning the topic and its legal research focus. Any 
researcher must determine the social order's perception under investigation to enable 
them to identify the appropriate paradigm to guide the research.71 The method utilised 
by a researcher in discovering knowledge is what is technically referred to as 
methodology.72 It includes the techniques for collecting data utilised for the research 
and an explanation of how the data is used to address the objectives of the study.  
 
Max Weber once wrote that a 'professional methodologist employs a complex and 
highly specialized battery of technical, logical concepts'.73  While not purporting to be 
'a professional methodologist', this researcher considers the use of the concept of 
'counterfeits pharmaceuticals'. It has a technical connotation because of its 
association in the medical and legal fields, it has a logical appreciation.  
 
71 Mark Saunders, Peter Lewis and Adrian Thornhill, Research Methods for Business Students, (New 
Jersey, Prentice Hall, 2007, p. 102).  
72 Ibid. 
73 Max Weber, supra p.1803.  
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The thesis adopts the qualitative methodology involving a case study to achieve the 
research objectives. Qualitative research is the application of qualitative techniques 
within a qualitative paradigm, which is different from a quantitative paradigm. A 
paradigm is a belief that guides the way we do things or a pattern or research system.74  
Legal research is different from pure sciences and social sciences, which raises the 
concern over whether the paradigm concept is necessary for studying a legal inquiry. 
Hergret stated that there is no scientific description of the law75, but a legal paradigm 
is essential to categorize identifiable legal concepts needed in theory building.76 
Qualitative research involves using words in describing the findings of the 
investigation. It is characterized by the researcher being closely involved with the 
context under study.77 Qualitative research is about meanings: it is critical and 
exploratory. It uses multiple sources of data, and it does not provide a single answer 
to questions. This methodology focuses on small-scale studies that allow for a detailed 
and in-depth description of the issue under investigation. Such studies usually adopt 
a holistic approach to provide a complete picture of the problem being investigated 
rather than just focusing on studying isolated sets of variables.78 It is opposed to 
quantitative research that involves numbers, identification of variables, and it requires 
theory-testing and deduction and values objectivity. In other words, quantitative 
analysis emphasizes the use of numbers in describing the findings of the research.7980 
 
74 Juergen Habermas Knowledge and Human Interest, (London: Heinemann Publishing 1970). 
75 James E Hergret ‘The Scientific Study of Law: A Critique,’ (1984) Vol. 24, No. 2 Jurimetrics, pp.99-
126. 
76 Peter Ziegler ‘A Paradigm of Legal Research,’ (1988) 51Modern Law Review 569-592. 
77  Ibid.  





Since the study investigates the viability of the WTO-TRIPS agreement to address the 
problem of counterfeit drugs via the qualitative methodology because the qualitative 
research process is characterised by its flexibility, adaptability, and openness to 
accommodate new variables that are likely to unfold during the research process. The 
research questions and objectives aim to unravel the meaning of 'counterfeit 
pharmaceuticals and construct a theoretical, analytical framework to study the WTO-
TRIPS regime and implementation in Nigeria to address counterfeit drugs to be 
conducted within such a flexible framework. Such an approach is akin to 'exploratory' 
research that is identified by Fisher. It advocates for enough flexibility to accommodate 
potential change during an investigation, mainly if the new data emerging necessitates 
change.81 
 
McConville and Chui perceive legal research methodology as systematic and 
complex.82 It can be internally focused, that is, a perception of law as a self-contained 
entity or through the insight of another discipline to investigate a legal problem.83. On 
this note, it is feasible for the thesis investigation on counterfeit drugs to broaden its 
perception to WTO-TRIPS law.  
This is done by adapting insight into 'counterfeit pharmaceutical' concept as applied in 
other disciplines to bring out its meaning to investigate the legal problem of counterfeit 
medicines under the global regulatory framework of the WTO-TRIPS law.  There are 
different legal methodology categories that one should examine to ascertain the most 
appropriate to attain the research objectives. The types of legal methodology include 
 
81 Exploratory research studies aim of investigating what is taking place, seeking novel insights, asking 
questions, and assessing the issue under investigation using a new perspective; see C. Fisher, 
Researching and Writing a Dissertation, Edinburgh, Pearson Education, 2007, p. 100.  





black letter methodology, doctrinal analysis, jurisprudential perspective, legal realism, 
critical legal studies, and postmodernist theories of law, queer theory, empirical 
research methodology, socio-legal research and Feminist legal theory.84 The doctrinal 
analysis is termed the purest form of legal methodology because it concerns itself with 
policy analysis, while the black letter methodology focuses on the language of the law 
as interpreted from statutes and case law.   
However, neither of these methods can adequately relate to policy documents like 
Critical Legal Studies (CLS), Socio-Legal research and Empirical research methods. 
The CLS is a technique of legal analysis that exposes the hidden political nature of 
law. It throws light on the interpretation of a legal language, especially in the context 
of rights. CLS believes that placing one's trust in the legal system is misplaced and 
may be subject to manipulation.85 However, critics of CLS believe that it is trivial for it 
attempts to prove the law is a matter of social policy and that legal rules must be 
identified by choosing between principles and procedures. Another similar opinion on 
critical legal studies is that it is radical. It assumes law to be politics between two 
competing interests with moral views that cannot be reconciled objectively.86 
Socio-legal research is interdisciplinary, emerging, and it is theoretical and 
methodologically a diverse sphere of socio science. Previous knowledge of socio 
science is not a requirement for a socio-legal researcher, it is an interface between 
Law and socio science. A shortcoming of socio-legal research is it is so modern it lacks 
a broad technique of investigation, unlike other methodology which is based on 
established traditions of research. Counterfeit pharmaceuticals and intellectual 
 
84Caroline Morris & Clan C Murphy. Getting a PhD in Law, (Oxford and Portland: Hart Publishing 2011). 
85 Ibid.  
86 Donald Brosnan, Serious but Not Critical, 60 Southern California Law Review 259, 396 (1986); 
John Stick, Can Nihilism Be Pragmatic, 100 Harvard Law Review. 332-401 (1986).  
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property is intertwined in this research, both are opposing theories. However, by using 
socio-legal research it can inform the study of law and society87. Counterfeit is a social 
condition that needs legal clarity to change the situation using continuous re-
examination and re-evaluation of concepts that existing methodologies cannot solve88.  
Empirical research is grounded in observation, experience, and investigation of the 
socio-legal approach to law. Empiricists want to know the impact of the law, how it 
works, how the actors in a legal system behave and the overall effect on people in the 
real world, otherwise called the rule of inference.89 To Epstein and King, every law or 
policy violates one or more rules of interference for it affects public policy; such rules 
become valueless because it contains many unfounded claims.90 
Another crucial legal methodology is legal realism; a legal realist assumes law is about 
the experience, not strict adherence to the courts' normative standard, statute and 
treatise. Kalman describes legal realism as a legal reasoning method and education, 
involving a form of functionalism or instrumentalism. The original realists sought to 
understand legal rules regarding their social consequences to understand better how 
law functions in reality.91 Law is what a court will do or say within the limit set by statute, 
and public opinion as such legal realism saves us from the consequences of legal 
order and social control. It is the practical applicability of the law to real-life situations 
by seeking a realistic attitude when interpreting the court's opinions or treatises. 
 
87 Banakar, Reza, and Max Travers, eds. Theory and method in socio-legal research. Bloomsbury 
Publishing, 2005. 
88 Schiff, David N. "Socio-legal theory: social structure and law." The Modern Law Review 39.3 (1976): 
287-310. 
89 Lee Epstein and Gary King, ‘The Rules of Inference,’ (2002) Vol 69, Issue 1, University of Chicago 
Law Review, pp.1-133. 
90 Jack Goldsmith and Adrian Vermeule, ‘Empirical Methodology and Legal Scholarship’, (2002) 
Vol.69 The University of Chicago Law review, pp.153-156. 
91 Hans Meyerhoff, ‘From Socrates to Plato, in The Critical Spirit Essays in Honour of Herbert 
Marcuse 187, 200 (K. Wolf & B. Moore eds. 1967).   
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According to Roscoe Pound, legal realism challenges the dominance of authority of 
the historical analytic schools established in the 19th century. In his view, legal realism 
sterns for reality on the basis that all legal movement within the last two hundred years 
grows from it, and as such legal realism existed, but only recently with a new name. 
Therefore, conceptualising legal realism, it is evident that the experience from reality 
is as important as a legal rule, doctrine, statute and concept.92 A legal realist believes 
that legal rules are often vague and ambiguous as they contain abstract concepts such 
as reasonableness, title and duress, which are subject to broad interpretation by a 
reasonable person. Secondly, realists argue that due to the lack of indeterminacy of 
abstract concepts and judicial precedents' manipulation, it is impossible to contradict 
rules. Legal realism hopes to discover the truth embedded in social practices to 
balance the interest between parties. Contrasting legal realism with CLS, realism 
engages in normative legal arguments without formalisation by focusing more on the 
relationship between the state, society law and the individual.  
This study will adopt a mixture of critical legal analysis, legal realism, socio-legal 
research and empirical research to test the international and domestic regulatory 
instruments that affect counterfeit drug production under the WTO-TRIPS. Empirical 
study and CLS is essential in this research because it will present a forum to 
understand the complexities within the WTO regime clearly. This approach will create 
a normative dimension in structuring what we look for, i.e., the definition and meaning 
of 'counterfeit pharmaceuticals' and what we see in international economic law,93 and 
its viability of the WTO-TRIPS agreement to address counterfeit drugs. Whereas 
 
92 Max Radin, ‘Legal Realism’ (1931), Vol.31, Issue 5 Columbia Law Review, pp.824-828. 
93 Gregory Shaffer, Power, Governance, and the WTO: A Comparative Institutional Approach, M. 
Barnett & R. Duvall (Ed) In Power in Global Governance, (Cambridge: Cambridge University Press 
2005), pp.130-160.   
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Socio-legal research is significant in this paper because it connects law to society by 
examining how the law is reflected or perceived against socio issues. 
Dunoff & Trachtman rightly affirm the advantage of empirical research, in providing a 
critical theory of law and economies,94 a benefit which our analytical, conceptual 
framework on 'counterfeit pharmaceutical should entail. Similarly, Goodman and Jinks 
also note that empirical research illustrates the law's conceptual analysis through the 
social influence mechanism.95 The exposition of the concept of counterfeit 
pharmaceuticals in a variety of frameworks including economic, human rights/social 
and political aspects will help us to analyse the Nigerian-TRIPS legal and regulatory 
system to ascertain the viability of the Global IPR regime under WTO-TRIPS. 
However, legal realism is vital to this research for the policy is based on intuitive 
judgements of rights and wrong, fairness, and unfairness.   
The thesis employs a case-study approach. The case study approach is used for 
evaluation, through which a researcher develops an in-depth analysis of a case or 
subject. 96 It describes a comprehensive examination of a single entity that uses 
various evidence sources, facilitating a holistic understanding of a particular topic.97 
The explored case can cover an organisation, a group of people, a community, a 
process, event or issue. It is perceived that data obtained from single case studies are 
often detailed and rich, although it is equally cautioned of the danger that findings in a 
case study research cannot always be generalised. 
 
94Jeffrey L Dunoff & Joel P Trachtman, ‘The Law and Economics of Humanitarian Law Violation in 
International Conflict’ (1996) 93 American Journal of International Law pp.394-409.  
95 Ryan Goodman & Derek Jinks, ‘International Law and State Socialization: Conceptual, Empirical and 
Normative Challenges’ (2005) 54 Duke Law Journal pp.983-998. 
96 Creswell, John W Research Design, (London: Sage 2014).    
97 Saunders, Lewis and Thornhill, p.102.   
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The thesis is organised under an inductive research approach that is characterised by 
an understanding of the meanings that people associated with events, intimate 
knowledge of the context of a study, collecting qualitative data, and using a flexible 
structure that allows changes, as the study progresses, can effectively resolve 
theoretical questions.98 So that in adopting the qualitative method to investigate 
'counterfeit' pharmaceuticals in varying permutations can test the effectiveness of the 
WTO-TRIPS and the Nigeria-TRIPS regulatory systems, the thesis places emphasis 
on having an in-depth and rich account of the counterfeit phenomena and its legal 
application as opposed to an attempt to emphasize generalizing the findings. 
Therefore, a case study approach will be a useful tool in providing the flexibility to 
question the counterfeit medicines conceptual framework within WTO-TRIPS and to 
determine the technical and legal realities associated with counterfeit pharmaceutical 
regulation in Nigeria given the TRIPS complexities. 
1.6.1 Data Collection 
 
Data for the research will be collected from primary and secondary sources. Evidence 
will be collected from various documentary sources (images and words), which, 
according to Fisher, must have been recorded devoid of the researcher’s 
intervention.99 Documents that will be used to shed light on the case study will be 
obtained from various sources, including digital, visual, sound, and printed forms over 
which they had no intervention. Primary documentation will mainly comprise legal and 
policy instruments from the WTO, Nigerian law and other legal instruments of 
international organisations. Secondary documents will be derived from books, 
 
98 Saunders, Lewis and Thornhill, p.98.  
99 Fisher, p. 102.  
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journals, reports, policy studies, legal encyclopaedias, periodicals, and technical data 
on drug distribution, working papers, conference proceedings, newspapers and 
electronic sources. These sources of documents will inform the chapters of the 
thesis.   
 
1.6.2 Ethical Considerations 
 
The research will be guided by professionalism and respect for ethical considerations, 
completing the UEL Graduate school research ethics training. This research will not 





1.7 RESEARCH SIGNIFICANCE AND CONTRIBUTION TO KNOWLEDGE 
 
From a conceptual point of view, this research will illuminate our understanding of the 
theory of counterfeit drugs by applying the theoretical perspectives of the 
pharmaceutical industry to study the suitability of the legal regime of WTO-TRIPS 
regulation of drugs IPR to address the problem of counterfeit medicines and 
consequently its impact on human health. As discussed above, scholars have focused 
more on providing drugs and protecting business rights and access to medicines. 
Several research and policy studies have been conducted on the WTO-TRIPS from 
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the perspective of human rights, poverty, access to medicine, public health, HIV Aids, 
and so on, mainly in relation to developing countries.100 
Counterfeit drugs have primarily been looked at outside legal literature, especially in 
technical and policy studies on medical and pharmaceutical or public health. It appears 
that the concept and issue of counterfeit medicines as a specific focus of study has 
not been pursued by way of legal research. The result of this non-legal outlook to 
counterfeit drugs negates a thorough appreciation of the depth and scope of 
dimensions of the problem and impact of counterfeit drugs and consequently, the 
legal, policy, regulatory, administrative, and judicial responses that may address it. 
This research will achieve a structured appreciation of the concept of counterfeit 
pharmaceuticals and the frame within which to explore the viability of current legal 
instruments and institutions on drug control deriving from the multilateral trade 
framework.  
The findings from this thesis will shed light on how developing countries can effectively 
eradicate counterfeit drugs without sole reliance on the WTO-TRIPS provision. It will 
equally contribute to the existing legal rules for regulating international trade, 
especially trade in counterfeit pharmaceuticals. The problem of counterfeit drugs is 
prevalent in developing countries in Africa, including Nigeria. By undertaking a case 
study on Nigeria, the largest economy in Africa with approximately 200 million people, 
the study will provide an important reference point for policy and legal development on 
 
100 Steve Charnovitz, ‘Triangulating the World Trade Organisation’, (2002) 96 American Journal of  
International Law, pp.28-55; Baskaran Balasingham ‘Trade in Pharmaceuticals under the TRIPS 
Agreement’ (2011) 11 University College Dublin Law Review, pp.1-24; Michael Blakeney ‘Intellectual 
property and Economic Development’ (1998) 14 International Trade Law and Economic Development 
pp.238-264; Carolyn Deere Birkbeck, The Implementation Game, The TRIPS Agreement And The 
Global Politics Of Intellectual Property Reforms In Developing Countries. (Oxford: Oxford University 
Press (2009); Susan K Sell, ‘TRIPS and Access to Medicine Campaign,’ (2002) 20(3) Wisconsin 
International Law Journal) pp.481-522. 
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addressing counterfeit drugs, but also other aspects of regulation, which the 
investigation will reveal.  
1.8 RESEARCH LIMITATION 
 
Given the pervasiveness of counterfeit drugs, which is further compounded by the 
problem of access to medicines in developing countries, there is a temptation to 
perceive the study as sociological research. Based on the impact of this phenomenon 
on poverty and invariable the more critical questions on development, public policy on 
health like the millennium development goals and domestic public health. While the 
thesis considers these topical issues, it does not purport in-depth studies of these, nor 
does it purport to proffer solutions.   
.   
1.9 LITERATURE   REVIEW 
 
The TRIPs agreement is known as the most comprehensive international legal 
instrument for regulating IPR; its framework provided patent protection for copyright, 
patent, plant breeders, geographical indications, trademark, industrial designs, and 
trade secrets. The agreement stipulated minimum standards and enforcement for 
these rights. This means that member countries cannot confer a lower level of 
protection than provided under TRIPs. All WTO-TRIPs members are therefore 
obligated to protect IPR in all fields of technology, including the patent for the 
pharmaceutical product (product and process). 
The WTO-TRIPS agreement did not give a clear definition of intellectual property 
rights. Still, generally, it can be defined as those rights imposed by a state upon 
individuals for a prescribed term, to prevent unauthorized exploitation as a benefit from 
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the creation of the human intellect101. The rationale for justifying IPR as a legal right is 
mostly for economic reasons. As Dutfield and Suthersanen rightly stated, IPR is an 
institutional means for firms to be rewarded or an incentive for research and 
development. 102. Firms depend on rewards as a form of return for inventive steps, 
and it is essential for growth. The TRIPS agreement guarantees protection of IPR 
within the WTO multilateral framework of ‘one size fits all system’. Scholars like 
Dutfield, posit that the one -size -fits all approach of the WTO-TRIPS agreement is 
strengthened by the extension, of the scope of patentable subject matter to crucial 
areas such as pharmaceutical, life form, genetics and plant varieties. The ruling 
regarding patentable subject matters includes anything under the sun made by 
man.103 This meant that TRIPs created stringent conditions, especially for developing 
countries, which lacked IPR to medicine nor hold productive capacity.  
Empowered by TRIPs, pharmaceutical companies set high prices for patented 
products. This high price is one of the critical factors restricting access to medicine in 
developing countries. According to Drahos & Braithwaite, the goal of having a global 
IPR paradigm is not to create a market economy for the developed countries but a 
needy population104 . However, Oguamanam did not support this point; he posits that 
the adverse health needs of developing countries, especially in Africa, show the 
negative impact of strict pharmaceutical IPR protection by multinational corporations 
 
101 Michael Blakeney, M Trade Related Aspect of Intellectual Property Rights: A Concise Guide to the 
TRIPs Agreement, (London: Sweet & Maxwell (1996), 
102 Gregory Dutfield & Uma Suthersanen, Global Intellectual Property Law Cheltenham: (Edward 
Elgar Publishing 2008).  
92   Carlos M Correa, Intellectual Property Rights, the WTO and Developing Countries, the TRIPS 
Policy Option (Zed books: London (2000).    
103 See the landmark case of Diamond V. Chakrabarty, where the Supreme Court held that patentable 
subject matters include anything under the sun made by man; see G Dutfield. ‘Does the One Size Fit 
All?’ (2006), 26 Harvard International Law Review, pp.50-54.  
104   Peter Drahos & John Braithwaite, Information Feudalism: Who Owns the Knowledge Economy, 
(New York: The New Press 2002). 
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without concern for the human rights implications105. The issue of human rights under 
the TRIPs agreement relates to access to essential medicine. The debate revolves 
around how to balance the inflated price of drugs and people's health needs.  
On this issue, Cynthia Ho argues that pharmaceutical companies' human rights 
implications concerning patenting needs should be considered because access to 
medicine affects all citizens of the world106. Therefore, knowledge about how drugs 
are protected should not be limited to a few people. Similarly, Sell examined the 
access to medicine debate from a political standpoint. Sell argued that the overall cost 
of TRIPs is steeper than dollars, but will be paid with human lives, especially in the 
face of the HIV/AIDS epidemic107. Adding to the access to medicine debate, Attaran 
researched by collecting data from 65 low-income countries and comparing it with the 
WHO list of essential medicine. His study proved that patent may not be a direct cause 
of essential medicine unavailability in developing countries. However, he suggests that 
poverty poses a far greater limit to access to medicines than patents108.   
Ho posits that an analysis of different patent perspectives should advance a better 
understanding of how to balance patent rights and access to medicine. According to 
Ho, this patent perspective will have a significant impact on how the law is perceived 
and how laws are interpreted109. So, access to medicine can be deemed a privilege to 
patent owners to promote innovation. On the other hand, Lazzarini introduced a 
 
105 Chidi Oguamanam, Intellectual Property in Global Governance, A Development Question (Routledge 
2012). 
106 Cynthia Ho, Access to Medicine in the Global Economy, (Oxford University: Press New York 2011),   
107 SK Sell, ‘TRIPS and Access to Medicine Campaign’, (2002), 20 Wisconsin International Law Journal, 
pp.481-522.  
108 Attaran, A.’ How do Patent and Economic Politics Affect Access to Essential Medicine in Developing 
Countries,’ (2004), 23(4) Health Affairs, pp.155-166. 
109 Cynthia Ho, ‘Global Access to Medicine: The Influence of Competitive Patent Perspective, (2011) 
Vol 35, Issue 1 Fordham International Law Journal 1-97, Zita Lazzarini.’ Making Access to 
Pharmaceuticals a Reality: Legal Options under TRIPS and The Case Study of Brazil’ , (2003), 6 Yale 
Human Rights and Development Journal, pp.103-138  
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different approach by stating that the conflict between IP and human rights could be 
resolved if the trade exceptions under TRIPs are fully utilized. This exception includes 
an exception from patentability, parallel imports and compulsory licensing; it is a 
powerful tool for countries with serious public health needs, especially developing 
countries. Ruth Gana argues that the real challenge facing developing countries is a 
developmental issue and not the defects of an international proprietary system such 
as access to medicine under TRIPs110.  Thus, she asserts that developing countries 
need to embark on comprehensive developmental strategies in education, marketing, 
economic policy, foreign investments and technological issues instead of blaming 
TRIPs.  
The focus of developing countries’ health advocates had been getting affordable drugs 
into their supply systems. This introduced the element of counterfeit pharmaceuticals 
into the system because the need for access to medicine became more important than 
the protection of IP rights under TRIPs. Counterfeit is a global problem. Even if its 
scope is still unknown, the WTO estimates that over half of the drugs in developing 
countries are counterfeit. Some of the arguments on counterfeit drugs are that 
counterfeit is primarily an issue of intellectual property. IP not only increased the price 
of innovative medicines but also aggravated counterfeit drugs111. Counterfeit 
pharmaceuticals become an even greater problem for firms given the huge margins 
between the market price of drugs, R & D costs and issues of patent infringement, and 
how less costly counterfeits erode firms' profit margins.   
 
110  Ruth L Gana, ‘Creativity Died in the Third World, Some Implications of the Internationalisation of 
Intellectual Property’  (1995-1996) 24 Denver. Journal of International Law & Policy, pp.109-144. 
111 Charles Clift ‘Combating Counterfeit, Falsified and Standard Medicines: Defining the way forward?’ 
Chatham House Briefing papers (2010). 
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Another major attribute to counterfeit highlighted by Bird is the inadequate laws, weak 
enforcement mechanisms and the absence of criminal penalties for counterfeiters112. 
Attaran, Bates and Rogers argue that counterfeit remains legal in international law, 
mostly due to the problems of the definitional scope of counterfeit. The term counterfeit 
has different meanings attributed to it by different countries, as up until now, no uniform 
definition has been proposed globally. To them, criminalizing counterfeit medicine on 
an international scale will offer significant results over the states' approach. They 
assert that the actus rea and mea rea of counterfeit medicine should be considered, 
which means offenders can be quickly punished113.  
The extent of counterfeit drugs is mostly unknown, but it keeps increasing daily. The 
WHO 2010 estimated that the counterfeit drug market could reach $ 75 billion as of 
2010, and 25% of counterfeit drugs are consumed in developing countries. WHO 
presents results from a survey conducted on 20 countries from 1999-2000? The result 
indicated that 60% of drug counterfeits occurred in developing countries114.  Some of 
the consequences of the consumption of counterfeit medicines include death, as seen 
in some developing countries. One example is the Republic of Niger in 1995, where 
2500 children died from fake meningitis vaccinations, 89 deaths in Haiti in 1995 from 
the consumption of counterfeit paracetamol syrup, and 30 deaths in Cambodia after 
taking fake anti-malaria drugs115. Another consequence of counterfeit stated by 
Nelson, Chang & Vizurraga is that it stifles economic investment and impedes the 
 
112 Robert C Bird, ‘Counterfeit Drugs a Global Consumer Perspective’ (2008) Vol 8 Issue 3 Wake Forest 
Intellectual Property Law Journal, p.387. 
113 Amir Attaran, Roger Bate, Megan Kendal, ‘Why and How to make an International Crime of Medicine 
Counterfeiting’, (2011) 9 Journal of International Criminal Justice, pp.325-354. 
114 World Health Organisation (2010) ‘Substandard and Counterfeit Drug Medicines, Available 
http://www.who.int/mediacenter/factsheets/2003/fs275/en/ 




economic growth of states.116. Counterfeiters have a total disregard for health and 
safety measures; neither are they concerned with product quality, nor do they pay 
import or export taxes.  
Research by Cockburn and others suggests that companies and governments are 
reluctant to publish the extent of counterfeit not harm sales of the brand–names 
product. They surveyed to check the presence of a reliable database on counterfeit 
drugs, and the findings showed that the WHO has received only 48 reports from 1999-
2002. This estimate is less compared to the death rate, so this report proved the point 
of non-disclosure117. Similarly, Newton and White conducted a survey in Cambodia, 
138 drugs were tested, and the result showed that 38% of the 138 were counterfeit 
drugs. 
A common theme from this literature discussed above is the anomaly around the 
TRIPs agreement, access to medicine, counterfeit drugs, IP regulation and disclosure. 
The primary intention of TRIPs is to create a legal and uniform patent administration 
system for members of the WTO. However, instead, it shifted its focus from IP 
protection to medicine without delimiting its focus. Scholars on TRIPS focused on the 
human rights, developmental and economic aspects of TRIPs, without considering the 
side effects of unregulated drugs, which are counterfeit pharmaceuticals. TRIPs set a 
viable administrative system and gave patent rights but failed to regulate the technical 
aspect of drugs production. Most research on counterfeit tends to test its 
consequence, extent and effect but fails to look at the legal aspects of counterfeit.  
 
116 Maria Nelson, Michelle Vizurraga and David Chang ‘Counterfeit Pharmaceutical a Worldwide 
Problem,’ (2006) 96 Trademark Review, pp.1068-1100.   
117 Robert Cockburn and others ‘The Global Threat of Counterfeit Drugs: and Why Government Must 
Communicate the Dangers,’ (2005), Vol. 2 (4) PLos Medicine e100  
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In conclusion, it can be suggested that there existed an anomaly or dichotomy of 
concepts, especially in respect of Pharmaceuticals, thus creating a regulatory paradox 
under the WTO. Hence from a legal viewpoint, some questions need clarifications 
such as what type of right is protected by TRIPS? Can procedural laws be relied on 
for the regulation of counterfeit? Is patent protection the problem, or is the problem in 
the developing world and Nigeria, particularly one of access to medicine? The 
International Federation on Pharmaceutical Manufacturer Associations (IFPMA) 
support this position in a statement that “patents have nothing to do with counterfeiting 
and counterfeiting has nothing to do with patents’’118 . Therefore, what type of 
medicines amounts to counterfeit, could it be substandard drugs, imitation, or fake 












The preceding chapter discussed the rationale for the inclusion of IP within the WTO-
TRIPS multilateral trade system. It presented an overview of the GATT/WTO 
 
118 International Federation of Pharmaceutical Manufacturers Association – IFPMA ‘10 principles of 
Counterfeit Medicine (May 2010) Available at www.ifpma.org>content>news>ifp.   
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framework and counterfeit in the Nigerian drug economy. It examined the origin of IP 
and its transition under the TRIPS agreement. The chapter also analysed the many 
problems of counterfeit and the International Organisation with the responsibility of 
tackling IP-related matters. To question the viability of the WTO TRIPS framework to 
regulate counterfeit pharmaceuticals. This chapter aims to unravel the distinctive 
nature of counterfeit in response to the theoretical issues raised about counterfeit, by 
evaluating the definition, implication and evidence of counterfeit, while considering the 
contextual scope of counterfeit products. It will provide an opportunity to clarify the link 
between IP and counterfeit pharmaceutical products. It will show that despite the 
definitional question, counterfeit has a direct significance to the current state of 
pharmaceutical regulation globally with reference to Nigeria.  
Counterfeit is regarded as a global catastrophe with perverse consequences. For 
example, counterfeit is said to be the major cause of unnecessary morbidity, mortality, 
and loss of public confidence in medicines and health facilities119.  It also leads to an 
untimely death, therapeutic failure or adverse severe effect or reactions. The threat of 
counterfeit pharmaceuticals is on the increase as it was estimated by the World Health 
Organisation (WHO) that counterfeit pharmaceutical sales would reach $75 billion 
globally by 2016120. Although there is no reliable estimate on the actual value of 
counterfeit pharmaceutical market size, getting a reliable figure is a challenge. Still, 
the best guess estimate is that it is over $4.35 Billion with lifestyle drugs, pain killers, 
and antibiotics leading the trend121. 
 
119 Robert Cockburn and ‘The Global Threat of Counterfeit Drugs: Why Industry and Governments Must 
Communicate the Dangers.’ (2005) PLoS Med 2(4): e100. doi: 10.1371/journal.pmed.0020100 
120 World Health Organisation –World Malaria Day , ‘The Growing Threat from Counterfeit Medicines 
‘(2016) Available http://www.who.int/bulletin/volumes/88/4/10-020410/en/ Accessed (25 April 2016)  
121 Securing Industry 2020, Study estimates world trade in fake medicines is worth €4bn Available 
https://www.securingindustry.com/pharmaceuticals/study-estimates-world-trade-in-fake-medicines-is-
worth-4bn/s40/a11550/#.X2Dz_3lKjIU Accessed (15 September 2020) 
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What then is ‘counterfeit'? It is a relative term, which is subject to different 
interpretations like a correlation of terms. The colloquial meaning of counterfeit differs 
from different countries or firms. Typically, there seems to be a connection between 
the legal impact of counterfeit in international trade and the economic, social, 
developmental, and humanitarian aspects of counterfeit. Indeed, to establish this 
connection, it is essential to understand the objective, scope, nature, and counterfeit 
scale. The World Customs Organization considers counterfeit as a crime of the 21 
century and a risk to every nation122. It is so dangerous that it can reduce a country’s 
economic output and industrial competitiveness123. 
The problem of counterfeit is believed to be more rampant in developing countries as 
against developed countries. The WHO estimates that about 30% of the medicines 
consumed in Africa is counterfeited and over 70% of the medicine sold in Nigeria is 
either counterfeit drugs or substandard. This results in over 700,000 deaths from 
counterfeit consumption annually in Africa, with most of the medicines originating from 
China, India, Mexico and Brazil124.  Another aspect recognized for the growth of 
counterfeit Pharmaceuticals is the existence of weak intellectual property laws in 
 
122 World custom organisation WCO (2004) The First Review on Customs and Counterfeit Available 
http://www.wcoomd.org/en/media/newsroom/2006/august/the-first-review-customs-and-counterfeiting-
2004.aspx (Accessed 22 April 2016) this review provides an overview of the alarming growth of the 
trade in counterfeit by the world custom organisation. By indicating possible measures to curb this 
menace within the organisation’s disposal, the Secretary General of WCO, Michel Danet, affirms that 
Counterfeiting and piracy have reached an intolerable proportion. It is a threat to public health and 
safety. Custom officials reported in 2004 a total of 4,000 cases on counterfeit and seized more than 166 
million worth of counterfeit goods.   
123 Peter H. Bloch, Ronald F. Bush and Leland Campbell, “Consumer Accomplices in Product 
Counterfeiting: A Demand Side Investigation’, (1993) Vol. 10 Issue 4 Journal of Consumer Marketing, 
PP 27.  Countries like Kenya lost a substantial amount of coffee crop due to counterfeit fertilizer, also 
in the USA Job losses as a result of counterfeit is estimated to 210, 000 jobs. The supply and demand 
aspect of counterfeit is analysed, the author points out that research is mainly conduced on the supply 
aspect of counterfeit, which in this article is not the case, major emphases is placed on the demand 
aspect of counterfeit. 
124 Jeremy M. Wilson, Roy Fenoff, ‘The Health and Economic Effect of Counterfeit Pharmaceuticals in 
Africa’ A-CAPPP Backgrounder, (2011)  Available 
http://acapp.msu.edu/sites/default/files/files/africabackgroundfinal.pdf Accessed (25 April 2016) 
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developing countries. Intellectual Property protects the right of manufacturers by 
providing absolute protection for ideas and creativity. It gives a manufacturer 
monopoly right over inventions to the exclusion of all others. A manufacturer relies on 
this right to protect marketable intellectual inventions given the high cost of research 
and development (R&D). In this light, IPR is a justification for the economic exploits of 
Pharmaceutical products. But this absolute right gives rise to counterfeit drugs which 
is an infringement to IP. 
Another key issue discussed within this chapter is the historical development of 
counterfeit, particularly how it is perceived, justified, and adapted to fit the 
circumstance or position the term finds itself. For without experience, future dynamics 
is incomprehensible in terms of law and legal history. The study of counterfeit needs 
to connect, alter, and advance the understanding of modern-day law and help identify 
relevant principles and practices concerning Counterfeit125.  The definitional problem 
analysis is expected to add to the existing definitions on the subject by adopting a 
workable interpretation of counterfeit from current definitions and terminologies. It will 
contrast and compare the concept of counterfeit with similar ideas like Knockoff, 
imitation, fake and substandard pharmaceuticals. It will identify the effect of 
globalisation, free trade, legal enforcement mechanisms on counterfeit distribution. 
The theoretical, legal and policy aspects of counterfeit medicines will be emphasized 
in constructing the framework for analysing the legal character of counterfeit in 
international trade. The chapter will also explore the economic, technical, and 
institutional aspects of counterfeit Pharmaceuticals to establish a conceptual and 
 
125Markus Dirk Dubber, ‘Historical Analysis of Law,’ (Spring, 1998) Vol. 16 No. 1, Law and History 
Review, pp. 159 
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theoretical framework for testing the viability of the WTO/TRIPS systems in the 
regulation of counterfeit. 
2.2 Evolution and Definition of counterfeit 
Understanding the evolution of a concept is instrumental in developing a theoretical 
meaning. In this scenario, the concept of counterfeit is a critical unresolved issue in 
international trade law126. To resolve this contextual issue, examining the history of 
counterfeit will provide a framework to decide its scope and its relation to modern-day 
international trade and health issues. Counterfeit first arose as a concept from the 
early 27BC after the discovery of counterfeit wine in Rome127. Similarly, coin 
counterfeiting gained prominence around the sixteenth and seventeenth centuries in 
France. The act of counterfeiting coins involves the smuggling, production, and use of 
forged coins usually carried out by goldsmiths, trade merchants, soldiers, and even 
priests. A typical example of counterfeit occurred in France where replicas of the 
official coinage of the protestant king were made by parallel minting by the supporters 
of the pope to undermine the reign of the king128.   
Similarly, historical evidence suggests that in Spain, criminals forged letters of credit 
used in monetary transactions to evade the law. For instance, at that time, financial 
institutions made an adverse decision not to disclose the extent of this crime to the 
 
126Davison Mark. Pharmaceutical anti-counterfeiting: combating the real danger from fake drugs. John 
Wiley & Sons, 2011, see also Agbaraji, Emmanuel C., Deborah O. Ochulor, and Gloria N. Ezeh. 
"Food and drug counterfeiting in the developing nations; the implications and way-out" Academic 
Research International 3.2 (2012): 24 
127 Tim Philips, Knockoff: The deadly Trade in Counterfeit  Goods: The True Story of the World’s Fastest 
Growing  Crime Wave( United States of America : Thomson Shore Ltd, 2005), see also Jason Rutter 
and Jo Bryce The consumption of counterfeit goods : Here be pirates , Sage publications, Vol. 42(6): 
(2008) 1146–1164 
128  Peggy Chaudhry, and Alan Zimmerman, protecting your Intellectual Property Right: Understanding 
the Role of Management, Government, consumers and Pirates (New York: Springer, 2013) 
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public does not undermine its authority or increase the scale of Counterfeit129. Another 
important reason attributed to the growth of counterfeit is the recognition of trademarks 
or similar marks. This proprietary mark of proof and quality is noted to have been in 
existence in China around 5000 years ago130. The introduction of trademarks or similar 
marks in trade made a significant impact on the course of trade and the perception of 
counterfeit. It created an opportunity for merchants to mark products uniquely in a bid 
to circumvent counterfeiters. These marks appeared in various products from pottery, 
brick and tiles, oil lamps, and paintings to textiles. However, enforcement of this mark 
was mostly unknown at that time, but it appears that punishment was meted out to 
offenders by Roman commercial institutions131.  
These marks extended to the middle age, with building merchants attaching symbols 
to distinguish their product from low-quality knockoffs. By the 13th century in England, 
the law became compulsory to have marks inscribed on products, and infringement 
on this mark amounted to prosecution such as imprisonment and capital punishment 
of perpetrators132. The first registration of trademark in England dates back to 1875133. 
However, the first known case in England for the prosecution of infringement of a mark 
is the Sandford case of 1584134. 
 
129 Mark Galeotti, Part of Wickedness and crime: The under World of the Renaissance Italian City, 
(Gonafalon Press: Italy, 2012) The growth of crime, counterfeit, murder and the harsh punishment 
melted out to offenders in renaissance Italy is evaluated. The area of counterfeit is traced from coinage 
to forged credit notes by educated Italians in a bid to elude the authorities and it was regarded as a 
norm. 
130  Shoen Ono, Overview of Japanese Trademark Law, (Yuhikaku: Japan, 1999) pp1-39 Trademark 
plays a vital role in the choices of consumers. Consumer rely on trademark to make product choices, it 
is unique in trade for without trademark goods cannot be identified. Without Trademarks manufacturers 
cannot profit from extensive corporate effort in research and development. Trademarks protect goods 
from counterfeit and knockoff or imitation. The main function of a trademark is for identification and it 
can be used in different capacity like a name, title, country, all signs, symbols, business mark, service 
mark etc 
131  Ibid Dr Shoen Ono, Overview of Japanese Trademark Law 
132 Abbott, G. W, Sporn, LS, Trademark counterfeiting (New York: Aspen Publishers 2011)  
133 Jeffery Belson, Certification marks, A special report (London: Sweet and Maxwell 2002) 
134 Sandforth case (1584) Cory’s Entries BL MS Hargrave 123 
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In addition to the limitation on trademark, the Venetian law of 1474 introduced 
protection for an invention in the form of patent by granting exclusive rights for 
inventive steps.135 Over the next 2000 years, the single act of copying resulted in the 
growth of counterfeit and in the words of Dr Fredrick Mostert ‘every product known to 
mankind can be entirely copied136’. This shows the extent to which products can be 
counterfeited. Products subject to counterfeit include luxury goods, consumer 
products, cars, bags, pharmaceuticals, computers, electronic products, etc. The list is 
endless; as technology increases, so do counterfeit goods also increase.  
Counterfeit products are sold through various channels from high street shops, black 
markets to online market platforms. However, trade-in counterfeit has uniquely 
adapted to changing trade policies to circumvent legal and regulatory impediments to 
its distribution. The intention behind counterfeit is ‘deceit’, meaning to portray what is 
not as what it ought to be to unsuspecting buyers or consumers. As seen in the words 
of Higgins that counterfeit in legal parlance is like passing off goods of low quality as 
the original aimed at deceiving the unsuspecting buyer and defeating the traditional 
purpose of the product137.  
 
135KamilI Idris, ‘Intellectual Property a Power Tool for Economic Growth’ (WIPO: Issue 888 of WIPO 
Publication, 2003) 
136 Fredrick W. Mostert, Martin B Schwimmer, ‘Notice and Takedown for Trademarks’ (2011), Vol.101, 
No.1 The Law Journal of International Trademark Association, 249- 281 
137 Richard Higgins, ‘Counterfeit Goods’, (1986) Vol. 29 Journal of Law and Economics, 211 This paper 
indicated the importance of trademark by stating that branded goods is purchased by a particular class 
of consumers to demonstrate the preference for that goods. Thus, counterfeiting of that product 
trademark affects the overall need of the makers of the product resulting in the change of motive of 
consumption with the growth of counterfeit. By examining the market factor behind counterfeit product 
purchase amongst Americans, the research showed that consumers are indifferent about the 
manufacturers of goods but about the quality and price. 
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2.2Liberalisation, Internet trade and Counterfeit 
 
A restrictive trade regime is practically impossible in this era of globalisation. This is 
mainly due to the liberalization of trade. Liberalization is regarded as the most 
important macroeconomic tool for developing and developed countries economies for 
higher economic growth138. It is the remover of restriction, the openness of trade, 
relaxation of laws and privatization. Essentially, liberalization promotes competition by 
stressing the significance of the flow of technology, knowledge and information across 
borders139. It encourages the growth of the private sector, facilitates FDI and the 
simplification of regulations. Nevertheless, it is essential to note that liberalisation of 
trade and counterfeit are two different issues, yet they are interconnected. Thus, it is 
pertinent to give a conceptual clarification to the theory of liberalization to identify the 
level at which its provision is consequential to the expansion of counterfeit in 
international trade, particularly pharmaceuticals. 
To provide context to the theory of liberalization, previous studies have expanded the 
different impacts of liberalization, starting from its complex quality, for example, it leads 
to the creation of trade agreements140, development of supranational organisations 
such as the WTO141 It allows for the movement of people and services, reduction in 
prices or price variation and it broadens the choice of quality goods and services 
 
138Iskra Stanceva-Gigov ‘The Benefits of Trade Liberalization and Its Contribution to Economic Growth 
Economic Development’ No. 3/ 2016 PP 166-178, 168  
139Ibid 
140 European commission on trade Available http://ec.europa.eu/trade/policy/countries-and-
regions/agreements/index_en.htm  Accessed (09 August 2017) Trade agreement is created to strength 
the economy of states and to create jobs , it equally enables business to compete more at a global  
forum without fear of marginalisation thus giving consumers wider choices of product and services at a 
lower cost. 
141 Eric. W. Bond, ‘Adjustment Costs and the Sequencing of Trade Liberalisation’, (2008) Vol 31, Issue 
1pp The World Economy 1467-19   
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available. Indigenous and non-indigenous companies also benefit from trade 
liberalization by channelling resources to where returns are highest, thereby 
increasing productivity142. 
Although to a large extent, liberalization of trade changed the perception of trade in all 
facets, it is not without its shortcoming, as highlighted by Goldberg and Nina Pavcnik 
According to them, trade liberalization can lead to increased migration, poverty, 
inequality, cultural globalization, and removal of border control143. Gerard Capri and 
Patrick Honohan observed that liberalization could influence the reduction of state 
control on the financial sector, which is deemed a stimulant to the increasing economic 
crisis. Notably, this shortfall can reduce the interest rate of states. For example, in 
Mexico, after the debt crisis, the interest rates were reduced to activate the growth of 
domestic resources144. LA Winters and McCulloch maintain that there is a direct link 
between poverty and liberalization of trade. Recent evidence proves that although free 
trade and openness can sustain the growth of an economy, there is no tangible proof 
to show that liberalisation eliminates poverty. For instance, sustainable growth of an 
economy depends mostly on increased productivity145  , but if productivity increases 
more than output, this could affect change. In the words of Kaplinsky, liberalization 
leads to instability146. The relative outcome of instability can cause diversion of output, 
 
142 OECD Trade Liberalization Available http://www.oecd.org/tad/tradeliberalisation.htm Accessed (09 
August 2017) 
143Goldberg, Pinelopi K., and Nina Pavcnik, Trade, Inequality, and Poverty: What do we Know? 
Evidence from recent trade liberalization episodes in developing countries No. w10593 National Bureau 
of Economic Research, 2004 
144 Gerard Caprio, Patrick Honohan and Joseph E. Stieglitz, (ed) Financial Liberalization, How far, How 
fast (Cambridge, 2006) pp10-11) 
145 Alan L. Winter, Neil McCullochi, Andrew McKay, ‘Trade Liberalisation and Poverty: The Evidence 
So Far, Journal of Economics Literature Vol XL.II (2004) PP72- 115, 74 




for which the consequence can cause the overflow of counterfeit goods as in the case 
of Nigeria. 
Besides this point, liberalization of trade increased the import and export of counterfeit 
goods such as pharmaceutical products, given the lax border control of states. WTO-
driven trade liberalization policies have accelerated this development.147 The WTO 
applies a systematic approach towards evaluating the impact of its trade policy on the 
running of the multilateral trade system. The WTO Trade Policy Review Mechanism 
(TPRM) is part of the WTO’s overall surveillance machinery, and in its scope, it covers 
matters relating to IP. It is regarded as an integral organ of the WTO system, with the 
sole purpose of 
 ‘’contributing to improved adherence by all members to the rules, discipline and 
commitment made under the multilateral trade system...for smoother functioning and 
greater transparency in and understanding of trade policies and practice of 
members.‘’148  
The idea that TPRM serves to monitor WTO member states application of its policies; 
for instance, free trade seems unrealistic, for there is no evidence to support the 
unique applicability of TPRM in the liberalization of trade. 
Nevertheless, the WTO is credited for the expansion of free trade through its 
liberalization policies which also include the principle of non-discrimination, most 
favourable nation policy, parallel importation and fair-trade policies. It allowed the 
 
147Robert L. Morris , ‘Trade Union and Globalisation : A Caribbean’s workers Education Guide’(Port of 
Spain: International Labour Organisation 2002) Available http://www.ilo.org/wcmsp5/groups/public/---
Americas/---or-lima/---sro-port_of_spain/documents/publication/wcms_224178.pdf (Accessed 29 
August 2016) The WTO policies include the principle of Non-discrimination, most favourable nation 
policy, parallel importation across all market, rule to promote fair trade and free competition, technical 
assistance to developing countries.  
148 World Trade Organisation (WTO)  ‘Trade Policy Review Mechanism’ 




reduction in tariff and non-tariff barriers, ensuring the integration of global trade149 and 
individualism. However, given the WTO policies on trade liberalization, it can be said 
to create a dilemma by allowing member states ‘trade’ without setting standards for 
the product and processes across different borders. Neither do member countries 
adhere to WTO policies; and even if they adhere, its approach can be restrictive in 
certain trade forums (developing/LDC). Therefore, it begs the question in this instance 
whether WTO trade liberalization policies conflict with the overall objective of the WTO. 
If this is the case, it could be asserted that the WTO is a liberalization mechanism 
responsible for reducing borders controls, which may have led to the growth of 
counterfeit. 
Trade Liberalization Versus Globalisation 
Another important aspect of trade liberalisation is the impact of globalisation on 
counterfeit. These paradigms are interconnected; they both stress the value of 
removing barriers to trade and privatization of public-owned firms, thus enhancing 
economic growth and creating one global marketplace. However, this study is not 
concerned with the entire concept of globalisation, but it specifically examines its 
complex influence on public health, particularly pharmaceuticals. Cornia argued that 
globalisation could lead to important health expansion if properly managed by 
generating high health returns150 and advanced domestic growth. On the contrary, this 
 
149 Gao Shangquan, ‘Economic globalisation: Trend, risk and Risk prevention’ Available 
http://www.un.org/en/development/desa/policy/cdp/cdp_background_papers/bp2000_1.pdf Accessed 
(30 August 2016) examined the impact of economic globalisation it reflect the continuing expansion and 
integration of world economies, an irreversible market trend. Two reasons are attributed for this growth, 
is science and technology and cross border division of labour. The advancement of technology reduced 
the cost of transportation and communication amongst nations. For example, ocean shipping cost half 
of the normal amount in the 1930’s even production and manufacturing of cars is not limited to just 
Germany, Britain and America but now produced in other countries. 
150 Giovanni Andrea Cornia, ‘Globalisation and Health:  Results and Options,’ (2001) Vol.79 No. 9 Bull 
World Health Organisation.  
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seems implausible because the suppression of borders has allowed trade in 
counterfeit to flourish. It can, therefore, be claimed that globalisation can exacerbate 
counterfeit. 
Having established this conflict, what then is globalisation, and what is the link 
between globalisation and counterfeit, particularly counterfeit pharmaceuticals? Does 
globalisation influence the way we perceive counterfeit, or is it possible that it may 
have made the problem of counterfeit bigger or worse? The meaning of globalisation 
is not fixed or definite151, as scholars like Ronald Robertson strenuously argued that 
the concept of globalization is essentially the compression of the world and global 
interdependence amongst states leading to the integration of culture, religion, 
economy and technology152. One consequence of globalisation153 is that it can reduce 
the number of regulatory obstacles to the movement of goods and services amongst 
states because it excludes the principle of territoriality. However, the benefit of 
globalisation is remarkable in every aspect, but the adverse consequence of 
globalisation is multifaceted. It is linked to terrorism154, migration, poverty, death, 
reduction in trade barriers155 and an increase in counterfeit drugs. 
 
151 John Goldring,’ Globalisation and Consumer Protection Laws,’ (2008) Vol. 8 8 Macquarie Law, 
Journal. pp 79-101. 
152 Ronald Robertson., Globalisation: Social Theory and Global Culture (Sage Publishing: London, 
1992). 
153 Globalisation replaced the concepts of internationalization and trans nationalisation, it is used to 
describe the global interaction of people, culture, trade, politics, technology, human right, migration 
etc. 
154Counterfeit Pharmaceutical a serious threat to patent safety Available 
http://www.pfizer.com/files/products/CounterfeitBrochure.pdf Accessed ( 29 August 2016) Counterfeit 
has become a lucrative business for criminals around the world. It is not subject to border restrictions 
and profit from counterfeit is more than profit made from the sale of heroin and cocaine.  Equally the 
penalty for trafficking counterfeit drugs is less than the penalties for hard drugs.  
155 Matthias Yao., ‘Trade Unions and Globalisation’, available  at 
<http//www.apro.techno.net.au/docs/apr922.doc Accessed (29 August ,2016). 
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The globalisation of counterfeit pharmaceuticals utilizes a complex production, 
distribution, and sale mechanism. It is an economic trend that is heightened by 
advanced technology and a restructured global economic system156. The globalisation 
of technology improves the reproduction and production of counterfeit 
pharmaceuticals, making them virtually identical to the original medicine. As the flow 
of technology between states is increasing, so are counterfeit pharmaceuticals. The 
technological equipment for counterfeiting is readily available at a reasonable price, 
making it possible for reverse engineering in the production of drugs. Counterfeiting is 
neither subject to any border restriction nor legal impediment, and therefore it can be 
produced in any country. Recent research compiled by Pfizer indicated that counterfeit 
Pfizer drugs had been found in 75 countries around the world157. The most famous 
case is the production and sale of counterfeit Pfizer Viagra Lipitor, Centrum Vitamins 
and Chapstick158. 
To compound further, the issue of counterfeit pharmaceuticals is the role of 
Multinational Corporations (MNC) as a result of the globalised economy. 
Pharmaceutical firms outsource the production and packaging of drugs to different 
countries in a bid to reduce production costs through cheap labour, more access to 
raw materials and thus more significant levels of profit. For example, API finished 
dosage manufacturing is shifting to developing countries, and Pill-fillers come from 
one country and coating from another source159. Pharmaceutical companies have 
 
156 Hsiao-Hung Chang, ‘Fake Logos, Fake Theory, Fake Globalization,’ (2004) 5: 2Inter-Asia Cultural 
Studies, 222.  
157 Counterfeit Pharmaceutical a serious threat to patent safety Available 
http://www.pfizer.com/files/products/CounterfeitBrochure.pdf Accessed ( 29 August 2016) 
158 Barbara Morgan  ‘Crack down on counterfeit  Pharmaceuticals,’ Available  
http://www.pbs.org/wgbh/nova/next/body/uncovering-counterfeit-medicines/ Accessed ( 29 August 
2016). 
159 The Economist , ‘Bad Medicine’, Available http://www.economist.com/node/21564546  Accessed 
(29 August 2016). 
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moved production sites to low-income countries like China and Indonesia. Firms ought 
to adopt a multi-faceted anti-counterfeit strategy for the protection of pharmaceuticals 
in these low-income countries160 . These strategies ought to be backed by sanctions 
to regulate production and distribution, but this is not the case. To Hopkins, Kontnik 
and Turnage, another reason for the growth of counterfeit pharmaceuticals includes 
low trade barriers, consumer complicity, expansion of markets, and the growth of 
brands161. The globalisation of the pharmaceutical industry affects intellectual property 
rights; for example, it affects patent, generic and biotech drugs. It also leads to a 
decline in the number of innovative drugs produced for the treatment of diseases.    
Common to the various analysis of globalisation, it is perceived to be unpredictable 
and complex or possibly optimistic (easy flow of trade, growth in world economy and 
technology advancement) or pessimistic. In the context of counterfeit drugs, 
globalisation demands that policymakers hold manufacturers of these products 
accountable for product quality per international standards and therefore adopt 
measures for a robust legal framework to regulate counterfeit drugs. 
  
Internet trade and counterfeit 
Counterfeit seems to thrive more because of the globalisation of trade from free trade 
zones to the growth of the internet. The sudden increase of the internet has heightened 
the counterfeit predicament by creating an enabling environment in cyberspace for 
counterfeit sellers and consumers to buy and sell counterfeit products. It creates a 
 
160 Kelvin Lewis, ‘The Fake and The Fatal: The consequences of Counterfeit’, Available 
https://www.iwu.edu/economics/PPE17/lewis.pdf Accessed (30 August 2016). 
161 Kenaway Molouk Kenaway, ‘The Economic Impact of Counterfeit Goods in Egypt’, (2013), Vol. 3, 
Issue 3 International Journal of Business and Management Research, p.111. 
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platform for anonymity, thus hiding the identity of counterfeiters, as counterfeiters do 
not need to bypass any border restriction or abide by any trade regulation. The issue 
of the safety of drugs purchased over the internet is a genuine concern for consumers 
and policymakers. A pharmaceutical purchase over the internet most often consists of 
the sale of outdated drugs, expired drugs or sale of medicines that contain no 
ingredient or a reduced amount of active ingredient and therefore provides no 
protection against diseases162 
The key factor attributed to the growth of counterfeit products online is the ease of 
website creation and removal. The implication of this is that counterfeit product sellers 
can reach consumers globally, and it is not limited to corporations anymore.  In the 
same way, consumers are exposed to the internet and have the freedom to purchase 
goods from any online seller without proper verification if the product is genuine or 
fake. The impact of online counterfeit trade on consumers is grave because 
consumers’ health and safety are at risk from the consumption of substandard and 
toxic goods. 
The solution to reducing online sales is complex and often problematic163, specifically 
the question of responsibility and legal measures to curb counterfeit product sales 
needs to be resolved. On this point, Gelin and Elings believe that instead of 
prosecuting counterfeiters, the service providers should be held accountable in 
 
162 John A. Vernon, Stephan Goupil and Joseph H. Golec, ‘The Internet and Pharmaceutical 
Importation: Economic Realities and other Related Issues,’ (2006)16 Alb. L.J. Sci. & Tech. 545   the 
focus of this research is on the safety of imported pharmaceuticals in the USA. This issue is broad, and 
complex been that there is no proper estimate of the inflow of drugs or the quality considered before 
sale over the internet. 
163International Trademark Association  INTA- ‘Addressing the Sale of Counterfeit over the Internet’ 




law.164Under the principle of contributory liability for IP infringement relying on the case 
of Inwood Labs Inc .v. Ives Labs Inc.165Here, the Supreme Court held the generic drug 
manufacturer could be held liable under contributory liability if they intentionally 
supplied goods knowing it was under a trademark, and this equally applies to third 
party supplies of patented goods such as internet service providers. 
However, the court took a different turn in the case of   Tiffany Inc V. eBay Inc166 by 
rejecting the argument of contributory liability. The court relied on the principle laid out 
in Inwood supra, that liability cannot be imposed on the defendant for failure to 
anticipate the possible sale of counterfeit products on its website. However, if the 
defendants failed to act upon information of possible counterfeit products, they were 
not held liable for damages. Relying on the contributory liability is a limited approach, 
for it does not extend to the international regulation of counterfeit; it is just within a 
jurisdiction.  
2.2.1 Free Economic Zone 
A free economic zone (FTZ), sometimes called free trade zone (FTZ) is defined by the 
International Trademark Association to be an area within the jurisdiction of a state 
where custom control is absent or reduced. Another definition by Grubel states that an 
FTZ is a geographically defined area where different economic activities take place 
without government taxation and regulation167. It is not subject to any international and 
 
164Scott Gelin, G Roxanne Elings ‘Contributory Liability for Trademark Counterfeiting in an Ecommerce 
world, NYU (2010) Vol.1, No 2 Journal of Intellectual Property and Entertainment Page 44. This paper 
provided tips for service providers for contributory liability. That a service provide should ensure that 
the immediate knowledge of any form of counterfeiting on its site should be reported accordingly and 
removed or else faced prosecution in law as seen in the case of Gucci America Inc V. Frontline 
Processing Corp 08 Civ.5065 (2008). 
165Inwood Labs Inc.V. Ives Labs Inc 456 U.S.844(1982)  
166 Tiffany Inc.V. eBay Inc No 08-3947-cv2010 U.S App 
167Herbert G. Grubel, ‘Towards a Theory of Free Economic Zones,’ Weltwirtschaftliches Archive 
Bd.118, H.1 (1982) PP39 
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local trade, banking, and tax laws. FTZ is characterized by warehouses, factories, 
industries, and wharves168. FTZ is particularly significant to trade for it creates a 
platform for legitimate businesses to play a vital role in international trade and 
development. It is estimated that there are over 3000 FTZ spanning across 116 
countries with the fundamental objective to enhance foreign exchange and develop 
export-oriented industries169.  
The benefit of FTZ is tremendous; FTZ creates a shift from import -substitution to 
export-led trade policies; it can reduce foreign exchange overheads; attracts foreign 
investment, and increase foreign earnings through exports. FTZ generates inter-firm 
communication and a new form of division of labour amongst industries. It involves a 
shift of labour-intensive industries from developed to developing countries, and thus, 
it creates employment opportunities for locals of the developing countries and 
increased output170. However, the rise of the FTZ leads to negative externalities, which 
according to the OECD in 2010 include money laundering, racketeering, fraud, 
smuggling and sale of counterfeit goods.171 
Counterfeiters use the FTZ to repackage, manufacture and re-label finished 
counterfeit drugs without fear of prosecution. It undermines the purpose for the 
creation of the free trade zone, which is trade liberalisation. To Liang, the FTZ provides 
 
168 International Trademark Association ,’ Role of Free Trade Zones and Free Port in the 
Transhipment and Transit of Counterfeit Goods’, (Nov 2006) Available 
http://www.inta.org/advocacy/pages/roleoffreetradezonesandfreeportsinthetransshipmentandtransitofc
ounterfitgoods.aspx   Accessed ( 14  April 2016) 
169 Angela Shah, ‘Free Trade Zones Attracts Criminals,’ New York Time Available 
http://www.nytimes.com/2010/11/11/world/middleast/11iht-m11mtrade.html?_r=0 Accessed (9 
September 2016) 
170 David Wall, ‘China's Economic Reform and Opening-Up Process: The Role of the Special 
Economic Zones,’ (1993) 11 Development Policy Review PP 243 
171 OECD-FATF, Money Laundering Vulnerabilities of Free Trade Zones ,2010 Available 
http://www.fatf-
gafi.org/media/fatf/document/reports/ml%20vulnerabilities%20free%20trade%20zones.pdf  Accessed  
(14 April 2016) 
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an “opportunity for unscrupulous individuals to whitewash counterfeit drugs in a bid to 
avoid regulatory oversight by states’’172. Also, a report by the New York Times 
indicates a link between the FTZ and the supply of counterfeit pharmaceuticals 
following the seizure of many counterfeit drugs in a Euro Gulf warehouse within the 
FTZ. This incident revealed how the FTZ is used to supply counterfeit from China to 
Hong Kong, to Britain and ultimately leading to the internet173. Over the internet, the 
medicine will be sold as the original product regardless of its consequence. As more 
countries create more free trade zone, so does the scale of counterfeit increase. A 
particularly recent example is the seizure of counterfeit drugs from Heathrow Airport 
in London, where customs officers intercepted counterfeit products from renowned 
companies such as Pfizer, Novartis, Procter and Gamble. Following a proper 
investigation, the counterfeit drugs were eventually traced to an FTZ in Dubai174.  
2.2.3 ACCULTURATION 
The objective of this section is to raise questions on the forces that can influence the 
escalation of counterfeit pharmaceuticals aside from the economic, legal and technical 
aspects. One of such concepts is the concept of acculturation. This section will assess 
the relationship between acculturation and counterfeit by suggesting that acculturation 
could be another reason for the growth of counterfeit. Acculturation is a rapidly 
changing field of study; it is a multidimensional concept175 on human diversity to 
 
172 Free trade zones and counterfeit drugs:’ An Interview with PSMs Bryan Liang and Netherland 
Antilles Chief of Staff of the Inspectorate of Public Health,’ (12 July 2010) , Available 
http://www.safemedicines.org/2010/07/free-trade-zones-and-counterfeit-drugs-an-interview-with-
psms-bryan-liang-and-netherlands-antilles-c.html  Accessed (09 September 2016) 
173Walt Bogdanich, ‘Counterfeit Drugs path Eased by Free Trade Zones,’ The New York Times 
(2007)https://www.nytimes.com/2007/12/17/world/middleeast/17freezone.html 
174Walt Bogdanich, ‘Counterfeit Drugs path Eased by Free Trade Zones,’ The New York Times 
(2007)https://www.nytimes.com/2007/12/17/world/middleeast/17freezone.html 
175 Berry J.W Acculturative as varieties of adaptation, in Acculturation: Theory, Models and Some New 
Finding (Boulder: West view, 1980) pp 9 
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change from one cultural context to another context. It is also the union of different 
cultures, values and beliefs resulting in changes to the way of life, religion, custom, 
culture and health176. 
Acculturation as a concept can be traced to the 1880s, and it is believed to have 
originated from Europe, during the colonial era resulting in the movement of people, 
culture, religion, and art over a long time177 . Acculturation can be defined as ‘’a 
phenomenal, which results when groups of individuals having different cultures178 
come into continuous first-hand contact, which subsequently changes the original 
cultural pattern of both groups’’179. This definition identifies the existence of two 
different cultures coming into play or interacting, which in turn may influence the 
actions of an individual. The action may be a positive influence or negative influence, 
some of which can remarkably alter the balance of society. 
Although it the most widely used definition of acculturation, ironically, this definition is 
somewhat perceived to be ambiguous or vague, for it only emphasizes the individuals, 
not on the actions of the acculturating individuals. For example, the interaction of 
different cultures, beliefs, lifestyles and values of individuals may result in the original 
culture being lost in transmission, thus leaving the individual to assimilate the new way 
of life resulting in individualism. The scary part of this, is the possibility of the influence 
 
176 Seth J. Schwartz and others, ‘Rethinking the Concept of Acculturation, Implication for Theory and 
Research,’ 2010 ,65(4) The American Psychologist 237 
177 Linda M. Hunt, Suzanne Schneider and Brendon Comer, ‘Should ‘acculturation’ be a variable in 
Health Research A Critical Review of Research on Hispanics,’ (2004) Vol 59, Social Science and 
Medicine 973 it’s becoming necessary in the United State to determine the culture of citizens in relation 
to their health sectors. Acculturation explains the root or behavioural pattern of individuals and 
corporation. People choose a pattern based on their cultural believes and ideas and it can influence 
their overall wellbeing. 
178 Culture means the way people feel, act and think in relation to their religion, region, nation, 
occupation, gender, ethnicity etc. 
179 David L. Sam and John W. Berry, ‘Acculturation: When individuals and Groups of Different Cultural 
Background Meet’(2010)  Volume 5,  Perspectives on Psychological Science Vol 472 
74 
 
of harmful vices on acculturating individuals in their modern society, for example, the 
increase in criminal activities, terrorism, human trafficking and counterfeiting. One 
suggested reason for this negative influence is the stress and conflict involved in the 
acculturation process within the individual as the individual acquires new cultural 
values which may influence the individual behaviour. Also, Ferrell and Gresham 
recognise the significance of the unique cultural difference in the decision-making 
process of the acculturating individual180. In this context, acculturation could be a 
stimulant to the rise in counterfeit pharmaceuticals as it influences the choice people 
make with regards to products. Instead of using available products with therapeutic 
effects, cultural shifts influence the decision-making ability of choice, which 
inadvertently leads to the purchase of counterfeit drugs. Also, by the process of 
acculturation, there is a shift from the use of Traditional African Medicine (TAM), for 
more sophisticated medicine. TAM is a cultural heritage particular to Africans; it is a 
skill passed on from the ancestors for the treatment of diseases 181; therefore, 
integrating TAM have been hindered due to acculturation. 
2.3 COUNTERFEIT PHARMACEUTICAL: MEANING AND DEFINITIONAL 
QUESTION (WHAT IT MEANS, HOW IT IS PERCEIVED AND APPLIED) 
 
A definition is the statement of the meaning of a concept; it ought to be clear and 
uncontroversial. If a definition is controversial, questioning established procedures and 
rules182 is necessary to determine how best to proffer a coherent meaning to the term. 
 
180 O.C Ferrell & Larry G Gresham, ‘A Contingency Framework for Understanding Ethical Decision 
Making in Marketing,’ (1985) Vol. 49, Issue 3 The Journal of Marketing), 87 
181Elujoba, Anthony A., O. M. Odeleye, and C. M. Ogunyemi. ‘Traditional Medicine Development for 
Medical and Dental Primary Health Care Delivery System in Africa.’ (2005) Vol 2 issue 1 African Journal 
of Traditional, Complementary and Alternative Medicine pp 46. 
182 Jerome E. Bickenbach, Jacqueline M. Davies, ‘Good Reasons for Better Arguments’ (Peterborough: 
Broadview Press, 1997) 
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This is precisely the position of counterfeit pharmaceuticals, which is an unresolved 
issue in international trade law. Conflict exists between the implicit and explicit 
interpretation of the definitions of counterfeit medicine. As Jackson rightly opined that 
‘’the lack of a clear widely accepted definition of counterfeit pharmaceuticals might be 
an obstacle to adopting an effective measure to tackle the issue’’183. Even the WHO 
rightly observes that ‘’ the definition of counterfeit used in different countries differs 
enough to create problems in the implementation of necessary measures to combat 
it’’184. 
The word ‘counterfeit’ is subject to multiple interpretations, and thus, arguably, there 
is no exact definition to the term counterfeit. Etymologically the word counterfeit comes 
from the Latin word ‘contra facere’ which means ‘to imitate’185. From a legal stance, 
the word counterfeit means to imitate, without authority to deceive or defraud by 
passing the forged item as the original186. Different organisations, agencies, 
Governments and Non-governmental organisations (NGOs)187 defined the word 
counterfeit to meet specific objectives or standards. Over time the definition of 
counterfeit has evolved to encompass different terms in place of counterfeit. These 
 
183Amir Attaran, Roger Bate, Megan Kendail, ’Why and How to Make an International Crime of Medicine 
Counterfeiting’, (2011) Vol.4, No.4 Journal of International Criminal Justice,) pp947-9 
184 WHO – ‘Combating Counterfeit Drugs: A Concept Paper For Effective Collaboration,’ Available 
http://www.who.int/medicines/services/counterfeit/combatingcounterfeitdrugs_conceptpapers.pdf  
Accessed(d 21 May 2016) 
185 Eric Przyswa, ‘Counterfeit Medicine and Criminal Organisations, International Institute of Research 
against Counterfeit Medicine’ (IRACM) 2013, Available www.iracm.com Accessed (16 May 2016) 
186 Black’s Law dictionary ,’ Definition of Counterfeit’ Available http://thelawdictionary.org/counterfeit/  
Accessed (16 May 2016) 
187 World Trade  Organization WTO (1994), ‘Agreement on Trade Related Aspects of Intellectual 
Property Rights, Including Trade in Counterfeit Goods’  Available 
http://www.wto.org/english/docs_e/legal_e/27-trips_05_e.htm ( Accessed 22 April 2016), OECD , The 
Economic Impact of Counterfeit , (2007)  Available https://www.oecd.org/sti/38707619.pdf  Accessed 
(22 April 2016),The International Organisation for standards (ISO),Crack Down on Counterfeit ( 2014)  
http://www.iso.org/iso/news.htm?refid=Ref1809 John Pink and others.  ‘Defining the Types 




terms include substandard drugs, fraudulent goods, piracy and imitation. This 
discrepancy made the task of defining counterfeit more complex. 
The need to have a universally acceptable definition of counterfeit is almost next to 
impossible since states have legislation on counterfeit that is unique to their 
environment and circumstances. For example, in Nigeria counterfeit drugs is defined 
by Section 12 of the Nigerian counterfeit and fake Drugs (Miscellaneous provision) 
Act, which states inter alia ‘that counterfeit drug is any medicine or pharmaceutical 
product, which is not what it purports to be, coloured, coated or polished which damage 
is far greater than the therapeutic value than it is188. Similarly, Section 96 of the Indian 
drug and cosmetic act 1940 define a counterfeit drug as (a) A drug imported under a 
name belonging to another drug (b) imitation, substitute or resembles another drug (c) 
if the label bears the name of an individual company purporting to be the manufacturer 
(d) if it been substituted, wholly partly by another drug and substance189. These 
definitions of counterfeit are similar and convincing, but it begs the question of 
counterfeit drugs regulation such as the inability of states to agree on a uniform 
definition of counterfeit. For instance, if the definition of counterfeit in India and Nigeria 
is similar, it will ease adjudication. This can create a consistent system where penalties 
are universal in all jurisdictions, thus reducing technicalities. Secondly, the definitions 
tend to stress the importance of counterfeit finished products as against the process 
or substance used in the creation of a counterfeit drug. This means that there is no 
explicit support for creativity or IP, which inadvertently creates a gap between what 
the law provides and what it ought to protect. It is equally logical that both laws should 
give legal recognition to counterfeit, but no distinction is made to address the 
 
188 Cap 34 LFN Nigeria 
189 Indian Parliamentary Standing Committee on Health and Family Welfare-Fifty-9 report on the 
function of the central drug standard control organisation (New Delhi, 2012) 
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difference between counterfeit drugs and other similar concepts like substandard 
drugs. 
Similarly, Counterfeit is defined by the WTO-TRIPS Agreement to include the use of 
a trademark or similar mark which is identical to a registered trademark without due 
authorization of the right owner of the mark190. This definition of counterfeit sets 
recognisable objectives and standards. It is unique for it recognised IPR, but in the 
aspect of Public health, it is vague, as it undermines the public health aspect of IP. It 
prioritises the enforcement of the right holder’s right over health. Equally, this definition 
fails to consider the extensive research and development undertaken by inventors in 
the context of Pharmaceuticals. 
 This creates confusion and can prevent access to much-needed medicines. Staake 
and Thiesse point out that the definition of counterfeit by TRIPS may be technically 
correct even though it fails to specifically clarify to what extent counterfeit will be a 
problem to access to medicine. It can be suggested that the definition of counterfeit 
permitted by the WTO can be reframed or redefined as the ‘’trade and imitation of 
pharmaceutical without the authorization of the right owner, which goes against the 
set standard and quality requirement permitted by Law’’191. This definition highlights 
 
190 World Trade Organization WTO -TRIPS 1994, Article 41 ‘Enforcement of Intellectual Property Rights 
‘Available http://www.wto.org/english/docs_e/legal_e/27-trips_05_e.htm  (Accessed 28 March 2016) 
For the purpose of the TRIPS agreement the right holder is a person who is legally entitled to assert a 
right over IP. Thus, the agreement defined counterfeit to include counterfeit trademark or any packaging 
bearing without due authorization a trademark which belongs to a right holder and this will infringe on 
the right of the holder.   
191 Thorsten Staake, Frederic Thiesse and Elgar Fleisch, ‘The Emergence of Counterfeit Trade: A 
Literature Review’ , (2009) Vol.43, Issue 3 European Journal of Marketing , pp320  This article 
discussed the issue of counterfeit and illicit supply chain from different management related aspect. It 
highlights the implication of counterfeit on international trade stating that counterfeit has developed into 
a severe threat to companies and consumers. Some of the implication faced by companies includes 
loss of revenue owing to substitution effect of fake goods and loss of brand name for fear of counterfeit.  
The authors traced the growth of counterfeit from early publication and research to differentiate the 
public perception of counterfeit  
78 
 
some fundamental principle which the TRIPS agreement omitted such as ‘standards’ 
and ‘quality. Another acceptable definition of counterfeit is the definition proposed by 
WIPO. It defined counterfeit as the imitation of product that gives the impression of 
being the original product made by the genuine manufacturer192. Equally, the U.S. 
International Trade Commission defined counterfeit as "the unlawful use of a 
registered trademark on a product that is identical or like the product for which the 
trademark is registered and used’’. The connotation in these definitions are similar but 
lacks uniform meaning which is misleading and can undermine possible solutions to 
counterfeit drugs.  
Similarly, the World Health Organisation (WHO) defined counterfeit medicine as ‘’one 
which is deliberately and fraudulently mislabelled concerning identity and source. It 
applies to both branded and generic medicine and may include a product with the 
correct ingredient or wrong ingredient’’. However, following the persistent demand by 
member states to the WHO for harmonisation, the old definition was amended to 
reflect other forms of counterfeit. Giving that the WHO is a standard-setting 
organisation it rightly amended the old definition to include ‘’sub-standards, spurious, 
falsely labelled, falsified, counterfeit, medical product (SSFFC)193’’.To Attaran and 
others, the new classification by the WHO may be misleading given the peculiar 
 
192 World Intellectual Property Organisation – WIPO Intellectual Property Handbook (2008) Available 
http://www.wipo.int/edocs/pubdocs/en/intproperty/489/wipo_pub_489.pdf  Accessed (22 April 2016) 
Counterfeit product belongs to the category of luxury goods with well-known trademark such as Gucci, 
Rolex and Cartier. This view on counterfeit fails to include other goods not sold under trademark but 
protected by other forms of intellectual property such as patent, copyright and design. The danger of 
counterfeit cannot be quantified but recent report from a farm in Africa estimates that counterfeit 
pesticide destroyed a year worth of crops on a farm, imagine the effect on humans. To make counterfeit 
actionable the law refers to such infringement as trademark infringement in some jurisdiction whereas 
in other jurisdiction counterfeiting is prevented by court infringement and fines but no solid punishment 
for offenders have been provided.  
193WHO. Report of the working group of member State on Substandard/Spurious/Falsely-
labelled/falsified/counterfeit medical product (2011), available 
http://apps.who.int/gb/ssffc/pdf_files/a_ssffc_wg2_3.en.pdf Accessed (19 September,2016 ) 
79 
 
attribute of each term to pharmaceuticals194.  As each term reflects a peculiar 
characteristic of fake medicines, merging all in one body removes the individuality of 
each term. For example, a substandard drug is different from a falsely labelled drug in 
all forms. In addition, this new classification circumvents the importance of intellectual 
property in the control of counterfeit pharmaceuticals. This definition broadens the 
scope of counterfeit, resulting in more definitional questioning. 
The GATT anti-counterfeiting code described counterfeit as ‘’the wrongful benefit 
through deceit with the intent to deceive consumers of a branded product ‘. In support 
of this definition, the United Nation Office on Drugs defines product counterfeit as a 
form of consumer fraud, where a product is sold, purporting to be something that it is 
not, which it is different from the crime of copyright195. It is evident that the definitions 
of counterfeit are all interrelated and for obvious reasons: there seem to be peculiar 
similarities between these definitions even to the extent of having the same phrase, 
hence the complexity reflected in the various meanings of counterfeit as highlighted 
above. 
One reason attributed to the inconsistencies amongst the definition of counterfeit is 
the ‘technical terminology’ in the definitions. There seems to be an over-arching need 
to balance infringement of intellectual property within the scope of counterfeit, which 
invariably will undermine the specific requirement of the different forms of IP. Also, the 
definitions failed to reflect the relationship between the cause and effect of counterfeit. 
 
194 Amir Attaran and others, ‘How to achieve International Action on Falsified and Substandard 
Pharmaceuticals,’ BMJ 2012 
195United Nation Office on Drug and Crime, Counterfeit Product Available 
https://www.unodc.org/documents/data-and-analysis/tocta   (Accessed 29 March 2016) 
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It only addressed the registered authority of intellectual property rights holders, not the 
problems of counterfeit.  
The definitions of counterfeit failed to specify the difference between pharmaceuticals 
and other consumer products; it classified all the definitions as one. The health 
implications, for example, the degree of harm, due to the consumption of counterfeit 
pharmaceuticals, supersedes the responsibility for the protection of IPRs. Medicines 
ought to be compound administered to restore a medical diagnosis in humans, which 
is subject to strict protection196. Instead, the economic aspect of counterfeit is 
applauded more than health repercussions. It would be more apt to treat both issues 
together by having a uniform definition that encompasses both health and economics. 
Equally, the definitions fail to state the theoretical approach to counterfeit drugs. For 
example, the fundamentals and weaknesses of each definition are not considered. 
Given this, it is necessary to examine the other relative terms used in place of 
counterfeit if it will reflect or undermine the definition of counterfeit pharmaceutical. 
2.3.1 TECHNICAL ASPECTS: KNOCKOFF, IMITATION, FAKE AND 
SUBSTANDARD PHARMACEUTICALS 
Different terms have been used in place of counterfeit, thus creating confusion on the 
actual word to use when discussing counterfeit pharmaceuticals. These terms include 
substandard, knock-off goods, falsification, and imitation, all of which fall within the 
component needed for the violation of IP rights. It is, therefore, essential to examine 
these terms in lieu of counterfeit pharmaceuticals in a bid to determine if the right 
words can effectively tackle the public health issue of unsafe medicines. If proper 
 
196WHO- Essential Medicine and Health Product, Available 
http://www.who.int/medicines/services/essmedicines_def/en/  Accessed ( 16 May 2016) 
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technical terminology can be established, it will improve how institutions or 
organisations such as the WTO can set standards for the regulation of counterfeit. 
 The first technical terminology is Knock off goods, these are products which to some 
extent are like the original product, but it is not sold as the actual product197 , for 
example, passing Gucci watches as Guuci, Seiko as Aseikon. Knockoff mainly affects 
the trade name as opposed to counterfeit this involves the full product. A knockoff is 
also regarded as another form of copying the tangible property right of a product; it 
restricts innovation and loss of monopoly by the creator. It is evident from this definition 
of Knockoff that it cannot be equated with counterfeit pharmaceuticals but mainly 
associated with luxury goods such as phones, cars, bags, clothes which exhibit a 
particular brand associated with prestige apart from its practical utility198. The sale of 
knock off goods is run by a huge criminal empire, and its size can be equated with the 
size of Wal-Mart, mostly products from china199. 
It is vital to differentiate between knockoff goods and mislabelled goods. Firstly, 
knockoff goods do not include pharmaceuticals, whereas mislabelled goods mainly 
affect the pharmaceutical product. It involves the sale of medicine in a different 
package other than the original package with the sole intention of deceiving an 
unsuspecting buyer. The package is altered to fit the peculiar features of the original 
medicine such as manufacturing number, batch number and any other unique attribute 
in the original drug. In a bid to bypass border control, health regulators and law 
 
197 Gary Bamossy, Debra L. Scammon, ‘Product Counterfeiting: Consumer and Manufacturers Beware’ 
in NA- Advances in consumer research vol. 12, Eds Elizabeth C. Hirschman and Morris B. Holbrook, 
Provo UT: Association for consumer research, pg. 34 
198Arghavan Nia and Judith Lynne Zaichkowsky, ‘Do Counterfeit Devalue the Ownership of Luxury 
Brands?’ (2000) Vol.9, No7 Journal of Product and Brand Management, pp 485-497 
199 Tim Philips Knockoff: The Deadly Trade in Counterfeit Goods: The True Story of the World Fastest 
Growing Crime (Kogan Page: London, 2005) 
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enforcement agencies, a famous example is the purported sale of a weight loss 
medicine Xenical- or Listat in the USA.  The packaging appeared to be so authentic 
that it was difficult to differentiate the mislabelled medicine from the original200. 
 Whereas, substandard pharmaceuticals are drugs that do not meet the required 
standard whether it is health and safety standards and the medicine contains little or 
no active ingredient needed to make up a drug compound, or it fails to meet other 
required standards necessary to qualify the medicine as safe for treatment. Such 
medicine may or may not be legitimately produced to meet the specific standard 
required by law201. Sometimes, substandard medicine may contain the same active 
ingredient found in the original medicine, but it is of low quality which invariably means 
the drug will be inactive or useless202. Also, substandard medicine is usually produced 
by authorized manufacturers, but it fails to meet the quality standard prearranged for 
it. This means the medicine is defective for failing to meet the specification set out for 
it by the authorising body or country. However, differences exist between substandard 
pharmaceuticals and fake pharmaceuticals. 
A fake pharmaceutical is a medicine that claims to be what it is not, and it is solely 
intended to mislead the consumer. According to Medicine Sans Frontiers, a fake 
medicine is deliberately and fraudulently mislabelled to give false information on the 
medicine, in a bid to mislead the public as to its source and content. It creates a serious 
threat to the general public, for it contains no active ingredient203. In the broader 
 
200 Ten M.Ham , ‘Health Risks of Counterfeit Pharmaceuticals, Drug Safety’ Vol.26 (2003), R.Jotcham, 
991-997Understanding and Evaluating Security Technologies for Pharmaceuticals, in Combating 
pharmaceutical fraud and counterfeiting, SMI conference Documentation, London, SMI Publishing, 
2003. 
201 Medicine Sans Frontiers (MSF), ‘Substandard and Counterfeit Medicines,’ Available  
http://www.msfaccess.org/spotlight-on/substandard-counterfeit-medicines  Accessed ( 16 May 2016) 
202Ajoy Bera and Ashish Mukherjee, ‘Counterfeit and Spurious Drugs: Big Challenge to the Health Care 
System’ Worldwide,’ (2013) vol.4 issue 3 International Journal of Pharmaceutical Sciences PP48 
203 MSF IBID 17 
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context of counterfeit pharmaceuticals, the definitions provided for fake, substandard 
and knock-off, if synchronized, could fit the particular purpose and framework of 
counterfeit drugs. Subsequently, the definition which reflects all these features in one 
body is seen in the definition by the WHO on counterfeit pharmaceutical stating that 
‘’counterfeit medicine is deliberately and fraudulently mislabelled concerning identity 
and source. Counterfeiting can apply to both branded and generic products, and 
counterfeit products may include products with the correct ingredients or with the 
wrong ingredients, without active ingredients, with insufficient (inadequate quantities 
of ingredient(s) or with fake packaging204’’ This definition tries to reflect key element 
found in the definition of substandard, fake and counterfeit pharmaceuticals.  As such, 
instead of dwelling on the definitional issues, strategies should be adopted to address 
the problem of counterfeit. 
 It is important to note that the definition by the World Health Organisation (WHO) 
introduced a new element to the concept of counterfeit pharmaceutical, which is a 
generic medicine. This has been a subject of several arguments amongst scholars on 
the place of generic medicine within the framework of counterfeit pharmaceuticals. It 
is thus important to know the meaning of generic medicine. According to the, WHO 
generic medicine is generally manufactured without a license from the inventor, and it 
is sold after the expiration of patent rights205. Also, the European Union Medicine 
Agency defines generic medicine as a medicine that is developed to be the same as 
 
204  World Health Organisation WHO, ‘ Essential Medicine and Health Product,’ Available 
http://www.who.int/medicines/regulation/ssffc/definitions/en/ Accessed (18 May 2016) Substandard 
medicine called OOS product is said to be genuine medicine produced by manufacturers authorised by 
the NMRA. As such giving a universally agreed definition will be essential for clarity but it cannot alter 
the position of member state legislation, with stated rules in place for regulating counterfeit. 
205WHO–‘Generic Drug, ‘Availablehttp://www.who.int/trade/glossary/story034/en/index.html.  Accessed 
(18 May 206) 
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a medicine that has already been authorized, and it contains the same active 
substances as found in the initial dose206. 
 It is different from counterfeit medicine based on the following reasons. Firstly, from 
a physiological perspective, generic medicine is similar to the original for its 
bioavailability is the same as the molar dose, and it has the same effect, efficacy and 
safety as the original medicine207. Secondly, generic medicine is cheaper than the 
actual medicine because generic manufacturers do not conduct preclinical trials and 
clinical studies given that these trials and studies have already been carried out by the 
IPR holder or manufacturer and the necessary cost borne accordingly208 . Thirdly, the 
economic benefit of generic medicine cannot be ignored; most countries use generic 
medicine to control healthcare costs. Hence generic medicine is identical to the 
original medicine for it contains the same composition of the active ingredient. 
However, generic medicine can be counterfeited because it makes essential medicine 
less expensive and accessible to the poor in developing countries. In conclusion, 
generic medicine is not the same as counterfeit medicine; nonetheless, generic 
medicine can be counterfeited owing to the failure to adhere to regulatory obligations. 
 
2.3.2 ECONOMIC DEVELOPMENT ASPECT OF COUNTERFEIT –DRUGS 
                Imagination is more important than knowledge Albert Einstein 
 
206 European Medicine Union, ‘Question and Answer Available’ http://ec.europa.eu/health/auhorisation-
procedures_en.htm  Accessed (20 May 2016) Generic medicine marketing approval in the EU can be 
authorised in three ways, firstly the approval of the centralised procedure, followed by the decentralised 
procedure and the national procedure. 
207 Suzanne Dunne and others, ‘A Review of the Differences and Similarities between Generic Drugs 
and their Originator Counterparts, including Economic Benefits Associated with Usage of Generic 
Medicines, Using Ireland as a Case Study,’ BMC Pharmacology and Toxicology Vol.14, No.1, pp2-19 
208 Generic  Drugs: Overview of ANDA review process, Available 
http://www.fda.gov/downloads/drugs/newsevnts/ucm167310.pdf Accessed (20 May 2016) 
85 
 
The purpose of this section is to provide an overview of the economic implication of 
counterfeit, whilst still reiterating the possibility of regulating counterfeit within the 
WTO-TRIPs framework. This part will examine the acuity of protecting investor’s 
rights, the cost of producing and the affordability of drugs, but first, the impact of 
counterfeit will be discussed briefly. It is difficult but not impossible to quantify the 
economic impact of counterfeit pharmaceuticals, nevertheless no matter the value 
implicated in counterfeiting; this practice results in the loss of legitimate goods and 
goodwill of pharmaceutical companies. To Peter Bloch, Ronald Bush and Leland 
Campbell a high percentage of producers of legitimate goods incur damage to brand 
reputation as a result of counterfeit. Thus, producers in a bid to save brand name fail 
to inform consumers of the potential existence of counterfeit pharmaceuticals.  
The economic impact of counterfeit is multifaceted; it causes financial mayhem to 
business. Secondly, it is a continuum of problems ranging from loss of technical know-
how, loss of IP right, low productivity, loss of income and brand name. Accordingly, to 
the International Chamber of Commerce (ICC), counterfeiting will cost businesses 
between US$500 million to US$700 million annually. Also, the Organisation for 
Economic Cooperation and Development (OECD) estimates that over 5% of global 
trade involves trade in counterfeit goods amounting to the tune of US$176 billion as of 
2007209. Along this line, Price Water House Cooper (PWC) estimates the global impact 
of counterfeit on trade and investment to reach US$650bn per annum, with product 
 
209  OECD, ‘The Economic Impact of Counterfeit’ (1998) Available http://www.oecd.org>sti>ind  
Accessed ( 27 March 2016) This report states the impact of counterfeit trade that anything can be 
counterfeited ranging from clothes , watches, food, electronics, airplanes, electronics, pharmaceuticals 
etc. Counterfeit goods are mainly produced in China, India, Philippine, turkey, USA and in Africa. The 
overall effect according to this report is total lack of product safety but the sole goal of making profit has 
made counterfeiting a global phenomenon .Equally part of the reasons attributed for counterfeit includes 
lack of proper information as to the scale of counterfeit by states, corporations in a bid to protecting 
brand names or identity. Also, countries with weak IP regulations mostly in developing economies 
allows counterfeit to thrive. 
86 
 
seizures in Europe estimated to the tune of almost €1bn210. A recent report by the ICC 
projected the global economic and social impact of counterfeit would reach $1.77 
trillion by 2015. It is equally estimated that domestic production and consumption will 
reach $370 billion to 570 billion globally211. These figures result in the increase of low-
quality products at excessive prices to unsuspecting consumers regardless of the 
dangers from its application.  
Counterfeit goods can be purchased all over the globe, as the world customs 
organisation opined in 2008 when counterfeit goods destined to 140 unsuspecting 
nations was discovered by the organisation.212 This goes to show the extent to which 
counterfeit products can be found in almost every country. It is mainly smuggled to 
avoid paying import tax and border inspection. A recent data collated by the World 
Customs Organisation shows that 65% of counterfeit shipment comes from China, 
making it two-third of global trade. This problem is not limited to Asia alone: counterfeit 
is produced in South America, Europe and Africa. In 2008 over 200 million counterfeit 
products were discovered in the European borders, and this number has increased in 
the last ten years. This goes to show that the network for trading in counterfeit is the 
largest multibillion-dollar underground investment, with a sophisticated supply chain 
amongst states. Counterfeit results in the loss of investments in both developing and 
 
210Price Waterhouse Coopers, ‘Counterfeit Goods in the UK, Who is buying what and why?’ (October 
2013) Availablehttps://www.pwc.co.uk/.../anti-counterfeiting-consumer-survey-October  (Feb 
211Global impact study International  Chamber of Commerce , ‘The Impact of Counterfeiting and Piracy;  
to reach US$1.7 Trillion by 2015 (Feb 2011) Available 
http://www.iccwbo.org/news/articles/2011/impact-of-counterfeiting-and-piracy Accessed (29 March 
2016)  This report is an update from the old OECD report on counterfeit that states the estimate of 
counterfeit as of 2008 is us$250 billion. But this study shows a up to date estimates and additional 
impact of counterfeit not specifically treated by the OECD. This report posits that counterfeit exist 
outside the framework of the law which makes the estimate challenging to identify. 
212 World custom organisation detection of counterfeit product destined to 140 nations 
87 
 
developed economies; it provides cheap alternatives for ignorant and helpless 
consumers with little or no knowledge of the quality of the counterfeit product. 
Grossman and Shapiro have examined the economic effect of counterfeit by using a 
two-country model (Deceptive Counterfeit). The model suggests that it is not unusual 
for multinational firms, to produce low-quality generic products as well as imitate brand 
name domestic products. This, in turn, affects a consumer’s ability to differentiate from 
the original product213. The fundamental inference drawn from this model is that the 
outcome of counterfeit creates the problem of imperfect information and imperfect 
intellectual property right. This model equally highlights some rational economic 
expectations of counterfeiting, such as it creates an additional avenue for import, and 
raises the price of generic products. Counterfeiting also harms consumers of brand 
name products, and it can alter the cost and quality of goods.  
On a similar note, the OECD adopted a two-phased model to determine the economic 
impact of counterfeit. By differentiating the demand and supply aspect of counterfeit, 
the OECD posits that the demand aspect of counterfeit is driven by three key factors 
namely, product quality and price, quality of consumer and institutional environment 
of the said product. Whereas the supply aspect is driven by the market forces available 
at a time, distribution network and the risk factor in perpetuating the criminal act of 
counterfeit214. Based on what has been said, both models itemized the economic 
 
213Gene .M .Grossman, Carl Shapiro,’ Counterfeit Product Trade’, NBER Working Paper No. 1876 (Also 
Reprint No. r1086)Issued in March 1986, (1988) Vol 78, No 1 American economic review, pp 59, The 
authors used a two-country model approach to determine trade in both legitimate and counterfeit 
Products .By stating that Domestic firms trademarks on products is infringed by the effect of counterfeit, 
with the use of foreign suppliers to deliver low quality products to legitimate market. The effect of this 
on unsuspecting countries with no technological know how to deal with this issue, however the authors 
describe the normative effect of counterfeit to consumers and Finally, provided a welfare analysis of 
border inspection policies on counterfeit. 
214 0ECD/ EUIPO, ‘Trade in Counterfeit and Pirated Goods, Mapping the Economic Impact’ (OECD 
Publishing, Paris 2016) This report highlights the difference between primary and secondary market, 
stating that primary market are markets where are deceived to believe that they are purchasing 
legitimate goods whereas secondary market is a market where consumers willingly purchase 
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problems of counterfeit; they rightly point out the importance of protecting IPR of 
companies, to achieve this, the legal requirement must be clearly defined. To 
effectively discuss this point, the thesis will examine the company, price, individuals, 
and government perspective on counterfeit. The rationale here is to demonstrate how 
counterfeit undermines the growth of IP in society.  
(I)Pharmaceutical Companies perspective on counterfeit- The overall economic 
impact of counterfeit on pharmaceutical companies cannot be overemphasized.  This 
is primarily due to the lack of quantitative data used to verify the scale of damage by 
counterfeit on the economy. Companies operating illegally usually do215 not disclose 
their activities or earnings to relevant government agencies for fear of prosecution. On 
the other hand, legitimate firms, especially pharmaceutical companies, obviously 
suffer a loss of revenues from royalties, sales and profit, and they also incur the 
unnecessary cost of fighting counterfeiters. This cost undermines future investment in 
research and development (R&D), thereby decreasing innovation. Manufacturers of 
pharmaceuticals invest billions of dollars in R&D, for it is the life wire of any 
pharmaceutical company, and if properly harnessed, it will be beneficial to the world, 
irrespective of class. R&D involves innovative steps such as clinical trials, regulatory 
approval, drug manufacturing, marketing, branding, which are all capital intensive and 
time-consuming (between 10- 15 years). 
The long-time frame for the development of pharmaceutical R&D can be attributed to 
the persistent discovery of new diseases that afflict the human body without end due 
 
counterfeit products having been influenced by the demand and supply aspect of trade. Counterfeit 
drives major economies of states due to the conditions as globalisation, e-commerce, post crisis revival 
of trade etc.  
215  The Global Growth of Counterfeit Trade, Available 
file:///C:/Users/ifueko/Downloads/9781461455677-c1%20(1).pdf  Accessed (10 October 2016) 
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to changing life patterns, demographics, globalisation, technological advancement 
and environmental dynamics thus necessitating increasing inquiry into the 
development of new drugs216. Equally, pharmaceutical research deals with 
experimental or theoretical work undertaken primarily to acquire new knowledge of the 
underlying foundations about observable facts, without any application or use in view 
of properties and structures will be evaluated to test hypotheses, theories and law. 
Pharmaceutical researchers focus on broad fields of general interest, with an explicit 
intention to discover a broad range of future applications217. The pharmaceutical 
industry contends that the regime of patent is not adequate to guarantee the risk factor 
involved in Pharmaceutical R&D. It compels researchers to advocate for longer terms 
of patent to have leverage over market competition and to hinder the sale of counterfeit 
drugs in the market218. 
It is essential to point out also that R&D in the pharmaceutical field encourages the 
growth of foreign direct investment (FDI). For example, in Brazil, the introduction of 
the Brazilian intellectual property law in 1996 increased the percentage of FDI from 
$4.4 billion in 1995 to $32.8 billion in 2000. IP is regarded as a ‘’hidden treasure’’ and 
a significant contributor to the growth of any company. For example, following the 
discovery of the antibiotic azithromycin by Pliva in 1980 and licensed to Pfizer, Pliva 
recorded a growth rate of over $1.5 billion by 2001219. This shows the extent IP can 
enhance the earning power of a company; its value cannot be quantified. 
 
216 Chidi Oguamanam, ‘Patent and Pharmaceutical R&D: Consolidating Private –Public Partnership 
Approach to Global Public Health Crisis,’ (2010) Vol. 13, No4 The Journal Of World Intellectual Property, 
Pp556-557 
217 Frascati Manual ‘Proposed Standard Practice For Survey’- OECD(2002): At 
Www.Oecd.Org/.../Frascatimanualproposed...Accessed  (11 August. 2014) This Manual Contains 
Definitions of Basic Concepts, Data Collection Guidelines and Classification for Compiling Statistics 
218Ibid 
219 John Reed , ‘Drug Maker Pliva Launches’ Wall Street Journal, GDR to Raises $270 Million, Available 
http://www.wsj.com/articles/sb893710917765008500 Accessed (16 October 2016) 
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The relevance of IP to the pharmaceutical industry cannot be over-emphasized; it 
protects the pharmaceutical investor’s right. But can the protection of investor’s right 
guarantee safer lifesaving drugs? It seems rather unlikely in this present circumstance 
where free trade subsists purely for financial motivation rather than global health 
needs220. In the words of Sachs, ‘’Global market force inevitably skews the direction 
of research and development towards diseases that assure the highest financial 
gains’’221. 
(II)Price motive 
Generally, counterfeit goods and pharmaceuticals are produced in countries with lax 
IP laws and weak labour standards. Weak laws allow manufacturers to trim down the 
actual price of production to make excessive profit from the sale of counterfeit goods. 
As the United Nations office on drugs and crime points out, large numbers of 
counterfeit seizures originate from China and India222. Despite laws prohibiting the 
production and sale of counterfeit pharmaceuticals, it has become a norm in recent 
times, mainly due to the price of drugs.   
The comparative prices of drugs vary from state to state, and the demand and supply 
of drugs fluctuate because of price. It is a significant public health concern that the 
primary focus of most pharmaceutical companies is profit-making not on the efficacy 
of drugs. This notion of profit is further emphasised with the sale of life-saving 
 
220Patrice Trouiller and others, ‘Drugs for Neglected Diseases: A Failure of the Market and a Public 
Health Failure,’ (2001) Vol 6, issue 11Tropical Medicine and International Health, PP 945 
221Jeffrey Sachs, ‘Helping the World’s Poorest’, (1999) Vol 14 Economist PP 17 
222United Nation Office on Drug and Crime, Counterfeit Product Available 
https://www.unodc.org/documents/data-and-analysis/tocta   (Accessed 29 March 2016) Counterfeit 
product is different from product counterfeit. Product counterfeit is a form of consumer fraud perpetuated 
by organised group activity. Usually most countries treat counterfeiting offence as a serious offence, 
which is why counterfeit is carried out in countries with lax IP laws. This research identifies the supply 
and production sites of counterfeit, indicating countries like china and India. With the annual market 
value of 2 billion per year and an annual monetary value of US$.2 billion. The growth of counterfeit in 
these countries is attributed to high productivity and low cost of production. 
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medicines for an exorbitant price for the benefit of investors. For instance, during the 
HIV/Aids223 Epidemic, the price of antiretroviral drugs varied between developed and 
developed countries. The South African HIV crisis is a perfect example of exorbitant 
drug pricing. The percentage of people living with HIV in South Africa was estimated 
to be 12.2% of the total population which amounts to 6.4 million people living with the 
virus. The new infection rate was estimated to be 500,000 in 2004, 430, 000 in 2009 
and 330, 000 by 2014224. Likewise, the United Nations Program on HIV/AIDS (UNIAID) 
estimated that by 2015 the number of people living with HIV in South Africa would be 
approximately between 6,700 000 - 7 400 000 million people225. Given this large 
number of people, obtaining medical care and Antiretroviral Drugs (ARV) (a drug that 
helps to reduce the reproduction of HIV).  
This anomaly is owing to the ridiculous price of ARV: most ARV drugs are novel and 
protected by patent, thus making them expensive and relatively of low quantity giving 
the number of people in need of it. A study by the Centre for International Health and 
Development Boston University reviewed the cost of acquiring ARV in South Africa is 
estimated at over $ 1,700 per patient in a year showing both higher input price and 
complete cost estimates226. Compare this figure to 15 years earlier when the ARV cost 
 
223 Acquired immunodeficiency syndrome (AIDS) is caused by a virus that carries RNA instead of the 
DNA, resulting in the destruction of the human immune system by the Human Immunodeficiency virus.  
The HIV virus invades the body using reverse transcriptase enzyme. HIV virus was first discovered by 
the National Institute of Health, the Harvard University and the Pasteur Institute in France. 
224 HIV Statistics South Africa – Prevalence, province, antiretroviral treatment (ART 
https://www.tbfacts.org/hiv-statistics-south-africa/ Accessed (25 August 2017) 
225UNIAIDHIV/AIDSestimate2015, South Africa, Available 
http://www.unaids.org/en/regionscountries/countries/southafrica   Assessed (25 August 2017) 
226Sydney Rosen and Lawrence Long, How Much Does It Cost to Provide Antiretroviral Therapy for 
HIV/AIDS in Africa? Health and Development Discussion Paper No. 9 October 2006 Centre for 
International Health and Development,  
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more than $10,000 per person a year, but gradually this price reduced to $350 then to 
$150 per year following the introduction of generic medicine227 . 
Generic medicine has made it possible to treat HIV at a relatively low cost for 
developing countries. It is essential to understand the impact of a generic drug on the 
general development of counterfeit. A generic medicine is seen as a reliable substitute 
to patented highly-priced drugs. A BBC report suggests that a generic drug can cost 
between 30% and 80% less than the original drug, and the generic drug market 
globally is estimated to be worth more than $225 billion. This figure might increase to 
$358 Billion if more patented drugs expire228, and this is a significant concern for 
investors. However, the issue of generic medicine will not be discussed in detail.  
Nevertheless, it is worth reiterating that the price of a drug is linked to the business 
commitment of investors, which is profit, and this can create an enabling environment 
for the growth of counterfeit drugs. 
III. State/ individual economic perspective- From the discussions above, it can be 
inferred that the most important economic task of pharmaceuticals companies is profit 
maximization, given this goal, is there a social responsibility on states to deliver 
innovative drugs to its ailing population? According to Milton Friedman, the primary 
role of a state is the provision of defence, protection of citizen’s rights and the 
establishment of a viable economy by enforcing contracts and free trade229. Based on 
 
227 United Nation Development Programme UNDP, World AIDS Day: record drop in cost of HIV 
treatment. Nov 30, 2015, Available 
http://www.undp.org/content/undp/en/home/presscenter/articles/2015/11/30/world-aids-day-
record-drop-in-cost-of-hiv-treatment.html Accessed (25 August 2017) 
228 James Brumley, ‘What’s the Real Impact of Generic Drugs? Expiring patents hurt market share for 
big Pharma Names,’ Investors Place Feature Writer June 28, 2012, Available 
http://investorplace.com/2012/06/whats-the-real-impact-of-generic-drugs/#.WaFj77pFzIUAccessed 
(26 July 2017)  
229 Milton Friedman The Role of Government in Education (1955) 
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this last function, a State’ government plays a crucial role in the sale and distribution 
of drugs.  
In pursuit of this goal of a viable economy, a state can intervene in different instances. 
For example, a state can set standards, policies, goals for the regulation of 
pharmaceuticals within its territory. However, the high fixed cost of pharmaceuticals 
may undermine potential government control, but it cannot obstruct a states directive 
on drugs. This cost needs to be balanced against the societal needs for new drugs; 
this can only be achieved by state involvement in the pricing and rationing of drugs230. 
Given the complex market structure of pharmaceuticals, state or government 
involvement is essential for the pharmaceutical market to function effectively.  
The responsibilities of states provided by the WTO include the following: 
• The provision of licensing, examination of premises, registration of drugs, 
control of marketing and independent drug information. 
• Policies on professional licensing standards for pharmacists, doctors and other 
health professionals and the establishment of codes of conduct 
• Ensure access to pharmaceuticals by subsidizing essential drugs for the poor 
through public health service  
• Rationalizing the use of the drug for the public231 
Given the above responsibilities, it seems that the primary function of a national 
government is to ensure access to health care, including essential drugs. Government 
is to ensure the eradication of counterfeit pharmaceuticals from the entire population. 
 
230 Richard G. Frank, ‘Government Commitment and Regulation of Prescription Drugs, Health Affairs’ 
Vol.22 No. 3, (2003) PP 46 
231 Sara Bennett, Jonathan D. Quick and German Velasquez, ‘Public –Private Roles in the 




It is rather disturbing to imagine a state without formal government policies on drugs. 
Such a situation will stimulate the growth of counterfeit drugs. In conclusion, this 
section examined the economic instances for the sudden increase of counterfeit drugs 
from a hike in price, to the need to make a profit and preserve research and 
development by pharmaceutical firms. 
2.3.3 Human right and social aspects of counterfeit Pharmaceutical 
 
‘’The evil of fake drugs is worse than the combined scourge of malaria, HIV/Aids, 
armed robbery and illicit drugs’’ Dora Akunyili (2002) 
Ever since the inception of the pharmaceutical industry, it has been known for integrity 
and good organization, but more recently, it has been plagued by different institutional 
and non-institutional dynamics such as the patentability of drugs, TRIPS flexibilities, 
accessibility and counterfeit pharmaceuticals. The problem of counterfeit 
pharmaceuticals knows no border, and it involves people from different continents, 
particularly the developing and least developed countries. The key objective of this 
section is to create a benchmark on the human and social aspects of counterfeit drugs 
on people, which is the access to medicine issue. The next section will discuss briefly 
the impact of counterfeit medicines in Nigeria to develop a framework for solving the 
problem. Before considering the different arguments on drugs, it is important to 
examine the history of pharmaceuticals in a bid to discover their fundamental nature 
and correlation to man.  
Medicine is regarded as a substance that has a physiological effect when ingested or 
otherwise introduced into the body. However, it is worth knowing that there is a clear 
delimitation between medicine and pharmaceuticals, as the latter relates to the 
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manufacture and sale of medicines232whilst relying on IP rights and market 
agreement. The system created by the pharmaceutical industry spurred innovation 
and productivity for investors, but it relied mainly on cost control measures for survival. 
In the words of Cockburn, ‘’Drug development in today’s new institutional 
arrangements could turn out to be faster and better, but not cheaper’’ 233 which 
inadvertently restricts accessibility to life-saving drugs for the treatment of infectious 
diseases such as HIV, Tuberculosis, malaria and Ebola234 with patients in developing 
countries who cannot afford to pay for the needed drug.  For example, during the Ebola 
epidemic in Liberia, Guinea, Sierra Leone and Nigeria235 thousands of lives were lost 
to the virus, the question was not about patent, IP protection or brand name but the 
availability of drugs. The method of getting drugs does not matter to a sick person in 
a developing country, but the availability of anything that can bring aid.  
The focus of developing countries like Nigeria is getting affordable drugs into its supply 
chain. This can introduce the element of counterfeit pharmaceuticals into the system 
because access to medicine is more important than the protection of IP rights. 
Counterfeit is a global problem; while there might be uncertainty about its true scope. 
WTO estimates that over half of the drugs in developing countries are counterfeit. 
Some scholars argue that counterfeit is primarily an auxiliary from intellectual property. 
 
232Pharmaceutical." Merriam-Webster.com. Merriam-Webster, n.d. Web 19 June 2017.A 
pharmaceutical can be in different form, can be a drug, ointment, prescription drug, tonic, tablet, 
portion, palliative and syringe etc. 
233 Iain M. Cockburn, ‘The Changing Structure of the Pharmaceutical Industry,’ (2004) Vol. 23 No 1, 
Health Affairs PP 10 
234 Lawrence O Gostin, Daniel Lucey and Alexander Phelan, ‘The Ebola Epidemic: A Global Health 
Emergency’. (2014) Vol.312(11), Jama, pp.1095.The Ebola virus is carried by Fruit bats likely to infect 
the human body by close contact with the body fluid such as bush meat, pigs, and other animals. 
Symptoms are similar to the symptoms of malaria and typhoid fever—as well as endemic haemorrhagic 
fevers such as Lassa—rendering symptomatic differential diagnosis difficult. 
235 Lawrence O. Gostin, Eric A. Friedman, ‘Ebola a Crisis in Global Health Leadership,’ (2014) Vol. 384, 
The Lancet PP 1323 
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IP not only increased the price of an innovative drug but also aggravated the problems 
of counterfeit drugs. Accessibility is a pervasive problem given the considerable 
margins between the market price of drugs, R&D cost and issues of patent 
infringement. All these facilitate the growth of counterfeit pharmaceuticals. 
Underlying motivations 
The problem of counterfeit pharmaceuticals remains a significant challenge for states, 
particularly in Africa. Inadequate medicines and other public health issues affect 
people’s health in developing countries. There is hardly any comprehensive data to 
quantify the scale of counterfeit. The reporting system in most countries is weak, with 
no freedom of the press in most jurisdictions. Even when there is freedom of the press, 
gaps exist in the decimation of information between the developed and developing 
countries. Equally, on the reach of counterfeit pharmaceuticals, Hyeonho points out 
that the health risk of counterfeit pharmaceuticals is numerous. For example, the 
discovery of a lethal amount of melanin in baby formula and the sale of 
pharmaceuticals with little or no active ingredients236. 
The danger of counterfeit Pharmaceuticals is particularly severe in Africa, although it 
is difficult to estimate the extent of counterfeit due to the non-availability of reliable 
data from states. However, data from national governments in Africa, police seizures 
and sample data collected from the international organisation will be used to develop 
the body of evidence on counterfeit drugs in Africa. The WHO estimates that 10 
percent of drugs sold globally are counterfeit237 and out of this 10%, 30% is drugs sold 
 
236 Elizabeth G.Denis ‘Crackdown on Counterfeiting’  International Standard Organisation (Jan 2014), 
Available http://www.iso.org/iso/news.htm?refid=ref1809  Accessed (30 March 2016)  
237 BBC NEWS, ‘Counterfeit Drugs ‘May Kill You or cause Superbugs ’  September 2013  Available 
http://www.bbc.co.uk/news/health-24270737  Accessed (16 May 2016) 
97 
 
in Africa, from this estimate shows that 50 % of the total drugs produced globally is 
sold and consumed in Africa. 
The Nigerian Government, on the other hand, is confronted with the major task of 
providing essential medicine and proper health facilities for its citizens despite the 
prevalence of counterfeit medicine. Counterfeit remains a great issue to the Nigerian 
government, and it may appear most pharmaceuticals in Nigeria is fake, substandard 
or counterfeit238. The menace of counterfeit pharmaceuticals in Nigeria can be traced 
from 1985 to 2000, and the situation has not changed to date239. It is imperative to 
examine the drug situation in Nigeria, starting from the pharmaceutical market.  
The Nigerian pharmaceutical market is estimated to be worth more than US$600 
million as of 2009. It is expected to grow significantly at around 12 per cent yearly to 
reach US$ 717 million in 2011, but recent figures indicate that the Nigerian pharma 
market can rise as much as 9% a year over the next ten years reaching $3.6 billion by 
2026 making it, one of the largest pharmaceutical markets in Africa240. However, most 
of these pharmaceutical products are imported, despite the Nigerian Government best 
efforts to promote domestic production of pharmaceuticals. According to Okoli out of 
the 130 existing Pharmaceutical companies in Nigeria, only 60 are inactive 
manufacturing despite the installed capacity estimated to produce 50% to 70% of the 
total drug needed in Nigeria. This means that the capacity utilization of pharmaceutical 
companies is below 30%241.   
 
238Ohuabunwa, M,’ Health Care Delivery in Nigeria, Past Present and the Future, (2002)   Vol.31’ 
Nigerian Journal of Pharmacy pp15-17 
239W.O. Erhun, O. O. Babalola, M.O. Erhun, Drug regulation and control in Nigeria: The Challenge of 
Counterfeit drugs, (2001) Vol.4, Issue 2. Journal of Health and Population in Developing Countries pp 
23 
240 McKinsey and Company, Tainai Holt, Laura Millroy, Matthews Mmopi, Wining in Nigeria; Pharma’s 
next frontier 
241 S Okoli, ‘Pharma Industry in Distress’ (2000) Vol22 Issue 3 Pharma News pp 1 
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Equally, the delivery of an essential drug in Nigeria is chaotic; drugs are sold 
everywhere from sale in the open market, sales in patent medicine stores, wholesalers 
and pharmaceutical manufacturers. There is no proper mechanism in place to make 
checks and balances of the inflow of drugs in the health sector in Nigeria. It is a 
common occurrence to see a public display of drugs in the market and motor parks, 
without proper consideration of the weather condition that enables the breakdown of 
the active ingredient in the drug.242  From the above facts, it is evident that the Nigerian 
public health care system is poorly organised and mismanaged. It is so disheartening 
that the WHO in the year 2000, ranked the Nigerian health care system as 187 out of 
191, which is extremely low compared to other countries. At the same time, the 
mortality rate at birth for an average Nigerian is estimated at 46 years for males and 
47 years for females, compared to Ghana and South Africa whose life expectance is 
estimated to be about 55 and 50 years243. However, it is worth reiterating that access 
to the right medicine will address public health issues in Nigeria significantly. 
2.3.4 Legal Aspect to counterfeit Pharmaceutical  
Counterfeit pharmaceuticals lead to therapeutic failure and ultimately, death. It 
demoralizes public trust in the health care system of a state. To guarantee public 
health, states penalise acts that are deemed illegal to the proper distribution of 
pharmaceuticals. The legal aspect of counterfeit pharmaceuticals will be the 
requirement mandated by law for the production, protection, distribution and sale of 
pharmaceutical products. The black’s law dictionary defined a counterfeit drug ‘as a 
drug made by a person other than the genuine manufacturer, by copying or imitating 
 
242Adelusi Adeluyi, ‘Drug Distribution: Challenges and Effects on the Nigerian Society,’ Keynote 
speaker at the 73rd Annual National Conference of the Pharmaceutical Society of Nigeria, November 
2000 
243 WHO Mortality Fact Sheet 2006 
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an original product without authority or right with a view to deceiving or defrauding and 
marketing the forged drug as the original’. This definition highlights specific legal flaws, 
for example, intention to deceive (Fraud), the act of copying (imitation), without 
authority (intellectual property right). Existing laws of states can penalise these acts 
locally and internationally. 
 The law will only penalise an offender if a breach has occurred, and it can be 
established within the law as a breach. Counterfeit pharmaceutical is the breach of IP 
rights, rights which accrue to the owner of the creation of the mind. This right ensures 
that the right holder is empowered to deal with it to the exemption of all others after it 
has been recognised as a right by the state.   Countries set out rules and procedures 
for regulating infringement of IP right244 by both civil and criminal proceedings. The 
penalties for counterfeit vary from country to country. Generally, brand owners can 
sue counterfeiters in a civil court for damages and injunctions, and the government 
can sue counterfeiters in a criminal court. The penalties include fines and 
imprisonment. For example, in Nigeria protection of IP right is found within the patent 
and design Act of 1970245 and Nigeria is also a signatory to other international 
conventions that advocate for IP, such as WIPO, and Paris Convention etc. Once the 
right has been granted, nobody can deal with it or use it for any commercial purpose. 
In case of infringement, section 25 of the Patents and Designs Act 197 provides for 
remedies of damages, account and injunction with Federal High Court retains 
exclusive jurisdiction to entertain such matters.  
 
244 Margot E. Kaminski, ‘An Overview and the Evolution of the Anti-Counterfeiting Trade Agreement.’ 
PIJIP Research Paper no. 17, (2011) American University Washington College of Law, Washington, 
DC 
245Patents and Designs Act of 1970. Cap 344 of Laws of the Federation of Nigeria 1990 
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One of the international agreements Nigeria ratified is the WTO- TRIPS agreement 
whose framework advocates for free trade. It creates safeguards for the affordability 
and availability of pharmaceuticals246, which include parallel imports and compulsory 
licence. Given this safeguard, does IP right include the removal of protection with the 
prevalence of counterfeit? One dispute is the interpretation of legal provisions within 
the WTO-TRIPS. To ensure clarity on this subject, Lyons argues that law as it is or as 
it ought to be are two different concepts. A legal provision is typically ambiguous or 
inconsistent; problems will arise if a complex term such as the definition of counterfeit 
pharmaceutical interferes with the specific mandate of TRIPs law247. TRIPs set out 
standards, guidelines for regulating pharmaceuticals, and there is an assumption that 
states ratify these standards for the regulation of counterfeit drugs. However, if TRIPS 
law is too old to define what counterfeit is or how to prosecute or curtail it, it means 
the problem of counterfeit has grown more than the WTO and law. So how is the law 
applied in this instance, if the WTO has no adequate legal machinery to protect IP 
rights and pharmaceuticals?  
For clarity, this thesis will briefly assess some sections (Article 41 & 61) of the WTO-
TRIPS Agreement to highlight certain ambiguities in the law. Article 41( 1)- ‘’States 
Members shall ensure that enforcement procedures as specified in this Part are 
available under their law to permit effective action against any act of infringement of 
intellectual property rights covered by this Agreement, including expeditious remedies 
to prevent infringements and remedies which constitute a deterrent to further 
 
246 Umar Abubakar Dubagari ‘An Appraisal of Nigeria’s Membership and Participation in the World 
Trade Organisation (WTO), (2016} Volume 21, Issue 7,) IOSR Journal Of Humanities And Social 
Science (IOSR-JHSS) PP 56-65 
247 David Lyons, Moral Aspect of Legal Theory; Essay on law, Justice and Political Responsibility 
(Cambridge University Press, 1993) 
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infringements.  These procedures shall be applied in such a manner as to avoid the 
creation of barriers to legitimate trade and to provide for safeguards against their 
abuse’’. 
Comment- Article 41 deals with all the provisions of Part III and as such affects Article 
41- Article 61. This clause provides that the procedures shall be applied to avoid “. 
Creation of barriers to legitimate trade and to provide for safeguards against their 
abuse," which is very ambiguous especially in the context of Articles 41-61. 
 There are some flaws in these articles: what constitutes legitimate trade is not defined 
and is therefore left to individual members own local laws as set out in paragraph 5 
below. This leads to a lack of uniformity in which what is legitimate trade in one 
member country may be deemed illegitimate in another. To circumvent the provisions, 
a member must make laws to fit the activities that are unfavourable into the unlawful 
classification. Although there is a provision to safeguard against the abuse of such 
provisions, it is hard to determine what an abuse of the process would be. Suppose a 
party lays claims to violation of the requirements, in that case, it will be difficult to 
determine or justify why that party is entitled to the same right legally in a member 
state, and it is illegal in another.  
2- ‘’Procedures concerning the enforcement of intellectual property rights shall be fair 
and equitable.  They shall not be unnecessarily complicated or costly, or entail 
unreasonable time-limits or unwarranted delays.’’ 
Comments- 
a) The provisions requiring fairness and equity in enforcement comes with an 




i. It only guarantees protection as much as the jurisdiction or member within 
which a dispute arises. Building on the points in paragraph 1 above and 
bearing in mind the effects of paragraph 5 below, the complexity and cost 
aspects would be invariably different between members.  
ii. The complexity issues mentioned would be made more pronounced given 
the conduct is illegal in one member state or at least carries a severe 
penalty like a hefty fine or imprisonment or light penalty, however in other 
states this illegal activity may be acceptable.  
iii. Since in paragraph 5 below it is made explicitly clear that there is no 
obligation to adopt or provide a different legal regime for Intellectual 
Property to that of local laws, the speed of the enforcement process will 
differ significantly.  
 Section 3 ‘’Decisions on the merits of a case shall preferably be in writing and 
reasoned. They shall be made available at least to the parties to the proceeding 
without undue delay.  Decisions on the merits of a case shall be based only on 
evidence in respect of which parties were offered the opportunity to be heard’’. 
Comment- 
b) The provision that decisions on the merits of a case should "preferably" be in writing 
with reasons is a very wide loophole for members to pick the preferable option 
which might not necessarily be just. This means decisions on the eligibility of a 
person to bring a claim can be made orally and the claim dismissed for lack of merit 
if the panel members prefer to take such a stand. This automatically shuts the 
doors for a just system as it is open to abuse and defeats the stated aims in 
paragraph 1 above of preventing abuse of the enforcement process. 
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4. ‘’Parties to a proceeding shall have an opportunity for review by a judicial 
authority of final administrative decisions and, subject to jurisdictional provisions in a 
Member's law concerning the importance of a case, of at least the legal aspects of 
initial judicial decisions on the merits of a case.  However, there shall be no obligation 
to provide an opportunity for review of acquittals in criminal cases’’. 
Comment- 
c) The provision of a right to review by a judicial authority is not an explicit right to 
appeal. Furthermore, such a review becomes more complicated if the decision not 
to pursue a case or that a claim is without merit was made orally and no reasons 
or next to none is given. There is also no obligation to restore a claim even if the 
review makes a finding that there was a case to answer, in essence, it would be 
more like a post-mortem as opposed to part of the process of enforcement, 
depending on what the member concerned determines. 
5. ‘’It is understood that this Part does not create any obligation to put in place a 
judicial system for the enforcement of intellectual property rights distinct from that for 
the enforcement of the law in general, nor does it affect the capacity of Members to 
enforce their law in general.  Nothing in this Part creates any obligation concerning the 
distribution of resources as between enforcement of intellectual property rights and 
the enforcement of the law in general.’’ 
d) This is the most important damaging clause to focus on when assessing Article 41. 
As mentioned in all the paragraphs above, it is not a binding process and is subject 
to manipulation by individual members. It is also subject to the strength and 
weaknesses of member judicial systems.  
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Article 61- ‘’Members shall provide for criminal procedures and penalties to be applied 
at least in cases of wilful trademark counterfeiting or copyright piracy on a commercial 
scale.  Remedies available shall include imprisonment and monetary fines enough to 
provide a deterrent, consistently with the level of penalties applied for crimes of a 
corresponding gravity.  In some cases, remedies available shall also include the 
seizure, forfeiture and destruction of the infringing goods and of any materials and 
implements the predominant use of which has been in the commission of the 
offence.  Members may provide for criminal procedures and penalties to be applied in 
other cases of infringement of intellectual property rights, where they are committed 
wilfully and on a commercial scale.’’ 
Comments: -There is a provision therefor criminal sanctions, including imprisonment 
and or fines. Such remedies could be given “...in cases of wilful trademark 
counterfeiting or copyright piracy on a commercial scale.” However, given the 
loopholes in Article 41 that allows members to adopt different standards of justice 
suitable to their respective jurisdictions then it risks individuals being imprisoned for 
conduct within one jurisdiction in which they would otherwise be fined for in another.  
The definitions of (1) Wilful trademark counterfeiting and (2) Copyright piracy on a 
commercial scale will both have to be looked at within individual jurisdictions. Also, it 
is worth noting that the remedies “shall” be provided for, which is an obligatory term. 
But the provision (as worded) is made as an alternative provision of (1) or (2) above 
which means a member can choose to make such remedies available for one and not 
the other. So, after scaling the hurdles of definition, then a party seeking remedy must 
contend with which provision is provided for in a jurisdiction whether (1) or (2). There 
will inevitably be severe inconsistencies across jurisdictions regarding definitions and 
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provisions for remedies between members, and as such, there is a lack of uniformity 
in the process. Justice must be uniform; otherwise, it will be deemed unequal. 
Section B 
2.4 Dealing with the definitional question of counterfeit Pharmaceutical 
 
Attaining a workable interpretation of counterfeit pharmaceutical, consist of any law, 
treaty and policy which must essentially work towards the goal of a regulating standard 
within the economic, social, legal and technical framework not just about law or 
business, but all aspects are unified in one all-encompassing definition. From what 
has been gathered previously, to attain a viable definition of counterfeit, the concepts 
must necessarily cohabit towards achieving a specific goal: various institutions can 
work to accomplish a common goal, which is a clear definition of counterfeit 
pharmaceutical instead of using the wrong alternative or connotation. Counterfeit is 
not a standard that should be met, but what is perceived as wrong within the various 
institutions. Therefore, it is the responsibility of the state to protect the owners of the 
property right through legal means. A state should protect, promote and implement all 
human rights. 
2.4‘Counterfeit pharmaceuticals'- A Legal framework for trade 
Regulation.' 
 
This section reviews the legal framework for regulating counterfeit pharmaceuticals, 
which will be able to provide for access to medicine, investors rights whilst advocating 
for a practical and effecting law, enactment, and decree to control counterfeit. This 
framework is needed to establish a persuasive national regulatory authority to ensure 
the production, use and access to pharmaceuticals is effective and uniform nationally. 
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In this context, emphasises will be placed on the Nigerian legal system for guidance 
on its substantive and the procedural rule of law on pharmaceuticals. 
Nationally, various laws and policies exist in Nigeria for the regulation and control of 
drugs248, each of which plays a specific function depending on the legal responsibility 
of each institution. The Law on drugs must be unambiguous and comprehensive, 
clearly stating the manufacturer, drugs, invention, process, product, consumers, and 
rights. For example, who is the manufacturer and is his licence to manufacture valid 
within a particular jurisdiction, as well as what right accrues to the IP right holder.   
The role of law is to establish national drug policies, regulatory bodies, courts, and 
enforcement mechanisms to continually enforce the law. Some of the pharmaceuticals 
policies and laws in Nigeria include: 
• Drugs and related products Decree 19 (1993) 
• Poisons and Pharmacy Act Cap 535 LFN 1990 
• Food and Drug Act Cap 10 LFN 1990 
• National Drug Law Enforcement Agency Cap 253 LFN 190 
• Patent and Proprietary Medicine Vendor License 
• Consumer Protection Council Decree No. 66 of 1992  
•  Trade Malpractices (Miscellaneous Offenses Decree No. 67 of 1992)  
• Counterfeit and Fake Drugs Miscellaneous Provisions Act (Cap 73, Law 
of the Federation, 1990)  
• Counterfeit and Fake Drugs and Unwholesome Processed Foods 
(Miscellaneous Decree 25 of 1999) 6Essential Drug list 
• Drug Revolving Fund 
 
248 Olusegun Akinyandenu, ‘Counterfeit Drugs in Nigeria: A Threat to Public Health,’ (2013)  Vol.7 
Issue 36 African Journal of Pharmacy and Pharmacology, PP 2571 
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• National Health Insurance Scheme 
• National Primary Health Care 
• HIV/AIDS Emergency Action Plan- 2001 
• National Antiretroviral Programme -2001249 
• National Agency For food and Drug Administration and Control 
(NAFDAC) 
These policies are an enactment of government legislation on drugs to promote 
access to a safe, effective and affordable non-counterfeit drug250. To enhance 
uniformity, a new framework should be developed by parties involved in the sale and 
manufacturer of pharmaceuticals, such as industry, lawyers, scientists, pharmacists, 
medical practitioners, government agencies and economists 251. It is crucial not to 
interpret legal provisions narrowly, so doing will undermine compliance to legal rules, 
hence creating a viable environment for counterfeit drugs to thrive. 
2.5.1 Intellectual Property Rights 
 
 IP rights are also necessary within the legal framework of trade in counterfeit, both at 
the national and international level. At the international level, rules for the protection 
of IP can be found in the Berne Convention for the protection of literary and artistic 
work, the Paris Convention for the protection of industrial property, the WIPO Patent 
Law Treaty, WIPO Corporation Treaty and the WTO-TRIPS Agreement. This research 
core emphasis will be the WTO-TRIPS, this agreement provides for the administrative, 
 
249 Kristin Peterson and Olatubosun Obileye, ‘Access to Drugs For HIV/AIDS and Related 
Opportunistic Infections in Nigeria,’ A status report on the socio-political , economic and policy climate 
on drug availability for people living in with HIV/AIDS and recommendation for future access, Policy 
Project Nigeria Available http://pdf.usaids.gov/pdf_docs/pnacr139.pdf Access  (30 August 2017)  
250 National Drug Policy, Federal Ministry of Health in Collaboration with the WHO 2005 Available 
http://pdf.usaid.gov/pdf_docs/pnacr139.pdf  Accessed (30 August 2017)  
251 Ransome O. Kuti, ‘National Drug Policy in Nigeria,’ (1992) Vol.13, No 3 Journal of Public Health 
policy PP 367 
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criminal and civil enforcement measures of IP rights whilst preventing trade in 
counterfeit.  
One of the rights protected by TRIPS is the prevention of use by a third party without 
the consent of the right holder. If infringed, the right holder can obtain an injunction to 
restrict usage, and damages in the form of compensation can be awarded. Also, there 
will be payment of pre-established damage by the infringer and the destruction of 
infringing goods. A Member state is duty-bound to implement procedures and 
penalties in the case of wilful counterfeiting, which must include penalties such as 
imprisonment and fines252. 
As a signatory to the TRIPS Agreement, Nigeria is duty-bound to comply with all the 
provisions of the agreement, including standards on IPR by being a member of the 
WTO. Given the fact that Nigeria is a developing country, the TRIP agreement 
stipulates that, by 2000, Nigeria ought to bring its National IP laws in line with TRIPS 
standards. Such standard includes changing its existing IP (patent) rules to fit the 
TRIPS requirement. A typical example of this is the extension of Patent life span to 20 
years for new pharmaceutical products and processes. The inclusion of patent 
protection within the WTO rules monopolised drugs, and it escalated the issue of 
access to drugs and introduced counterfeit Pharmaceuticals253.   
The standards of TRIPs on pharmaceuticals include the availability of protection for 
products and processes for new innovative drugs, security and availability of the 
patented drug at a national level. To mitigate any negative impact of patent protection, 
TRIPS made provisions for public health safeguards, in the Doha Declaration 
 
252Peggy E. Chaudhry and Michael G. Walsh, ‘An Assessment of the Impact of Counterfeiting in 
International Markets: A Piracy Paradox Persists,’ (1996) , Vol 31(3)  Columbia Journal of  World 
Business PP 34 
253 P. Boulet  and others ‘Pharmaceuticals and the WTO Agreement, Question and Answer’ , March 




permitting members to take measures to protect public health. The measures include 
compulsory licence, parallel importation and extension of the Transition period for 
Least –Developed Countries (LDC).  On the other hand, the pharmaceutical industry 
argues against TRIP safeguards, especially against Compulsory licence, saying it will 
have a devastating consequence on patent and may reduce the incentive on future 
R& D254 and lead to a cultural change255 if the standard of TRIPS is adopted entirely. 
However, the question remains how does counterfeit not become counterfeit, having 
established these laws and policies? In the face of this question, if counterfeit 
pharmaceutical is to be used, it should correlate with stated purpose within a Legal 
framework because the law is known to manage relationships whilst still maintain 
social order. In conclusion, counterfeit is a significant issue, which needs particular 
attention both at a national and state level. Although TRIPS has created standards, it 
is evident that the agreement places more value on public safety and access than on 
IPR as seen in the Doha declaration.  
 
2.5.2 Economic Rights 
 
The previous sections examined the protection of investor rights; the cost of 
production, price and the overall economic implication of counterfeit. This part is going 
to test the relationship between the legal institution of trade and economic rights to 
pharmaceuticals. It has been established that the pharmaceutical industry thrives on 
the right to patent, which is a legal right for protection against counterfeit. Therefore, 
 
254WHO- Essential Medicine and Health Product, ‘The Doha Declaration on the TRIPS Agreement 
and Public Health’ Available http://www.who.int/medicine/areas/policy/doha_declaration/en/ Access 
(31 August 2017) 
255 Ellen ‘T Hoen ,’TRIPS , Pharmaceutical Patent and Access to Essential Medicine Settle, Doha and 




the rights of a pharmaceutical investor will be discussed to determine if, the right is 
excessive or disproportionate. The right of an investor according to the OECD can be 
protected by a stable legal and regulatory framework domestically or internationally, 
which must be adequate, transparent and predictable to withstand changing conditions 
of trade, for example, counterfeit pharmaceuticals.  
Pharmaceutical Investors can recoup the cost of production by IPR protection; it is a 
valuable component for any investor; it is the keystone of the pharmaceutical industry.  
IP can be used to protect new inventive steps, R&D, promotion etc. which is all capital 
intensive and cumbersome. Scholars such as Lincoln posit that ‘the patent system 
fuels the interest to the fire of genius256, it ensures strong market position, exclusivity, 
licencing and positive image. Therefore, obtaining IPR is a strategic necessity for 
firms. For this work, emphasis will be placed on the WTO Law. The first issue to be 
tested with the WTO standard is the price of pharmaceuticals. The cost of 
pharmaceuticals determines the development, market value and availability of drugs. 
Price control is purely within the prerogative of drug companies, even though this right 
is authorized by the rule of government and international law. From previous 
definitions of IP, states have the prerogative to grant the right to IP and regulate how 
this right will be exercised. It may seem that there is a disparity in who is controlling 
what especially with regards to pricing. This issue transcends the contingent quality of 
pharmaceutical products.  
The second issue to be tested is the responsibility of states to ensure the right to safe 
drugs at a national level with its policies, institutions and rules. It is the primary 
responsibility of a state to provide access to safe medicine within its jurisdiction by 
 
256 Gerald J. Mossinghoff and Thomas Bombelles, ‘Intellectual Property Protection and the 
Pharmaceutical Industry’ (1996) Vol. 31, Issue 1 Columbia Journal of World Business PP 33 
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passing TRIPS flexibilities into legislation. States can equally amend measures on 
import duties on drugs, ensure equal opportunity of drug distribution in a bid to 
attaining the highest standard of health. 
 
  
2.5.3 Technological Right 
 
The legal framework of trade includes laws, code, policies, legislation which provide 
standards for the protection of property right. To ensure security, the WTO made 
provision in Article 7 for the enforcement of IP rights, such right ‘’shall contribute to the 
promotion of technological innovation, dissemination of technology, to the advantage 
of the producer which is beneficial to social and economic needs and the stability of 
right and obligation‘’257. The need to balance rights and infringement of IP within the 
all-encompassing scope of the WTO invariably undermines the regulation of 
counterfeit pharmaceuticals within WTO-TRIPS law. The TRIPS rule on technology 
ought to address health policy, product safety, access and the quality of drugs safety 
standards. If a drug does not meet the quality standard proposed by the WTO-TRIPS 
law, does it mean it is counterfeit? A useful measure on drugs should give a specific 
meaning first, instead of the different connotations proffered this includes fake, 
substandard, imitation, and counterfeit drug. 
 
 Conclusion 
The purpose of this chapter is to unravel the unique form of counterfeit, by identifying 
the different phases and implications of counterfeit, more so the complex contribution 
 
257 WTO TRIPS-Issue on Technology Transfer, Available 
http://www.wto.org/english/tratop_e/trips_e/techtransfer_e.htm Accessed (2 September 2017) 
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of liberalisation and globalisation to the growth of counterfeit pharmaceuticals seems 
to influence the perception of counterfeit globally. For example, it introduced the 
concept of free trade to reduce border control which increased the movement of goods 
and services across nations, including counterfeit pharmaceuticals. 
Also, this section emphasized, the impact of globalisation on the surge of 
counterfeiting. It introduced the element of technology, which improved the production 
and distribution of counterfeit, thus making the original product similar to reverse 
engineering. Visibly, the negative side of globalisation usually out weights the positive 
effect. However, with the same technology, counterfeits can be detected using 
holograms, and the use of forensic technology will make it difficult for counterfeit drugs 
to enter the market. 
Another important issue discussed above is the definitional question; there is no 
definite meaning to it? Different institutions, states, scholars have given diverse 
meanings to counterfeit to fit their various organisational needs. For instance, the 
economist perceives counterfeit as product imitation, passing off, deceptive, whereas 
a legal expert believes counterfeit as a crime of defrauding, altering, falsification which 
is punishable within the law. In comparison, the human rights aspect perceives 
counterfeit from the public health purview, given access to medicine problems in 
developing countries. The confusion from these terms indicates that the problem 
cannot be solved if there is no harmonization amongst all stakeholders. Counterfeit 
results in loss of investments in both developing and developed economies; it provides 
a cheap alternative for ignorant and helpless consumers with little or no knowledge of 






Chapter 3 The WTO-TRIPS Agreement and Regulation of 
Counterfeit Pharmaceuticals  
Section A  
3.1 The TRIPS Agreement  
 
The fundamental principle of the TRIPS agreement's will be discussed starting with 
the linkage between the General Agreement on Trade and Tariff/World Trade 
Organization (GATT/WTO). Without these two interrelated trade instruments, there will 
be no TRIPS agreement. The WTO came into existence on 1 January 1995. Part of 
the deal negotiated by the contracting parties to GATT.124 countries signed this 
multilateral agreement to supersede the GATT that came into existence in 1948. The 
WTO agreement is essentially the constitution for world trade. In principle, it is an 
embodiment of rules, procedures, laws for regulating international and national trade 
amongst ratifying states 258and considered the new GATT259. 
The WTO agreement is formed from the principles pre-negotiated at the General 
Agreement on Tariff and Trade (GATT)260. It is designed to boost international trade 
by eliminating unnecessary quotas, tariffs, and states' subsidies. The WTO is a typical 
example of a free trade agreement (FTA); FTAs significantly impact the liberalization 
 
258 Member states to the WTO are now 164. The countries include Afghanistan, Albania, Armenia, the 
united kingdom, the united states of America, France, Germany, Belgium, Poland, India, Brazil, Demark, 
South Africa, Mali, Togo, Nigeria, Algeria, Italy, Netherlands, Australia, Holland, Finland, Fiji, Guyana, 
Gambia, Gabon, China, Jamaica, Japan, Jordan, Liberia, Luxembourg, Latvia, Malta, Morocco, 
Mongolia, Mexico, Norway, Namibia, Oman, Pakistan, Panama, Peru, Philippines, Quarter, Rwanda, 
Russia, Romania, Sierra Leone, Slovenia, Sri Lanka, Sweden Etc.  
259 Adrian Otten' The TRIPS negotiations: An overview' Page 55 in 'The Making of the TRIPS Agreement 
Personal insights from the Uruguay Round negotiations' Edited by Jayashree Watal and Antony 
Taubman 
Available  https://www.wto.org/english/res_e/booksp_e/trips_agree_e/chapter_3_e.pdf Accessed (19 
November 2018) 
260 23-member countries signed GATT. It's an offshoot from the International Trade Agreement. It came 
into force on 30 June 1948, with the sole aim of tariff reduction 
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of trade261. The effect of this reduction increased world economic growth, making 
GATT/WTO one of the most successful international organizations262. 
 
The creation of a robust WTO was not surprising. Despite the hopes of the GATT of 
the immediate post War era, and notwithstanding the various rounds of trade talks 
conducted under its umbrella and authority, the GATT failed to effectively check the 
rise and abuse of a myriad of Non-Tariff Measures (NTM) that had come to replace 
tariff barriers. The new trade barriers were primarily regulations, such as dumping 
orders and subsidies that distorted international trade. These practices were 
particularly problematic for developing country members of the GATT. Moreover, the 
GATT did not have a robust enforcement mechanism. Neither did GATT members 
predict the changing nature of the global economy and changing comparative 
advantage. Therefore, the GATT did not cover trade in services and intellectual 
property's impact on international trade. Subramanian and Wei contend that GATT 
promotes unevenly reciprocal liberalization of business by allowing developed 
countries to have leverage over developing countries, by exempting the former from 
trade obligations263, thereby encouraging protectionism. 
 
It was these gaps in the trading system that necessitated the negotiation and creation 
of the WTO- a global trade organization. The WTO Agreement is more in tune with the 
currents of globalization, the demand for open markets via heightened trade 
 
261 Omiunu, Ohiocheoya, Ohio. "Is there any Coherence on the Role of Sub-National Actors in the 
Evolving Mechanisms for International Trade Interactions? A Comparative Analysis of Belgium and 
Canada." (2016) 
262 Judith L Goldstein, Douglas Rivers, and Michael Tommz, 'Institutions in International Relations: 
Understanding the Effect of GATT on World Trade,' (2007) 61(1),) International Organization pp.37 
263 Arvind Subramanian & Shang-Jin Wei 'The WTO Promotes Trade, Strongly But Unevenly,' 2007 vol. 




liberalization, and an organization that responded to shifts in the global economy, new 
comparative advantage in the emerging field of trade in services strides in intellectual 
property. Therefore, the WTO agreement emerged as a complex legal text covering a 
wide range of rules, procedures, and fundamental principles of trade in a multilateral 
system. Some of these guiding principles include non-discrimination, reciprocity, 
transparency, and special and differential treatment. The WTO is classified as a 
negotiating forum, liberalization forum, legalization forum, and dispute settlement 
forum. Therefore, as a prelude to my thesis's core, the WTO rules on intellectual 
property, emergence, and the principle will be discussed below. 
 
3.1.1 WTO as a Product of Negotiation 
 
As noted earlier, the WTO agreement is a product of negotiation within the GATT 
Agreement. Approximately seven rounds created a unique all-encompassing 
multilateral agreement. The main content of the WTO agreement comes from the 
Uruguay negotiation from1986-1994. Still, the other rounds include tariffs reduction, 
the Kennedy round (anti-dumping), and the Tokyo round, which is equally significant. 
These negotiations helped liberalize trade, reduce protectionism, non-tariff barriers, 
protect least developed countries, and now liberalize trade-in service and protect 
Intellectual Property. 
Table 1. GATT and WTO Negotiating Rounds of Multilateral Trade GATT trade rounds 
Year Place/name Subjects covered Countries 
1947 Geneva Tariffs 23 
1949 Annecy Tariffs 13 
1951 Torquay Tariffs 38 
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Tariffs, non-tariff measures, rules, 
services, intellectual property, dispute 
settlement, textiles, agriculture, creation 
of WTO, etc. 
123 
264 
The Geneva talks of 1947 are the first round of negotiations within the GATT 
framework. It is a significant determinant of the successes of GATT in the reduction of 
trade barriers globally. Before this reduction, protectionism was the norm, given the 
fact that states had stiff tariff measures, tight import quotas, and state control of the 
foreign exchange. Thus, protectionism in high tariffs and import quotas stifled the 
growth and expansion of global trade265. Twenty-three states met to negotiate tariff 
reduction; Bown and Irwin estimate the average tariff in 1947 to be around 40% with 
GATT reducing tariff to an average of 22% for industrialized states over the years, 
which had a minimal impact on trade, especially for non-GATT members. It is 
 
264Source - The GATT years: from Havana to Marrakesh 
https://www.wto.org/english/thewto_e/whatis_e/tif_e/fact4_e.htm?sid=qSjyTN 
265 The GATT years: from Havana to Marrakesh, 
Available https://www.wto.org/english/thewto_e/whatis_e/tif_e/fact4_e.htm#rounds Accessed 
(November 01, 2018) 
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important to note that figure might not be accurate owing to the lack of credible official 
data on the average tariff quotas of states266. To further reduce trade tariffs, from 1949- 
1964, four trade rounds, namely Annecy, Torquay, Geneva, and Geneva Dillon 
Rounds, were concluded by state members in GATT. 
 
The general justification for the progressive revision of GATT rules has always been 
to avoid making them obsolete. Thus, the members have consistently identified key 
areas that needed to be strengthened to prepare GATT for new ventures or 
circumstances. Such recent events include the involvement of developing and L.D.C. 
in rules-making and I.P. The dramatic expansion of GATT began with the Tokyo round 
of trade talks. Whether this round was successful or not is subject to debate, it 
demonstrated GATT's ability to go beyond traditional measures in a bid to protect 
trade.  
The GATT needed to expand its scope and deepen its rules with the expansion of 
developing country membership and the increasing power of the European Union (now 
bargaining as a single entity). Therefore, the Tokyo round of 1973-1979 is needed. 
This round lasted for five years, with very tough issues put forward for dialogue such 
as international trade rules on dumping, and the anti-dumping codes of governments, 
eliminating the delay of import licenses, government procurement, restructuring the 
current trading system to facilitate granting trade preferences to developing countries, 
rules on resolving disputes, etc.267 The Tokyo round created a framework for 
 
266 Chad P Bown and Douglas A. Irwin, 'The GATTs Starting Point, Tariff Levels' Circa 1947, World 
Bank Development and Research Group and International Integration Team April 2016, policy research 
working Papers 7649 
267 GATT Doc. MTN/26fRev 2 (April 11, 1979) reported that delegations representing 
twenty-two nations had drawn up "comprehensive records" of their reciprocal tariff commitments and 
that these delegations had undertaken to conclude their tariff negotiations by June 30. These twenty-
two countries were Australia, Austria, Bulgaria, Canada, Czechoslovakia, the E.E.C. Nine, Finland, 
Hungary, Japan, New Zealand, Norway, Sweden, Switzerland, and the United States 
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improving international trade, with particular importance to differential, special, and 
favourable treatment to developing countries in feasible aspects of a universally 
accepted trade mechanism268. It revised the anti-dumping rules to include the length 
of the investigation, set price for export/import, the imposition of anti-dumping duties, 
and the type of injury. It also introduced six codes of non-tariff measure binding on 
ratifying members. Despite this round's significant success, it was not detailed enough 
to accommodate new market opportunities based on the liberalization of trade in 
service, trade-in I.P., etc. The apparent failure of intellectual property, the early 
initiatives, did suggest the possibility of a trade institution expanding its reach to 
encompass issues tangentially related to trade in goods. Thus, the Tokyo round laid 
the groundwork for the GATT as a body to regulate counterfeiting.  
The world trade is altered by the Uruguay Round when the international economy 
struggled due to recession and uncertainty. It led to the creation of the W.T.O., an 
organization with a distinctive trade structure not found in other agreements such as 
the dispute settlement system for the resolution of trade disputes amongst member 
states269. Secondly, the agreement made provision for the development of new trade 
areas, thereby expanding the GATT agreement's scope to include trade-in service and 
intellectual property. Thirdly, the number of participating members of the developing 
and L.D.C. continued to increase, giving these members an increasingly influential 
voice in decision making. By this means, it restored confidence in the multilateral 
trading system of the GATT agreement. 
 
 
268 Thomas R Graham, "Reforming the international trading system: the Tokyo Round trade negotiations 
in the final stage" (1979) Vol 12 Issue 1 Cornell International Law Journal, pp.1-42.  
269Winham R Gibert (ed), An Interpretative History of the Uruguay Negotiations, in The World Trade 
Organisation: Legal, Economic and Political Analysis (Patrick F.J Macrory, Arthur E. Appleton, Michael 




3.1.2 Trade Forum 
 
Trade is the act of buying and selling goods and services, whereas a forum is the 
exchange of ideas or views on trade. Therefore, the WTO is a trade forum based on 
the following reasons. The WTO is a multilateral agreement that provides a framework 
for trade in goods and services and intellectual property. It is a comprehensive legal 
text covering agriculture, telecommunication, textile, clothing, banking, food 
regulation, pharmaceuticals, industrial standards, and intellectual property for its 
member country270. The WTO covers most aspects of trade with the sole purpose of 
ensuring a free, fair, and foreseeable trade environment for the benefit of all 
members271. 
The current Director-General of the WTO, Roberto Azevêdo, has painted a picture that 
affirms the WTO's impact as a trade creating and trade facilitating international 
organization. In the World trade statistical review, he notes that the WTO maintains 
and enhances economic development and the reduction of poverty. The estimates 
currently available are on the back of the WTO World merchandise export have 
increased by 32% since 2006 to 64%, reaching $16 trillion in 2016. The bulk of this 
growth has been in the manufacturing and agricultural sectors of the World Economic, 
which increased from 37% to 67%272. 
The WTO also adopted the Trade Facilitation Agreement (TFA) to boost trade by 
restructuring export and import, custom measures and speeding up the flow of goods 
and services across member state borders. It is anticipated that the TFA could 
 
270 WTO- Principles of a trading system 
Available,https://www.wto.org/english/thewto_e/whatis_e/tif_e/fact2_e.htm Accessed (24 October 
2018) 
271 Rose, Andrew K. 'Do we really know that the WTO increases trade' (200) Review 94.1 
4): American Economic 98-114. 
272 World Trade Statistical Review 2017, 




increase overall trade by 2.7% while at the same time reducing the financial cost 
associated with trade by 14.3%, thus boosting business by $1 trillion a year. This 
agreement ensures special and differential treatment for developing and Least 
Developing Countries (LDC). Such treatment includes early warning mechanisms, 
expert groups, shifts between categories, and grace periods to improve the global flow 
of goods. For example, in Nigeria, the TFA helped the Nigerian customs service 
modernize its information system to a single platform to lodge standardized documents 
at a single entry point for all exports and imports in the country273. 
The GATT/WTO also acts as a trade catalyst for productivity and growth by granting 
member states some economic benefits. For example, the WTO imposes less 
stringent conditions on trade by promoting free trade, unlike what is obtained when 
protectionism, non-tariff barriers, industrial policies, and subsidies designed to 
encourage industrial development lead to economic stagnation. Advocates for free 
trade argue that eliminating trade barriers will increase economic growth, decrease 
preferential policies, abolish tariffs, and reduce government interference in trade. 
However, it is worth mentioning that it did, to a certain extent, looking at the growth of 
export and import rate from 1970 to 2016. 
 
Table 2. World export of goods and services  
 
273 It allows the Nigerian custom to operate in a line of international best practices, with a short waiting 





This data put together by the World Bank indicates a steady growth of world export, 
mostly because of free trading rules proffered by the WTO directed at the rapid 
industrialization of member states, particularly the developing and least developed 
countries. Although this data shows growth, one would wonder at what expense this 
growth is achieved. Economic scholars like Chang speculate that free trade generates 
a perverse outcome that induces the demand for dependency, such as the evolution 
of poor working conditions, slavery, outsourcing of jobs, working below the minimum 
wage, and economic and environmental275 damage. In his view," free trade hurts the 
developing countries, as it imposes on them neo-liberal macroeconomic policies that 
hamper their ability to invest in its economies and create jobs" 276. Therefore, the drive 
 
274World Bank national accounts data, and OECD National Accounts data files   Available 
https://data.worldbank.org/indicator/NE.TRD.GNFS.ZS Accessed (26 October 2018) 
275 Werner, Antweiler, Brian R. Copeland, and M. Scott Taylor "Is Free Trade Good for the Environment? 
(2001) Vol 91, issue 4, American Economic Review 877. This paper analyses the effect of openness of 
the market to the increase of pollution in the Environment using a theoretical model on the impact on 
pollution by grouping it into scale, composition and then examine this theory using data on sulphur 
dioxide concentrations from the Global Environment Monitoring Project. 
276 Ha-Joon Chang, Bad Samaritans: The Myth of Free Trade and the Secret History of Capitalism. 
(Bloomsbury Publishing USA, 2010) 
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towards free trade as spearheaded by the WTO has its advantages, but a more critical 
standpoint exposes its flaws: the developing countries have not developed. Instead, 
they are duty-bound by WTO trade policies, rules, and regulations. Developing 
countries are compelled to encounter developed countries in an arena that does not 
accommodate their interests and aspirations.277  
Another benefit of the WTO is that it operates a transparent trade policy for member 
states government using notifications to inform other member states and the WTO of 
new systems, laws, and measures278. This policy's primary rationale is to regularly 
monitor trade practices to increase transparency and understanding between states. 
It will also periodically assess the effect of multilateral trade policies on the world 
trading system, and as a result, improve the quality of intergovernmental debate. This 
practice steers the unification of trade policies and considers the economic and 
developmental policies of states (Developing/LDC), but this notification is not without 





3.1.3 Forum of International Rules   
 
Pacta sunt servanda is a fundamental principle of international law that stresses that 
states comply with international obligations, and this tenet applies to WTO law. It is an 
 
277 Frank Garcia, (2007) "Is Free Trade "Free"? Is It Even "Trade"? Oppression and Consent in 
Hemispheric Trade Agreements," Seattle Journal for Social Justice: Vol. 5: Issue. 2, pp.505-532. 
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essential legal principle that states are bound to comply with treaty obligations for 
ratifying to it279; Breach of a state's international obligation opens it up to sanctions 
permitted by law. More precisely, this rule has its foundation from the rule of 
law propounded by Grotius in his words, "rules transcend national borders, and they 
are significant to international law." Law will only be obeyed if it is certain that the world 
will be chaotic without laws. On this note, the WTO is formed as a legal entity made 
up of rules, rights can sue, be sued, and obligations, which is binding on member 
states for the regulation of international trade. To determine the status of the WTO, 
Article VIII provides that as follows: 
1. The WTO shall have a legal personality and shall be accorded by each of its 
Members such legal capacity as necessary for the exercise of its functions.  
2. The WTO shall be accorded by each of its Members such privileges and immunities 
as are essential for the exercise of its functions.  
3. The officials of the WTO and the representatives of the Members shall similarly be 
accorded by each of its Members such privileges and immunities as are necessary for 
the independent exercise of their functions in connection with the WTO.  
 4. The privileges and immunities to be accorded by a Member to the WTO, its officials, 
and the representatives of its Members shall be similar to the rights and immunities 
stipulated in the Convention on the Privileges and Immunities of the Specialized 
Agencies, approved by the General Assembly of the United Nations on 21 November 
1947280.  
 
279 Tarcisio Gazzini, 'The Legal Nature of WTO Obligations and the Consequences of their Violation, 
European 2006 Volume 17, Issue 4, Journal of International Law, Pages 
723, https://doi.org/10.1093/ejil/chl024 
280 WTO Analytical Index WTO Agreement – Article VIII (Practice) 
Available https://www.wto.org/english/res_e/publications_e/ai17_e/wto_agree_art8_oth.pdfAccessed 




This means WTO has its own legal identity in international trade, for it is the first 
agreement with a viable framework on trade. The WTO differs from its predecessor, 
the GATT, for it recognized and gave legal status to states by regarding them 
as member states instead of contracting parties. It provided member states protection 
against unfair trade practices and the ability to carry out trade without interference. To 
solidify its status as a truly international organization, the WTO member, therefore, 
constitutes it as a body of legal order to govern its member states' activities. The WTO 
is an integrated and distinctive legal order that governs the actions of member states.  
 
Forum for the Settlement of dispute  
 
The WTO has a significant organ for resolving trade disputes and maintains the ‘rule 
of law’ amongst state members to the WTO. This vital forum is what distinguishes the 
WTO from its predecessor, the GATT agreement. Although the GATT agreement had 
a provision for Dispute Settlement Understanding (DSU), whose rules provided for 
consultation instead of adjudication, and this provision is found in Article XXII and XXIII 
of GATT 1947, which states inter alia  
 ‘’Each contracting party shall accord sympathetic consideration to, and shall afford 
adequate opportunity for consultation regarding, such representations as may be 
made by another contracting party concerning any matter affecting the operation of 
this Agreement and reach a satisfactory solution’’281. 
This provision mandated member states to make the consultation a means of resolving 
disputes, and Article XXIII on nullification and impairment required contracting parties 
to investigate and make an appropriate ruling if there is no agreeable adjustment. 
 
281 Article XXII Consultation, 
Available https://www.wto.org/english/res_e/publications_e/ai17_e/gatt1994_art23_gatt47.p
df Accessed (16 October 2018) 
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Alternatively, in severe circumstances, parties can act, retaliate or suspend the 
application, make concessions if applicable, and parties have the right to withdraw 
from agreements pending due notice. This provision underlined some institutional 
shortcomings of the GATT agreement. For instance, Amin emphasizes that the GATT 
DSU is generally weak as it had no deadlines for the institution of claims, nor does it 
have a viable process to institute claims282, and the most worrisome is the lack of a 
binding legal ruling, interpretative issues, and ambiguity 283making way for a more 
legal and proficient DSU within the WTO.  
The newly reformed DSU under the WTO is unique, for it is an embodiment of binding 
rules and regulations for the settlement of a dispute. It is structured in an orderly 
manner to reduce trade conflict amongst member states. Additionally, the DSU under 
the WTO handles difficult and more technical issues. Moreover, the structural defects 
such as delays and the right to block the adoption of panel reports have firmed up the 
WTO DSU in comparison to its GATT predecessor284. Under the WTO, the 
adjudication system is thought to be the most useful 285for it preserves right over 
might.286 Statically, the prominence of the DSU is remarkable, for it is used frequently 
by a member state for the settlement of a dispute. For instance, the number of 
consultation requests by member states increased from 1995 to 2016, with over 350 
 
282 Amir Alavi, ‘African Countries and the WTO Dispute Settlement Mechanism’ 2007 Vol 25(1) 
Development Policy Review, PP 25-42 
283 John H. Jackson, ‘The World Trading System,’ (1990) Volume 14, Issue 1 Fordham International 
Law Journal  
284 Evaluation of the WTO Dispute Settlement System: Result to date 
available  https://www.wto.org/english/tratop_e/dispu_e/disp_settlement_cbt_e/c12s2p1_e.htm Acces
sed (18 October 2018). 
285 R E Hudec, The Adequacy of WTO Dispute Settlement Remedies: A Developing Country 
Perspective” in Development, Trade, and the WTO: (Hoekman, B., Mattoo, A., English, Ped (2002). 
286 Julio Lacarte-Muró and Petina Gappah, ‘Developing Countries and the WTO Legal and Dispute 
Settlement System: A View from the Bench.’ (2000) Vol 3 issue 3 Journal of International Economic 
Law, pp.395-401.  
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dispute settlement decisions and over 573 287consultation requests288. This trend has 
continued upwards and is thus a big leap from what is previously obtained in the GATT 
Agreement. 
The newly restructured DSU is recognised; it is deemed to be less political and more 
legally oriented. Developing countries quickly utilized it by initiating more disputes to 
protect their market rights. However, observers of the WTO have pointed out various 
shortcomings of the DSU to include the fact that it is technical and complex for 
developing countries' development. Busch and Reinhardt approached this issue by 
suggesting that the number of concessions developing countries retain within the WTO 
could affect getting a favourable trade policy289 without fear of trade retaliation. The 
DSU is problematic in developing countries lacking the appropriate legal capacity 
during proceedings, unlike their developed counterparts. This gap remains 
unresolved, given the vast inequality existing between the former and the latter. 
Busch and Reinhardt also posit that the gap between developing and developing 
countries created a breach in the legal capability to bring an action before the Dispute 
Settlement system290, for example, the cost factor. To prepare, file proceedings, an 
experienced workforce such as staff, diplomats, economic experts, and an outstanding 
legal team needs to be assembled to have a viable case, but it is an unlikely situation 
for Developing and LDC who lack this resource. These problems subsist until now, 
 
287 Arie Reich, The effectiveness of the WTO dispute settlement system:A statistical analysis. 
Transnational Commercial and consumer Law, (Springer:Singapore, 2018) 
288 Evaluation of the WTO Dispute Settlement System: Result to date available Statistics: the first 
eight years of 
experience, https://www.wto.org/english/tratop_e/dispu_e/disp_settlement_cbt_e/c12s2p1_e.htmAcce
ssed (18 October 2018). 
289 Marc L. Busch & Eric Reinhardt ‘Developing Countries and General Agreement on Tariffs and 
trade/world Trade Organization Dispute Settlement.’ (2003) Vol 37 issue (4): Journal of World Trade 
PP 719 
 
290 March L Busch and Eric Reinhardt, ’Developing Countries and GATT/WTO Dispute Settlement 
‘(2003a) Vol 37 issue (4) Journal of World Trade PP 719 
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even after various calls for a systematic re-evaluation 291of member states' legal 
capacity. This is because proceedings are lengthy and complicated, comprising new 
and old legal obligations uprooted from the GATT, trade rounds, and previous 
decisions that are binding on all members as a single integrated undertaking. 
In conclusion, the shift from being an international trade entity under GATT to a 
renowned legal regime, backed by a viable dispute settlement mechanism, not only 
increased participation but made trade easier for fear of prosecution. Its legality is 
unique, but where do developing countries with limited legal resources fit into this 
system. 
 
3.1.4 Innovation and TRIPs Agreement 
 
This section discusses the reasons for protecting intellectual property and why a 
specialized agreement WTO /TRIPS is created within the WTO to deal with issues 
relating to IPR. The factors that influence the creation of IPR, such as product, 
competition, market availability, research, and development, are examined. The role 
of IPR within different industries, particularly the pharmaceutical industry, and the legal 
characteristics for the protection of IPR, will be analysed to determine if IP ensures 
legitimate protection for creativity or just a mere economic tool proliferated by 
multinational corporations. The previous chapter discussed the historical development 
of IPR, but this section will start by describing the meaning of innovation and creativity 
that apportion strict ownership to a potential invention.  
 
 
291 Marc L. Busch, Eric Reinhardt, and Gregory Shaffer, ‘Does Legal Capacity Matter? Explaining 
Patterns of Protectionism in the Shadow of WTO Litigation’ (2008) 
Available https://pdfs.semanticscholar.org/318b/da42b9b060372795c8b9428511296bda704c.pdf  




All innovation starts from a concept, enabling new ideas such as improvement of 
quality or quantity. It can also be a technological or scientific process to such an extent 
that a right accrues from it. IP preserves the proprietor's right of inventors by turning it 
into income, and it gives complete control to sales, marketing, and packaging. IP 
confers dignity and authority to an inventive step. However, Merge is sceptical about 
this all-encompassing right, as it may restrict free and open access to viable 
knowledge. Therefore, he advocates establishing boundaries or legal constraints to 
manage IP within a specific perimeter292. 
IP confers a right on creators, thus making it a right to IP. Such right comprises patents, 
copyright, trademark, trade secret, and industrial design. This protection's moral 
justification encourages innovation and prevents third parties from exploiting the 
benefit accrued from it293. This right is not automatic: WIPO states that an invention 
must meet several criteria for it to be eligible for protection. For example, patent, which 
is a core IP issue, requires that for a subject matter to be patentable, it must be new 
or novel, must be industrially applicable, must show sufficient inventive step towards 
its creation, and must meet the required standards laid down by statute294. 
 
Fundamentally, novelty can be determined by examination, and it must be undisputed. 
Also, the requirement for an inventive step refers to the question as to whether the 
invention "would have been obvious to a person having ordinary skill in the art" 295. It 
 
292 Robert Merges, Justifying Intellectual Property, (Harvard University Press: London,2011) This author 
discusses the issues relating to IP by emphasizing the importance of IP to producers, but is a skeptic 
on the freedom of access to knowledge but argues that IP should be based on some ethical foundation, 
firstly he traced the IP through the philosophy of Kant, Hegel, Locke, and issues of distributive justice 
and concluded that IP rights are indispensable right of a functioning society. 
293 European Patent Office, About Patent, Available www.epo.org/patent/grant-procedure/about-
patent.html Accessed (09 November 2018) 
294 World Intellectual Property Organisation (WIPO), WIPO Intellectual Property Handbook:  
'Policy, Law and Use' Available www.wipo.int/export/sites/www/about-ip/en/iprm/pdf/ch2.pdf Accessed 
(09 November 2018) 
295 IBID WIPO 
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is a difficult test to prove, but it can be determined by a thorough examination to 
warrant protection. However, certain subject matters are excluded from being 
patentable to preserve morality, or it is deemed unsuitable for the protection of public 
health, animal or plant life, the environment, and micro-organism. The next 
unpatentable subject matter includes diagnostic, therapeutic, and surgical treatment 
of humans and animals. The production of plants and animals using non-biological 
and microbiological processes296 . 
Undoubtedly, IP plays a vital role in the growth of the world economy, as knowledge 
obtained from technology increases revenue for firms and government; it allows 
competition between industries based on superior quality and price297, which is 
different from what is previously obtained, before the advent of technology. 
Competition yields more innovative products and drives prices, both of which benefit 
the consumer as hitherto expensive goods are now within reach. Also, goods can 
perform the task more efficiently. In the words of Cottier, "the absence of sufficient 
protection for IP creates an unfair competitive trade environment, especially for 
industries operating in a foreign environment" 298. IPR is a powerful tool for growth in 
invention, investment, innovation, and employment and needs to be protected. This is 
essential because it creates jobs, enables competition as well as protects consumers 
and investors. IP is relevant in all sectors of the economy, such as agriculture, 
education, medicine, entertainment, pharmaceutical, and culture. The list is endless. 
 
 
296 Article 27 (2) WTO-TRIPS agreement, an example of a biological process not patentable, is 
conventional animal breeding, such as tissue culture, gene creation from plants, and unethical scientific 
processes. 
297 Bart Verspagen,' Intellectual Property Right in World Economy,' Paper for the WIPO Arab Regional 
Symposium on the Economic Importance of Intellectual Property Rights, Muscat, Sultanate of Oman, 
February 22-24, 1999 Available http://meritbbs.unimaas.nl/verspagen.html Accessed (09 November 
2018) 
298 Thomas Cottier, 'The Prospects for Intellectual Property in GATT,' (1991) Vol 28 Common Market 
Law Review, pp385 
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Critics of IP oppose this submission, bearing on the fact that the impact of IP depends 
on states' developmental advantage. The higher the level of development, the more 
robust IP would be to its growth. For example, developed countries recorded an 
increase in growth via IP protection, unlike their developing and LDC counterparts, 
where providing more robust IP protection would cripple its local industries299 and 
'' may cause wasteful duplication of investment in R&D" 300. Also, in support of this 
point, stricter IP will give a sole monopoly to Multinational industries with the right 
technological capacities to the detriment of developing countries and LDCs. It is one 
of the arguments upheld by countries like India, South Africa, Brazil.  
To Keith Makus, IP is a vital asset with economic value and recognized ownership 
right backed by law to control the idea301 solely. Some known benefits to the IP creator 
include access to novel markets, income generation302, and dynamic competition. 
Besides, it leads to the advancement of technological knowledge and permissible right 
of distribution and protection. As noted, the need to have more excellent protection of 
IP became necessary since it enhances innovation. After examining 100 firms in the 
USA, scholars like Mansfield suggest that if not for IP protection, inventions would not 




299 Elhanan Helpman, 'Innovation, Imitation, and Intellectual Property Rights' (1993) Vol.61 No 6, 
Econometrica, pp. 1247 Argues that the North invents new technology and the South imitates them. 
Stating that the protection of IPR hurts developing/LDC resulting in imitation in order to meet up with 
the status of goods even if such imitation might be unbeneficial to its economy  
300 Maskus, Keith Eugene, Intellectual Property Rights in the Global Economy (Peterson Institute, 2000) 
301 IBID 
302Saha, Chandra Nath & Sanjib Bhattacharya' Intellectual property rights: An overview and implications 
in the pharmaceutical industry' (2011) Vol. 2 issues, 2): Journal of Advanced Pharmaceutical 
Technology & Research 88  
303 Edwin Mansfield, 'Patent and Innovation: An Empirical Study' (1986) Vol 32 issue 2 Management 
Science PP 173 
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IPR can be credited for the surge in the global pharmaceutical industry, predominantly 
in the area of medical research. It costs around $750 million and between 12-15years 
of clinical trials to develop, market, and sell a single drug. Strong protection will enable 
firms to recoup research and development costs and make good returns on 
investment. Thus, obtaining a legal document to protect the general public's invention 
is wise, with a minimum term of 20 years from the date of application. This requirement 
applies in both Developing and LDCs for product and process. Although, before the 
advent of the WTO-TRIPS Agreement, states only provided patent protection for a 
process (method, technology, or chemical composition or steps), not the product (the 
finished drug) for fear of imitation through the process of reverse engineering. The 
protection of the process enabled manufacturers to produce a generic version of the 
original, giving the transitional period provided by the WTO-TRIPS304. However, once 
the patent right expires, companies are free to create generic versions of the actual 
product without investing in R&D; this medium increased the manufacturing of generic 
drugs globally, accounting for over $5billion in drug sales annually305.  
The need to safeguard valuable economic growth necessitated policymakers to 
negotiate and institutionalize laws and policies to regulate changing circumstances of 
trade to conform to modern realities and harmonize the rules of IP. The establishment 
of a rule-based system in the WTO-TRIPS Agreement sets a minimum standard for 
the regulation of IPR, and it gives IP legal status. TRIPS standard defined the subject 
matter; it protected and allowed permissible exceptions. It set a minimum duration for 
protection for member states of the TRIPS agreement by the substantive obligation 
 
304 WTO -Essential medicine and Health Product, Available 
http://www.who.int/medicines/areas/policy/wto_trips/en/ Accessed ( 13 November 2019) 
305Lara J. Glasgow, ‘Stretching the Limits of Intellectual Property Rights: Has the Pharmaceutical 
Industry Gone too far?’ (2001) Vol 41 Number 2 The Journal of Law and Technology, PP 227 
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provided in the Paris Convention, for the protection of industrial property ( Paris 
convention), the Berne Convention for the protection of literary and artistic work( Berne 
Convention)306, the World Intellectual Property Organisation (WIPO)307.  
In order words, the TRIPs agreement is known as the Berne and Paris-plus 
agreement308. Amongst these stated agreements, TRIPs is considered the most 
successful for it combined provisions from Berne, WIPO, and Paris Agreement and 
added a new mechanism for the regulation of IP, such as the dispute settlement 
mechanism, parallel imports, national treatment, Doha declaration, and other 
necessary TRIP flexibilities. With this new mandate, the WTO/TRIPS agreement 
enjoyed widespread acceptance and domestic compliance from states. Therefore, to 
fully understand the purpose of the TRIPs agreement, it is pertinent to examine the 
objective of creating the TRIPs Agreement that allowed TRIPs to enjoy widespread 
ratification and domestic compliance by member states. 
  
3.1.5 Post TRIPs Era  
Negotiation on Trade-related aspects of intellectual property was initiated in the Punta 
Del Este Declaration of 1986, which resulted in the legal framework of a multilateral 
agreement within the WTO known as the TRIPs agreement. The name Trade-related 
aspect of IPR suggests to policymakers and negotiators that a link truly exists between 
 
306Berne Convention for the Protection of Literary and Artistic Works, 
Availablehttp://www.wipo.int/treaties/en/ip/berne/ Access (15 November 2018) ,The Berne Convention, 
adopted in 1886, ensures the protection of the right and work of authors such as poets, painters, 
musicians, and authors  etc. By providing minimum protection to regulate, control, who use of the 
creation 
307 Convention Establishing the World Intellectual Property Organisation (WIPO) Available 
http://www.wipo.int/treaties/en/convention/ Accessed (15 November 2018) 
308 The provision relating to the Paris Convention and to the Berne Convention is found in Articles 2.1 
and 9.1 of the TRIPS Agreement, the Agreement adds additional obligations on pre-existing issues 
previous conventions were inefficient or silent on. 
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Trade and IP. Practically, global industries recognized that intellectual property 
protection stems from innovation, creation, and invention and guarantees continual 
competitiveness in world trade. However, before the implementation of the TRIPs 
agreement, various arguments, both positive and negative, arose amongst negotiating 
member states, such as GATT’s vague IP provision, the political ideology of states 
members, the involvement of non-state actors, the original mandate of the 
negotiations, trade-off and linkage with other essential areas of negotiations, needs of 
developing state members and finally the legal status of previous IP organization 
(WIPO). 
I. Vague IP provision in GATT agreement: The GATT agreement provided a 
multilateral framework for trade in goods. It is regarded as all-encompassing 
and unique, for it allowed several modifications to its framework to fit new trade 
regimes for 47 years. The GATT agreement modified several critical aspects in 
its provisions, such as providing trade and development, national treatment, 
most favourable nation’s policy. However, the provision on IP the GATT was 
deemed vague and needed amendment in the Uruguay round of negotiations. 
The discrepancy stemmed from earlier international agreements before GATT. 
For example, the patent provision in the Paris Convention granted a short 
length of time for patent protection, although it ought to be longer to ensure that 
right holders benefit from creation. Most of these conventions failed to provide 
minimum protection for IPR; neither did they stop counterfeit or piracy. 
However, the GATT agreement recognized the critical link between trade and 




‘’IV. The products of the territory of any member state imported into the territory 
of any other contracting party shall be accorded treatment which is not less 
favourable than that accorded  to like products of national origin in respect of 
all laws, regulations and requirements affecting their internal sale, offering for 
sale, purchase, transportation, distribution or use.’’309 
Also, in Article XX: (d): GATT General Exceptions to secure compliance with 
laws or regulations which are not inconsistent with the provisions of this 
Agreement, relating to patent protection, trademarks, copyright and the 
prevention of deceptive practices310. 
GATT 1947 provided the basic rules of the trading system, but it lacked standards311. 
What is the point of having an IP rule that undermines what it aims to protect? Besides, 
the IP rule did not enforce the obligation on members for breach of its rules. In the 
GATT agreement, the enforcement mechanism allows parties to seek remedies in 
domestic courts, unlike what is obtained in the TRIPS Agreement312. The inadequacy 
of a viable enforcement and dispute settlement mechanism within GATT made GATT 
an inadequate IP forum 
 
II. On the issues of non-state actors, the private sector consisting of industries, 
firms, and banks313 canvassed for IP protection on the negotiating agenda 
given the potential value of IP.In the operation of global trade, especially the 
 
309 THE GENERAL AGREEMENT ON TARIFFS AND TRADE   ("GATT 1947") Available   
http://www.worldtradelaw.net/uragreements/gatt.pdf.download Accessed (22 November 2018) 
310 Ibid  
311 Huala Adolf, ‘Trade-Related Aspect of Intellectual Property Rights and Developing Countries, The 
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United States private sector, which campaigned for a more robust IP regime 
different from what is obtained in the GATT agreement, in a bid to get maximum 
profit from IP related goods. The Uruguay round created an avenue for greater 
protection by increasing negotiation. It develops a comprehensive agreement 
to address inadequate IP regime that upholds the growth of imitation, 
counterfeit, and piracy, constituting severe loss to domestic and local IP based 
industries. Given the resources used for research and the development of new 
ideas, getting a financial reward for R&D will stimulate the expansion and 
growth of new technologies. As counterfeit increases, it becomes more 
problematic to regain economic returns on innovative products, which will deter 
innovation. However, a contrary view of the innovation theories is, that IP rights 
may be used for profit to control the entire market rather than the protection of 
innovation. 
III. During the negotiation in the Uruguay round, developing / LDC opposed having 
a more robust IP regime. It would deter the growth of local industries, and it 
would merge corporate ownership of ideas, increasing the technological gap 
between the north and south314. A more robust IP will discourage the prospect 
of future development on these stated grounds developing, and LDCs refused 
to negotiate. Nevertheless, the proposed agreement did not permit member 
states to choose; it is one complete agreement. Developed /LDC realized it 
would be impossible to negotiate the draft agreement without losing out on the 
TRIPS agreement's potential benefit. Such benefit includes increased access 
to the agricultural and textile market, having a reputable dispute settlement 
 
314 Carolyn Deere, The Implementation Game, The TRIPS Agreement and the Global Politics of 
Intellectual Property Reform in Developing Countries (Oxford University Press, England,2009) 
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mechanism. At the time of negotiation, developing countries exported mostly 
textiles and agricultural products; it is unlikely that IP would benefit their 
economy. Nevertheless, IP advocates, particularly the developed states, argue 
that adequate protection will stimulate local and international industries315. The 
developed countries demand excess protection far beyond what TRIPs initially 
offered, which ignores the unique economic, medical, and developmental 
needs of Developing/LDC. This made developing states vulnerable to the new 
IP standards and had to amend, update, interpret existing rules, guidelines, and 
laws on IP. The administration and enforcement mechanism needed re-
organization to reflect the TRIP’s standard despite the social and financial 
challenges in these countries.  
 
3.1.6 The Basic Principles of TRIPS Agreement 
 
The GATT and GATS agreements introduced the principles conveyed into the TRIPS 
agreement; this basic principle is found in article 1 of the GATT agreement provides 
for trading principles states ought to adhere to, such as the most favoured nation 
treatment, reciprocity, transparency, tariff binding and reduction316. Aiming to promote 
growth, facilitate trade, employment, and development amongst state members to the 
agreement. Each principle will be examined briefly, starting from the National 
Treatment policy found in Article 3(1) (2) of the Preamble of the WTO-TRIPs 
 
315 Carol J. Bilzi, Towards an Intellectual Property Agreement In the GATT: View from the Private 
Sector, GA., (1989) Vol 19, Issue 2 Journal of International & Comparative Law pp 343 
316 WTO- Part 1 General Provision and Basic Provisions 
Available  https://www.wto.org/english/docs_e/legal_e/27-trips_03_e.htm Accessed (28 November 
2018) 
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agreement. It provides inter alia that Member shall accord to the nationals of other 
Member states, treatment no less favourable than what it accords its nation on the 
subject of IP, by the provisions and exception found in the Paris Convention, Berne 
Convention, and the Rome Convention or the Treaty on Intellectual Property in 
Respect of Integrated Circuits.  
Members may benefit from the stated exceptions allowed within the judicial and 
administrative procedures, including the description of a place of service within the 
jurisdiction of a member state to ensure compliance to the provision of the agreement 
in order not to constitute a restriction to trade317. The language of this provision is 
straight forward although the use of the words ‘shall’ connote a future intention or 
action. In contrast, the word ‘may’ connote the existence of an obligation on member 
states to adhere to this provision. Still, the strength of this obligation cannot be 
determined if the provision made use of ‘must’ it would suggest absolute commitment 
for member states and would have reduced the power in the exceptions to this rule. 
The next provision is the most favoured nation treatment found in Article 4, which 
sums up as any privilege, favour, immunity on IP granted to members of a nation must 
be accorded immediately without conditions or prejudice to nationals of other 
Member’s states. By the international agreement for the protection of IP in existence 
before the establishment of TRIPs, neither should it constitute arbitrary or unjustifiable 
discrimination against nationals of other states Member of TRIPs. One reason for 
inserting this provision in the TRIPs Agreement is to prevent discriminatory trade 
practices such as offering a better IP deal to nationals of one state and not according 
to similar reciprocal treatment to other state members, thereby undermining the 
 
317J.H Reichmann, ‘Universal Minimum Standards of Intellectual Property Protection Under the TRIPs 




international IP system. But this provision is limited in scope for it only regulates some 
form of IP, for example, patent, copyright, trademark, industrial design, geographical 
indication, Trade secret, and integrated circuit design whilst omitting other key 
neighbouring rights protected by the Rome Convention and the international 
convention for the protection of performance318.  
The basic principle of the TRIPs agreement is not all-encompassing, theoretically strict 
adherence to this principle is narrow, for practical usage is not guaranteed amongst 
member states in securing a predictable trading environment. Equally, the framework 
of the WTO –TRIPS allow for basic exceptions and restrictions, which connotes 
different interpretations to fit a circumstance, for example, developing countries 
applied quantitative restrictions on imports in the agricultural and industrial sector, 
which is allowed as part of exception of the agreement. Part of the exceptions and 
restriction is the Most Favourable Nation (MFN) found in article XXIV, based on 
Regional Agreement, tariffs and trade barriers can be reduced, as such Regional 
Preferential arrangement is deemed an exception to the MFN rule. For example, in 
Africa, there are other regional agreements such as the Economic Community of West 
African States ( ECOWAS), the South African Development Community (SADC)319, 
All of which pose a threat to the enactment of the MFN policy by member states to the 
WTO-TRIPS. The African RECS perceived that the MFN policy will restrict Foreign 
 
318 J.H Reichmann, ‘Universal Minimum Standards of Intellectual Property Protection Under the TRIPs 
Component of the WTO Agreement’ (1995) Vol.29 No 2 International Lawyer pp 345 
 
319 WTO- Regional trade agreements and preferential trade arrangement, 
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Trade especially limiting the bargaining power of developing countries and would 
prefer preferential tariff treatment (duty-free entry) which can increase production and 
economic well-being of the continent. The TRIPS Agreement has an additional 
objective, which is, intellectual property protection should contribute to technical 
innovation and the transfer of technology. In such a way that both producers and users 
will benefit from it, at the same time enhance economic and social welfare. 
 
 
3.2 Core Objective of the TRIPS Agreement  
 
Explicitly, the objective is in the preamble of the TRIPs Agreement, in contrast, the 
general Principle of the TRIPs agreement is in Articles 7 and 8 of the Agreement. It is 
a bold declaration of purpose for the protection of IPR. To fully understand the TRIPS 
agreement, it is important to conceptualize the TRIPs framework to determine what it 
aims to protect from the beginning to use it to cross-examine the role of TRIPS in the 
regulation of Counterfeit pharmaceuticals. 
The objective of TRIPS in Article 7 includes, among other things; 
"The protection and enforcement of intellectual property rights should contribute to the 
promotion of technological innovation and the transfer and dissemination of 
technology, to the mutual advantage of producers and users of technological 
knowledge and in a manner conducive to social and economic welfare, and to a 
balance of rights and obligations." 
To interpret the text's language, Article 26 of the Vienna Convention on the law of 
treaties states that every treaty in force is binding upon the parties to it and must be 
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performed by them in good, and in the same faith320. This means that the makers of 
the TRIPS agreement's objective intend for it to be binding unconditionally on member 
states [to the Agreement] even if this provision is overlooked, it is an integral part of 
the TRIPs agreement. The statutory interpretation provides that a statute's words 
should be read in context in a clear and ordinary form321. In other words, this 
provision's scope creates rights and obligations on member states for the protection 
of IP to the benefit of producers and users of creative knowledge. 
Article 7 created a unique legal framework for the international IP regulation that 
promotes economic development for member states to the WTO. It laid IP standards 
to foster technological innovation, transfer, and dissemination of technology amongst 
member states to benefit both producers and consumers of technology within the 
confines of a rule-based IP system. However, suppose the focus of this objective is 
only on technology. In that case, other non-technological aspects of IP will suffer 
inadvertently, limiting the focus of article 7 on the technology-specific goal. However, 
from another perspective, the objectives in Article 7 can provide valuable guidance in 
implementing the TRIPS Agreement, following the IP obligations canvassed for by 
developed countries during the negotiation to promote technology transfer, 
cooperation, and legal assistance in developing and LDC322. The justification of IP 
held by developed states portrayed a monopolistic intent for the benefit of technology 
producers at the expense of developing user count. 
 
320 Vienna convention on the law of treaties 
Available http://legal.un.org/ilc/texts/instruments/english/conventions/1_1_1969.pdf Accessed (22 
November 2018) treaty" means an international agreement concluded between States in written form 
and governed by international law, whether embodied in a single instrument or in two or more related 
instruments and whatever its particular designation 
321 Lord Reid said in Pinner v Everett (1969), "In determining the meaning of a word or phrase 
provided in a statute, the question to ask is what is the natural and ordinary meaning of that word or 
phrase in its context in the statute." 
322 Peter K, Yu. 'The Objectives and Principles of the TRIPS Agreement.' (2009)  
Vol 46 Houston Law Review. PP 979 
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Article 8 provides for the Principles of TRIPs that,  
 1. Members may, in formulating or amending their laws and regulations, adopt 
measures necessary to protect public health and nutrition, and to promote the public 
interest in sectors of vital importance to their socio-economic and technological 
development, provided that such measures are consistent with the provisions of this 
Agreement. 
2. Appropriate measures, if consistent with the provisions of this Agreement, may be 
needed to prevent the abuse of intellectual property rights by right holders or the resort 
to practices that unreasonably restrain trade or adversely affect the international 
transfer of technology. 
The TRIPS agreement's minimum standard of protection is regarded as one of the 
most exceptional protection standards for intellectual property. The IP standard 
defined the right to be protected, the subject matter of protection, the rights to be 
conferred and permissible exceptions to those rights, and the minimum protection323. 
To determine the objective of article 8, Correa utilized the consistency test, which 
posits that member states are restricted from upholding their public interest in IPR 
legislation. However, it must be" consistent with the provisions of this 
Agreement.' Analytically, it gives member states conditions for IPR protection within 
the Agreement. Any deviation from the stipulated condition would amount to a breach 




323 Overview the TRIPS Agreement, 
Available https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm Accessed (11 October 2017) 
 
324 Carlos M. Correa, Intellectual Property Rights, the WTO, and Developing Countries, the TRIPS 
Agreement and Policy Options (Zed Books: London,2002) 
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Section B  
3.3. International Cooperation on Pharmaceuticals and Counterfeit  
 
Member states legally endorse the minimum standard specified by the WTO-TRIPS 
agreement. However, the issue of medicine counterfeit seems to undermine the 
TRIPS standard's applicability, resulting in member states seeking alternative 
measures to stop counterfeit medicine's manufacture and distribution. The problem of 
Counterfeit medicine is multidimensional, from its devastating health repercussion to 
the challenge of differentiating counterfeit medicine from authentic medicine. Above 
all, it is a public health risk. Therefore, international cooperation is needed to stop 
counterfeiters' activities by making them less lucrative, backed by enforceable 
sanctions. 
Trade-in counterfeit medicine is mostly made popular by the massive demand for 
inexpensive patented medicine, particularly in developing countries and LDCs, price 
is a driver for the growth of counterfeit drugs. A gap is created when the price of 
medicine varies in different jurisdictions because of PI. The outcome is the introduction 
of counterfeit in the supply chain. Equally, the right owner may have lost the IP right 
to sue for infringement or detect low quality or counterfeit products for PI erodes the 
legal right to IP. Counterfeiters have taken advantage of the weak enforcement 
mechanism to infiltrate the drug market in countries. Without proper enforcement, 
counterfeit pharmaceuticals will continue to grow because of global demand to the 
detriment of public health. It is vital to rekindle international cooperation, amongst 
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states to reduce exploitation and monopolization 325, especially given counterfeit 
drugs' perversity on international trade.  
Based on the stated supposition, international cooperation, if harnessed, can 
effectively foster a means to end counterfeit incidence. If only law enforcement 
organizations work together, sharing information on anti-counterfeit strategies, uniform 
accessible data service, staff training, develop policies and implement stringent legal 
remedies to tackle counterfeit activities. By having a unified organization consisting of 
pharmaceutical companies, distributors, customs officials, government agencies, 
government leaders, investigators, traders, and enforcement agencies. With the sole 
aim of setting up anti-counterfeit measures that include devices, methods, 
techniques326, and business practices to protect and distribute 
pharmaceuticals. International cooperation is essential as a preventive measure 
against the activities of counterfeiters and to protect IP. It can strengthen IP 
enforcement and protect the health and safety of consumers. Some notable 
organizations created from the international cooperative purpose of combating 
counterfeit will be discussed below to determine if anti-counterfeit strategies can thwart 
counterfeiters' activities beyond government, regional, and international law. 
 
   




325 Robert W Sussman, Paul A. Garber, and Jim M. Cheverud. "Importance of Cooperation and 
Affiliation in the Evolution of Primate Sociality." 2005 128.1: 8 American Journal of Physical 
Anthropology PP 4. 
326 Dipika Bansal and others, 'Anti-counterfeit Technologies: a Pharmaceutical Industry Perspective. 




This section will examine innovative policies that will combat counterfeit 
pharmaceuticals. The strengths and weaknesses of this policy will be reviewed to 
determine its capacity as a viable framework to curtail counterfeit.  Anti-Counterfeit 
Trade Agreement (ACTA) is a plurilateral agreement that consolidates all previous IP 
protection agreements to form one body of rules to improve IP enforcement. It is a 
standard-setting agreement negotiated for three years by the United States, Japan, 
the European Union, Switzerland, and other emerging economies with the sole goal 
of ensuring international corporation, enforcement practices, and the creation of a 
viable legal framework for the enforcement of IPR against counterfeit trade activity 
militating against the development of IP. It covers all the categories of IP subject matter 
from sections 1-7 of part II of the TRIPs agreement. Fundamentally, this agreement 
does not create new IP rights but creates an enabling standard against infringement 
of existing IP rights. The whole process leading to ACTA formation has been 
contentious as it has neither transparency nor accountability327. It is perceived as a 
threat because it contends with subsisting IP agreements such as WTO-TRIPs, and it 
restricts access to essential medicine and the overall development of IP.     
Counterfeit is the primary reason for IP infringement; it is so big that it is larger than 
the economies of over 150 nations. The International Chamber of commerce (ICC) 
postulates that counterfeit and piracy infringe on IP, reaching an estimated value of 
$917 billion as of 2015, with the cost of piracy to music and the movie industry 
amounting to $213 billion328. The International Chamber of Commerce-Counterfeiting 
and Piracy (BASCAP) predicts that, in the future. The scale of counterfeit in the 
 
327 Peter K, Yu. 'Six Secret s (and now open) fears of ACTA' Vol 64 (2011): SMUL Review 975. During 
the negotiation of the ACTA, it was highly secretive with its draft provision rarely published to include 
comments/observations from IP scholars, the World Intellectual Property Organization (WIPO), and the 
World Trade Organization (WTO). 
328 International Chamber of Commerce ICC, 5 Ways Counterfeiting Hurts Society, and what can we do 
about it. published 2017, Available http://iccwbo.org accessed (5 December 2018) 
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economy will range between $524-959 billion by 2022329. The risk posed by counterfeit 
products cannot be quantified. It goes from mild to life-threatening conditions, and 
even death from the use of counterfeit products 330. It undermines creativity and 
inventive steps, with counterfeiting so prevalent, especially in developing and LDC.  
To this end, ACTA is formed as an enforcement mechanism against counterfeit. The 
first part will briefly discuss the negotiating history of ACTA, giving reasons to 
undermine the multilateral trading system of existing IP forums. The second part 
analyses the innovative policies set up for counterfeit regulation and the critical treaty 
obligation members adhere to sustain the requirement of this agreement. Equally, the 
implication of ACTA rules on IP Trade-in countries like Nigeria, especially in the 
pharmaceutical sector, will be examined. Finally, it will conclude by stating the 
importance of ACTA to IP rights holders and its usefulness as an effective agreement 
to tackle unconventional IP practices.  
The effectiveness of trade to the economy of states cannot be simplified; it is the 
backbone of any nation, particularly in developed countries like the USA, Japan, and 
the European Union. The protection of creative knowledge is essential for these 
countries' economic growth, but this cannot be achieved without IP. IP is utilized in 
virtually all sectors of the economy from quality products (trademarks- used to 
distinguish products), technological and pharmaceutical industry (Patent-protects 
unauthorized usage of an inventive step), and the entertainment industry (copyright 
protects creative works). To this end, protection is essential in the face of large-scale 
imitation, piracy, and counterfeit activity that affect the economy, resulting in global 
 
329 ICC- The economic impact of counterfeiting and piracy – report prepared for BASCAP and INTA 
Available https://iccwbo.org/publication/economic-impacts-counterfeiting-piracy-report-prepared-
bascap-inta/ Accessed (5 December 2018) 
330 OECD named Products counterfeited includes clothing, literary and artistic work. Automotive, 
chemicals, electronics, electrical component, pharmaceuticals, tobacco, household goods, toys, 
furniture certificates, etc 
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trade issues. Counterfeit has devastating economic, human, and social costs, with its 
unlimited growth likely to cause more damage in future331. Counterfeit product is 
perpetually increasing and can be purchased from the internet, high street, and local 
markets, with products ranging from food, drinks, toys, clothes, technology, and 
pharmaceutical. This leads to loss of technical know-how, tax/ revenue, employment, 
and eventually death. The impact of each harmful effect stated above will be discussed 
briefly, starting from the impact on employment. 
Counterfeit can be credited to have led to the loss of 2.6 million jobs globally due to 
black market sales 332. In the EU alone, IP industries provide approximately 26% of 
employment, and OECD estimates that counterfeit results in the loss of around 
800,000 jobs and 14.3 billion in tax revenue333. The effect on employment is examined 
from two perspectives. Firstly, counterfeit creates shifts of rights from lawful IP 
manufacturers to unlawful infringing parties. Counterfeiters depend on the young to 
manufacture goods with perverse working conditions. Secondly, it damages the 
growth of legitimate companies' reputation and R&D built over the years resulting in 
loss of profit and sales334. Due to the perverse nature of counterfeit trade, 
counterfeiters avoid prosecution, neither do they obey quality standards nor regulatory 
authority like legitimate firms. Given the business's potential loss, the government 
equally loses much-needed revenue from sale diversions such as corporation tax, 
sales tax, and income tax of up to $89 billion per year. These funds should be used to 
 
331 Adrian Furnham, 'The Effect of Life Values and Materialism on Buying Counterfeit Product,' 2007 
Vol 36 Journal of Socio-Economics, pp 677 counterfeit is not a materialism product, but lack of value 
for branded product citing up bring and family values as a precondition for the surge of counterfeit.  
332 Arlee Sowder, 'The Harmful Effect of Counterfeit Goods,' (2013) Athens State 
University  https://www.athens.edu/journal/spring-2013/asowder-couterfeit/ 
333 European Economic and Social Committee, fake products cost 800,000 jobs annually 
available https://www.eesc.europa.eu/en/news-media/news/fake-products-cost-8000000-jobs-
annually accessed (December 4, 2018)  
334 International AntiCounterfeiting Coalition IACC, what is counterfeiting, 
available https://www.iacc.org Accessed (December 5, 2018) 
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run other areas like building roads, hospitals, R & D, and creating employment 
opportunities.  
Counterfeit poses a deadly health risk, especially pharmaceuticals. Consumption of 
an unregulated pharmaceutical product poses a health risk and even death. It can 
undermine the reputation of legitimate manufacturers of medicine and lead to loss of 
credibility and loss of expenditure used for R&D. Counterfeit pharmaceuticals could 
contain inactive or no active ingredient or unapproved drugs. A recent study by the 
WHO estimates that one in 10 medicines in developing countries and LDCs is 
counterfeit. An example is a drug for malaria, which accounts for 65% of counterfeit 
medicine and possibly responsible for the deaths of thousands of children from 
diseases such as malaria and pneumonia, and HIV every year335. Equally, the surge 
of counterfeit in developing countries continues daily. For example, cancer patients in 
America took Avastin, a cancer antibody treatment, only to discover336 it contained no 
active ingredient, thus jeopardizing consumers' health. The unending phenomenon 
compels strict actions by the government, businesses, and consumers to set up a 
viable organization to tackle the magnitude of counterfeit trade and equally harmonize 
the regulatory framework of trade in IP. 
The economy of the EU and other developed countries relies on IP protection against 
the act of counterfeit. Without durable protection, creativity will come to a halt, forming 
a joint coalition of like-minded states to stop patent infringement, copyright, trademark 
industrial design, geographical indication, and other necessary IP rights. 
 
335 The Guardian10% of drugs in developing countries are fake, says 
WHO Available, https://www.theguardian.com/global-development/2017/nov/28/10-of-drugs-in-poor-
countries-are-fake-says-who  
Accessed (December 5, 2018) 
336 Sean Riley, Keeping it Real – 'The Fight against Fake Drugs' The Association for Packaging and 
Processing Technologies, May 19, 2017, 
Availablehttps://www.pharmamanufacturing.com/articles/2017/keeping-it-real-the-fight-against-fake-
drugs/Accessed (December 5, 2018) 
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Counterfeiters abuse the IPR in great measure that it dwindles the economy of 
dependant states. It does not only affect the economy, but it creates severe social 
problems, as indicated above. All these factors resulted in the negotiation of ACTA to 
tackle counterfeiters. 
 The ACTA factsheet laid down the goal of the Agreement is to provide a robust 
international framework that improves existing enforcement laws on intellectual 
property rights (IPR) at both international and domestic levels backed up by sanctions 
in criminal and civil proceedings337 in a bid to sustain global economic growth. The 
preamble of the Agreement indicates that the agreement advocates for the 
enforcement of IP rights due to counterfeit goods' proliferation. With the desire to deter 
(financial, human, environmental, economic) risks posed by counterfeiters' criminal act 
to legitimate trade. ACTA is keen on ensuring a balance in states' legal systems within 
the scope of the Agreement not to create a conflict of interest while still respecting and 
recognizing the WTO-TRIPS Agreement's provisions as a guide it complements the 
TRIPs agreement338. 
The nature and scope of ACTA obligations are provided in article 2 inter alia that "Each 
Party shall give effect to the provisions of this Agreement…Can implement in its law 
more extensive enforcement of intellectual property rights than is required by this 
Agreement. This means that members can pick and choose an appropriate forum in 
the judicial, administrative, or legal enforcement authorities to implement ACTA 
 
337 Fact Sheet, The Anti-Counterfeiting Trade Agreement (ACTA) Updated November 2008, 
Available http://trade.ec.europa.eu/doclib/docs/2008/october/tradoc_140836.11.08.pdf Accessed 
(December 6, 2018)ACTA tackles large scale, criminal activities and it is not about limiting civil 
liberties or harassing unwilling consumers 
338Final Text of ACTA Agreement (May 2011), Final released the text of the Anti-Counterfeiting Trade 
Agreement (ACTA) Available, https://www.eff.org/document/final-text-acta-agreement-may-2011, 
Accessed (December 6, 2018)The Agreement is not a barrier to trade, it intends to create supportive 
measures to enforce IPR infringement including digital, copyright infringement in a bid to allow right 
holders benefit from their creativity  
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provisions within its legal system with the sole responsibility to initiate individual 
proceedings against the counterfeiter. If the word of ACTA is transcribed, it is worth 
noting that it gives prominence to the provisions of TRIPs, especially articles 7&8, i.e., 
The objective of TRIPs shall be read in such a way that the main point of the 
Agreement remains unchanged. For example, ACTA defines a counterfeit trademark 
as an infringement of goods, packaging without the authorization of a right-holder 
under the law of the country of the trademark owner supported by a requirement, which 
stipulates that the words of this Agreement should be interpreted in a like manner as 
words found in WTO-TRIPS. Therefore, there may not be a distinction between the 
rights protected by both agreements. What is the essence of ACTA, if TRIPs is 
protecting IPR? To discuss this, proponents of ACTA claim that ACTA's goal is not to 
alter the domestic laws of states, but rather to ensure countries with strong IP 
standards develop unified IP rules to tackle the surge of IP. 
 Another criticism of this Agreement is the issue of transparency during its 
negotiations. During the negotiations of ACTA, the procedure showed the Agreement 
is done mostly in secrecy outside the forum of all Intellectual Property standard-setting 
organizations, neither were IP stakeholders and civil society included in the negotiating 
process339. The issues raised by this group include (I) the undemocratic nature of 
ACTA, (ii) global domination of trade by developed countries, (iii) the invasion of 
privacy to restrict civil liberties, and (iv) will make the developing countries lower. 
Another worrisome issue is the notion that ACTA might compel internet providers to 
disclose users' information, which contravenes the fundamental human right to private 
 
339The negotiating process took four years, largely done in secrecy, with the outcome intended to affect 
millions of people economically, financially, and medically. One worrisome issue of compelling internet 
providers to disclose user’s information which contravenes the basic human right to private life 
guaranteed by the Magna carter   
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life guaranteed by Article 8 of the fundamental human rights Act 340. The ambiguous 
nature of ACTA leads to confusion for its stated aim to combat commercial counterfeit. 
Instead, it appears to extend willful infringement for financial gain, which is prejudicial 
to IP rights owners' interests. For example, it obstructs the privacy of ordinary citizens 
as well as the right of digital content providers341 
Nevertheless, the analysis of documents used during the negotiating round of ACTA 
indicates that member states exchanged and shared information amongst its 
minister’s present in the rounds. However, this document was not accessible to public 
members until June 2008 during the stakeholders meeting in Brussels, where issues 
and concerns raised by concerned groups were discussed and explained in detail.  
ACTA secrecy claim hinges on two points, firstly, if ACTA can be regarded as a trade 
agreement as it is not unusual to have secrecy during trade negotiation. Nonetheless, 
ACTA may not represent an actual trade agreement as it fails to promote free trade, 
but further inhibits trade, neither does its preamble portray it as a trade agreement. It 
only mentions international trade a few times without a clear indication to facilitate 
trade. Secondly, ACTA does not intend to change the domestic laws of member states, 
but it aims to advance a more robust international IP enforcement system already 
existing in these countries' domestic systems, so disclosure might not be unnecessary 
if the domestic laws will not be affected by the rules of ACTA342.  
 
340Equality and Human Right Commission, Article 8 Right to private Life, 
Available https://www.equalityhumanrights.com/en/human-rights-act/article-8-respect-your-private-
and-family-life Accessed(December 12, 2018) Article 8 protects your right to respect for your private 
life, your family life, your home and your correspondence (letters, telephone calls and emails, Also the 
Human Rights contains all the basic rights and freedoms to which all human beings are entitled to such 
as the right to life, liberty, right to civil and political rights, freedom of thought and speech and 
expression, the right to equality before the law, social, cultural and economic rights, the right to food, 
the right to work, and the right to education, etc.  
341 Charles R McManis, 'The Proposed Anti-Counterfeiting Trade Agreement (ACTA): Two Tales of a 
Treaty." Vol.46 (2009): Houston. Law Review PP 1235 
 
342 Kimberlee Weatherall, Politics, Compromise, Text and the Failures of the Anti-Counterfeiting Trade 
Agreement,' 2018), Vol.33 Sydney Law Review, PP 229 
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ACTA may be a typical case of forum shifting initiatives concluded by industrialized 
countries to protect private IP rights owners. It advocates for a stronger IP regime 
beyond the WTO-TRIPs Agreement, which will not contravene the provisions of 
TRIPs. Then again, ACTA goes beyond TRIPs in placing enforcement procedures on 
both export and import, thus infringing on the provision of TRIPs. Equally, the current 
ACTA agreement allows for the inclusion of intermediaries and third parties. It also 
goes beyond TRIPS by making damages within its text sufficient to compensate for 
any injury suffered from breach of counterfeit or imitation. For instance'' Article 9 
(damages) provides in the enforcement of intellectual property rights, its judicial 
authorities have the authority to order the infringer who, knowingly or with reasonable 
grounds to know, engaged in an infringing activity to pay the right holder damages 
adequate to compensate for the injury the right holder has suffered as a result of the 
infringement' 343. This value is not specific; it may include future loss or the market 
value of the goods. It is also notable that ACTA provides for the criminal procedure in 
Article 23 for wilful trademark counterfeiting or copyright and the related right to piracy 
on a commercial scale. This statement is quite ambiguous. Firstly, there is no measure 
to determine what amounts to a commercial scale; neither is the term related right said 
to include patent rights. In a bid to go over and above the WTO-TRIPS, the drafters of 
this Agreement made contradictions in the text of the Agreement, as seen above. 
 
343 Anti-Counterfeiting Trade Agreement December 3, 2010, Article 9 Damages, 
Available https://trade.ec.europa.eu/doclib/docs/2010/december/tradoc_147079.pdf Accessed 
(December 13, 2018)it states inter alia that Each Party to the Agreement shall provide, in civil judicial 
proceedings concerning the enforcement of IPR, its judicial authorities have the authority to order the 
infringer who, knowingly or with reasonable grounds to know, engaged in an infringing activity to pay 
the right holder damages. Adequate to compensate for the injury, the right holder has suffered as a 
result of the infringement.  
In determining the number of damages for infringement of intellectual property rights, a Party's judicial 
authorities shall have the authority to consider, among other things, any legitimate measure of value 
the right holder submits, which may include lost profits, the value of the infringed goods or services 
measured by the market price, or the suggested retail price 
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In this conclusion, the interest in developing countries is not considered by the 
negotiators of ACTA. Some developing countries registered their discontentment on 
ACTA; for example, Brazil criticized ACTA for propositioning a single remedy against 
counterfeit and piracy. Others believe that ACTA did not follow the TRIP standard or 
safeguard, for it provided only one remedy against counterfeiting and piracy: 
repression. For example, the Agreement failed to address the practice of seizing 
genuine generic medicine in transit through the EU port en route to South America 
and Africa, which was detained for breaching patent, for failing on its strict patent laws 
even if not protected in the country of destination344. ACTA restricts access to essential 
medicine as seen from the detention of funded medicine Aurobindo destined for 
Nigeria for the treatment of HIV/AIDS, claiming it is a counterfeit drug without 
substantial evidence to support this claim, as unknown to them that the medicine did 
not contain counterfeit neither did it infringe on any IP right345. ACTA does not 
harmonize the laws or standards of trade to allow access to pharmaceuticals for 
developing and LDCs like Nigeria, with no technological output or creative capacity for 
drug production, but who rely on counterfeited/generic drugs for its health care needs.  
From the analysis, ACTA enforcement procedure measures in Article 12 mandates 
the judicial authority to exercise jurisdiction to prevent IP infringement of goods from 
entering the channel of commerce, and the parties can request for an injunction 
against a broad class of actors, including third parties, and mandate interception of 
goods in transit by customs officials applying the IP law of the transit country''. 
 
344Henning Grosse Ruse-Khan, 'A Trade Agreement Creating Barriers to International Trade: ACTA 
Border Measures and Goods in Transit.' (2010): Vol 26 American University International Law 
Review, 645. An example is that the Netherlands' custom authorities detained a large stock of generic 
medicine destined for Africa, some of it is destroyed, and others were released after a considerable 
time lapse.  





Although this section excludes pharmaceutical patents, this exclusion is not 
guaranteed. It can be used to block the passage of generic drugs, for example. The 
German customs seized the shipment of Amoxicillin, which was held for four weeks 
for similarity to another drug produced by Glaxo Smith Klein (Amoxil). This and other 
similar incidents show the negative effect of ACTA on health care346. 
 
The negotiation of ACTA prompted various debates due to non-disclosure of 
provisions and other similar issues in the Agreement's text. While to the industrialized 
countries, ACTA is a unique platform for aggregating all the IP rights into a strong 
dynamic framework for the benefit of IP right providers, to the developing/LDC 
countries or non-party members of ACTA, some of its provisions go beyond TRIPS, 
especially the border measures, which restricts the distribution of much-needed 
medicine. ACTA is not an agreement for all; it is only for the selected few who favour 
profit over life, unlike its counterpart, the TRIPS agreement, which is open to all 
member states globally. It would not be astonishing that ACTA intends to replace the 
existing IP mechanism in the long run by consolidating/merging its framework within a 
single regime backed by sanctions imposed by the developed countries only.  
 
3.3.2. Principles and element of International Medical Product Anti Counterfeit 
Taskforce –IMPACT 
 
The growing trend towards protecting IP has been welcomed by developed and 
developing countries, given counterfeit perversity. Although the anti-counterfeit trade 
 
346 Andrew Rens, 'Collateral Damage: The Impact of ACTA and the Enforcement Agenda on the 
world's Poorest People." (2010) Vol.26 American University International law Review: 783.Brook 
K Baker,' ACTA-risks of third-party Enforcement for access to medicines' (2010) Vol. 26 American 
University International Law Review 579 
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agreement tried to enforce stiff penalties on defaulters of IP, developing countries 
perceived that this protection was mostly inadequate. It may be safe to suggest that 
this organization, even if it is themed "globally unique," is ineffective in reducing the 
scourge of counterfeit. Nonetheless, another organization created to regulate the 
scourge of counterfeit goods was inaugurated by the World Health Assembly (WHA) 
Resolution 41.16. This resolution permits the WHO to start programs for the prevention 
of import, export, and smuggling of counterfeited or substandard pharmaceuticals. 
One such initiative led to the establishment of the International Medical Products Anti-
Counterfeiting Taskforce (IMPACT) in 2006. This was the first of its kind, which was 
solely dedicated to pharmaceuticals and medico-surgical materials347. 
 The goal of IMPACT is to restrict the production, selling, marketing, and distribution 
of counterfeit pharmaceuticals. With the support of governmental and non-
governmental anti-counterfeit agencies, drug regulatory authorities, manufacturers of 
patented medicines, and all IP related organizations 348by adopting a transparent 
approach to combat counterfeit through any means possible with state of the art 
infrastructures, legislations, rules, procedures of enforcement and effective 
communications on counterfeit. 
This research will not seek to state IMPACT's history; it will focus on what it aims to 
achieve. It will seek to examine why, after 12 years of IMPACT's establishment, 
counterfeit pharmaceuticals are still on the increase. Therefore, questioning is crucial. 
The first part will discuss the definitional question of counterfeit, for, without a clear 
 
347Albert I. Wertheimer and Perry G. Wang, Counterfeit Medicine, Policy, Economies, and 
Countermeasures (ILM Publications, St Albans, 2012)  
348 IMPACT representatives include the following, Interpol, ), World Customs Organization for Economic 
Cooperation and Development (OECD, World Bank, World Intellectual Property Organization, World 
Trade Organization, International Federation of Pharmaceutical Manufacturers' Associations, Council 
of Europe International Generic Pharmaceuticals Alliance, ASEAN Secretariat, European Commission, 
International Pharmaceutical Federation, International Council of Nurses, World Medical Association, 




delimitation, enforcement is not possible. This is because, until now, there seems not 
to be a specific law to cover infringement of medicine without settling for the all-
encompassing generic definitions of counterfeit medicine. Even if the WHO attempted 
to define counterfeit medicine, is it sufficient if measured against the proportion. Lastly, 
the research will evaluate IMPACT's effect on the distribution and flow of medicines to 
developing countries.  
 
IMPACT has many objectives: creating a necessary mechanism to secure political 
commitment supported by a secure legal framework backed by sanctions. This 
collaboration facilitates progress in the following areas: securing political will and 
commitment, adequate legal framework, and implementation. Others include curtailing 
the surge of counterfeit medicine based on laid down rules and procedures of 
enforcement, defining roles, ensuring the availability of funds, useful administrative 
tools to create awareness of the severity of the counterfeit medicine on public 
health349. 
 Whereas the definitional question of counterfeit arises all the time, to establish the 
definition, it is vital to explain medicine's meaning. Medicine is any substance used to 
treat illness or restoring or modifying a physiological function in human beings. In 
contrast, essential medicines satisfy the urgent health care needs of the public350. 
Therefore, medicine is an essential substance used for the treatment of diseases in 
 
349 International Monitoring pact on Anti-counterfeit Taskforce –IMPACT, 
Available http://apps.who.int/medicinedocs/documents/s20967en/s20967en.pdf  Accessed (20 
December 2018) IMPACT Participants are encouraged to conduct activities which are consistent with 
the objectives mentioned above under their responsibility and according to their respective policies 
and principles. Fund-raising efforts of IMPACT Participants for their activities will be subject to their 
respective policies and principles    
350 World Health Organisation Essential Medicine and Health Product 
Available https://www.who.int/medicines/services/essmedicines_def/en/ Accessed (18 December 
2018) Essential medicines satisfy the priority health care needs of the population. The medicine that 
makes this list is selected due to health care needs and its relative relevance to the society and safety 
to ensure there is a standard or functioning health system, particularly in developing and LDC.  
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human beings. Medicine is an invention from human intellectual knowledge inevitably 
protected by law for either process or product from unauthorized usage. Counterfeit 
amounts to unauthorized use, which the World Health Organisation defines as follows: 
 
WHO definition of counterfeit medicine  IMPACT definition of counterfeit 
medicine  
‘’ is one which is deliberately and 
fraudulently mislabelled concerning its 
identity or source. Counterfeiting can 
apply to both branded and generic 
products and counterfeit products may 
include products with the correct or 
wrong ingredients, without active 
ingredients, with insufficient active 
ingredients or with fake packaging.” 
‘’ describes a medical product with a false 
representation of its identity or its source. 
This applies to the product, its container 
or other packaging or labelling 
information. Counterfeiting can apply to 
both branded and generic products. 
“Counterfeits may include products with 
correct ingredients/components or with 
wrong ingredients/components, without 
active ingredients, with incorrect 
amounts of active ingredients or with fake 
packaging.”351 
 
First, the WHO is a standard-setting organization, and this definition seems to be 
concerned about intellectual property protection rather than public health safety. 
Although it complements TRIPS' definition of counterfeit, Clift opines that the WHO 
should be more concerned about the quality, safety, and efficacy of pharmaceutical 
products352 rather than IP. However, after various deliberations, the WHO working 
group concluded that the definition of counterfeit medicine above would not sufficiently 
 
351 International Monitoring pact on Anti counterfeit Taskforce –IMPACT, 
Availablehttp://apps.who.int/medicinedocs/documents/s20967en/s20967en.pdfAccessed (20 
December 2018)     
352 Charles Clift,' Combating Counterfeit, Falsified and Substandard Medicines: Defining the Way 
Forward?' 
Centre on Global Health Security | November 2010, 
Available https://www.chathamhouse.org/sites/default/files/public/Research/Global%20Health/1110bp
_counterfeit.pf Accessed( 20 December 2017) 
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explain its intent and purpose. It is in contrast with public health. As such, a new 
definition (substandard/spurious/falsely labelled/falsified/counterfeit (SSFFC) medical 
products)353, with each specific term dealing with a cause instead of a complete legal 
text that bears no apparent meaning. The SSFFC arrangement is precise, for it divides 
the terminologies relating to counterfeit medicine and IP by removing terms like" one 
which is deliberately and fraudulently mislabelled concerning its identity and 
source," which is an IP term, as such, alienating it in the new SSFFC text. 
There appears to be a gap in this definition. Firstly, what does it aim to protect? 
Besides, can it be refined to ensure state agencies and regulatory bodies work 
together to achieve a common goal of safeguarding pharmaceuticals through the 
legislative provision of states and the stakeholders in the manufacturing, export, and 
import of pharmaceutical products? In the same vein, the Pharmaceutical Security 
Institute (PSI) supports this position by recognizing the definition proffered by 
regulatory bodies globally. However, since there is no concise official definition of 
counterfeit pharmaceuticals in most countries, how will counterfeit be resolved? 
 To PSI, "Counterfeit medicines are products deliberately and fraudulently produced 
and/or mislabelled concerning identity and source to make it appear to be a genuine 
product and applies to both branded and generic products" 354. Looking at this 
definition, it tends to partly originate from the definition proffered by the WHO, as 
clearly the wording of both organizations are similar. It may be possible that similarity 
connotes harmony as to purpose, not as to the problem's scope. Whereas the 
definition of counterfeit proffered by IMPACT complements the WHOs definition, for 
 
353 Substandard, spurious, falsely labelled, falsified and counterfeit medical products, Frequently 
Asked Questions, April 2014 
Available  https://www.who.int/medicines/services/counterfeit/faqs/SSFFC_FAQ_print.pdf  Accessed 
(18 December 2018) 
354 Pharmaceutical Security Institute Available http://www.psi-
inc.org/counterfeitsituation.cfm Accessed ( 17 December 2018)  
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example, the text "applies to the product, its container or other packaging or labelling 
information," which suggests the protection of trademark instead of public health. 
Undoubtedly, IMPACT is a tool of the WHO; it is not a legal entity; neither can it take 
any actions without the authorization of state members, agencies, organizations, or 
institutions. Its powers are, therefore, limited. 
 
One of the critical areas within the mandate of IMPACT is regulatory implementation 
to help the national authorities implement measures to control the export, import, and 
distribution of medicine to developing countries/LDC. It is done by maintaining an 
effective communication strategy, coordinating health authorities, customs, police 
force, manufacturers, distributors, and health professionals of state members of 
suspected counterfeit products 355. Nevertheless, lately, IMPACT's functions have 
been criticized for restricting access to essential medicine, and it advocates for a TRIP-
plus standard. The consequence of this move is detrimental to public health,356 given 
the first fact that IMPACT ought to regulate the scourge of counterfeit. However, it 
tends to restrict access to generic medicine, which is disastrous for developing and 
LDC. In summary, the need to regulate counterfeit supersedes public health concerns. 
However, IMPACT and ACTA's aim explicitly contravenes what TRIPS aims to 
achieve, especially with developing countries and LDCs, even though it has efficient 
regulatory policies on counterfeit drugs, its enforcement framework is beyond TRIPs.  
 
 
355 IMPACT- Counterfeit Drugs Kills, May 2008 
Available https://www.gphf.org/images/downloads/library/whoimpact2008_counterfeit_drugs_kill.pdf  
Accessed (20 December 2018) 
356 Paul N Newton and others' The Primacy of Public Health Considerations in Defining Poor Quality 
















This chapter examines the conditions that make counterfeit thrive in Nigeria 
irrespective of the national and international IP policies in place to regulate counterfeit 
pharmaceuticals. Part one of this research looks at Nigeria's geographical scope in 
chronological order from economic, social, and public health perspectives. Part two 
demonstrates through a historical purview how Nigeria's legal system evolved from 
colonialism to an enforceable legal institution based on the rule of law. Part three will 
analyse the intellectual property framework applicable in Nigeria before going into the 
core of the research, which is introducing the intellectual property framework in 
Nigeria. These include customary laws, rules, laws decree, edits concerning the rules 
set by TRIP. The issue is why counterfeit pharmaceutical is still on the increase despite 
TRIP rule and Nigeria domestic rules. The inquiry concludes with suggestions on how 
to make the Nigerian laws and WTO IPR work effectively together. 
Counterfeit pharmaceuticals, as the name connotes, is a replica of the original 
medicine devoid of any active ingredients used to treat diseases. Counterfeit medicine 
does not meet any regulatory standards, and it poses serious health problems, even 
160 
 
death357. It, therefore, begs the question of why counterfeit drug is is so prevalent in 
Nigeria. 
 
 In straightforward terms, counterfeit drug is persistent for the following reasons: (I) 
Price –In a country with a poverty headcount ratio of less than $1.90 a day and over 
53% of the population358 are living in abject poverty, counterfeit drugs are seen, as a 
cheaper alternative to brand-name drugs. In Nigeria, medicine is not state-funded like 
most developed countries: individuals must provide for their own health care needs. It 
is incredibly difficult to afford essential medicines due to the 20 years patent restriction 
placed on drugs. Pharmaceutical companies have the sole right to profit from the 
product of their research and development but not to the public's detriment. There 
should be symmetry between the needs of pharmaceutical companies and public 
health care for both parties' mutual benefit.  
On the price issue, big Pharma argues that the least amount spent on research and 
development is around 2.558 billion dollars. In other words, the amount of money 
spent on raw materials, manufacturing, clinical trials, failure until the drug is approved 
is enormous  359. More recently, the Tufts centre for the study of drug development 
pegs the cost of developing a new drug from invention to market approval to be around 
$2.6 billion. This report originates from information supplied by ten pharmaceutical 
companies from 106 randomly selected drugs within a specific time, with over half of 
these monies spent on post-approval development studies, such as the safety and 
 
357 Erwin A Blackstone, Joseph P Fuhr, and Steve Pociask' The Health and Economic Effects of 
Counterfeit Drugs.' 2014; Vol 7 issue (4): Am Health Drug Benefits pp216. 
358 The world Bank Poverty and equality data country indicator Nigeria, 
Available  http://povertydata.worldbank.org/poverty/country/NGAAccessed (February 9, 2019) in the 
words of Paul Orhii, of Nigeria's drug agency, part of the problem Nigeria faces is due to the presence 
of a shambolic system and porous borders". 
359 The Guardian Why do new medicine cost so much and what can we do, 
available https://www.theguardian.com/news/2018/apr/09/why-do-new-medicines-cost-so-much-and-
what-can-we-do-about-it Accessed (February 11, 2018) 
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efficiency of a drug. If successful, the next set of funds will be on marketing and the 
possibility of the new drug failing 360. For example, Biomarin and Genzyme's recent 
review estimates R & D's cost for medicines for the treatment of rare diseases, to be 
on an average between $195 million to $963 million361. Looking at this information 
begs the question of the feasibility of this data. Most pharmaceutical companies do not 
disclose data on the cost of production of medicines publicly, thus reducing the powers 
of price in medicines. The only available tool to reduce drugs' monopoly price is by 
generic competition362, such as the ones used in South Africa and India during the HIV 
crisis.  
There is no doubt that producing drugs is expensive, but there should be a balance 
between the initial and total cost of a drug to reach a fair price acceptable for 
consumers. Without the right price, access to medicine will be impossible, leaving 
room for counterfeit, especially in developing countries like Nigeria. The high cost of 
drugs, coupled with inaccessibility, triggers the surge of counterfeit medicine. Often 
supplied through an authorized and unspecified distribution network to an 
unsuspecting willing consumer, counterfeit medicine is welcomed as a cheaper 
alternative to brand known overpriced drugs363. Nigeria needs to adopt a strict 
standard for regulating and distributing drugs, for it is hailed as Africa's biggest 
economy and a frontier for pharmaceutical growth in Africa. Setting a precedent for 
 
360 Cost to Develop New Pharmaceutical Drug Now Exceeds $2.5B, and A benchmark report 
estimates that the cost of bringing a drug to market has more than doubled in the past ten years, 
By Rick Mullin, Chemical & Engineering News on November 24, 2014, 
Available, https://www.scientificamerican.com/article/cost-to-develop-new-pharmaceutical-drug-now-
exceeds-2-5b/Accessed (April 8, 2019) 
361 Forbes- The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely 
Bad, by Matthew Herper  Availablehttps://www.forbes.com/sites/matthewherper/2017/10/16/the-cost-
of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-
bad/#38fa21c2d459 Accessed (April 9, 2019) 
362 Andrew M Hill, Melissa J Barber and Dzintars Gotham, 'Estimated Costs of Production and 
Potential Prices for the WHO Essential Medicines List',2018;3 BMJ Global Health: e000571 
363 Chinwe Obuaku,' Essential Medicines in Nigeria: Foregrounding Access to Affordable Essential 
Medicines.' (2014) b Vol 18. Issue 2: African Sociological Review pp. 42. 
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other African nations should be the key objective of its government. Instead, it is 
marred with large-scale counterfeit drugs' consumption despite its government 
preventive steps to reduce counterfeit. Deaths caused by counterfeit drugs have 
soared steadily over the years in Nigeria, with deaths mostly undocumented364, which 
affects data accuracy on the scale of counterfeit medicines. One of the first 
documented cases of counterfeit death is the paracetamol syrup disaster of 1990, 
where 109 children died from consuming fake paracetamol syrup produced with the 
toxic substance diethylene glycol instead of propylene glycol365. Another similar death 
recorded in 2008, killing over 80 babies caused by contamination of my pikin Baby 
teething power with engine coolant diethylene glycol366.  
To effectively address the issue of counterfeit pharmaceuticals, it is pertinent to 
discuss the legal and institutional framework in Nigeria, for, without clarification, the 
reorganization will be impossible to achieve. Nigeria's anti-counterfeit procedure is not 
specific; it is subdivided into different rules and policies and border measures to fit a 
particular purpose, which applies to an IP right holder. Counterfeit pharmaceutical is 
a global issue. Counterfeit has eaten so deep into the structure of Nigeria's health and 
pharmaceutical sector, to the point of attaching more importance to profit than human 
life. For instance, the standard organization of Nigeria (SON) estimates that the federal 
government loses around #15 Billion annually to counterfeiters' activities, with 80% of 
counterfeit products originating from Asia and other countries around the world.367 It 
makes Nigeria the largest market for drugs in Africa. With such a unique position, the 
 
364 Paul N Newton, and others' Murder by Fake Drugs: Time for International Action.' (2002): 800-
801.  
365 S. Ogoh Alubo. 'Death for Sale: A Study of Drug Poisoning and Deaths in Nigeria.' (1994) Vol 38. 
Issue 1 Social Science & Medicine. PP97. 
366 Olusegun Akinyandenu.' Counterfeit drugs in Nigeria: A threat to public health.' (2013) Vol 7, Issue 
36: African Journal of Pharmacy and Pharmacology, pp. 2571. 
367 The Leadership, Nigeria loses #15 billion annually to fake products annually, 
Available   https://leadership.ng/2018/02/07/nigeria-loses-n15bn-fake-products-annually/ Accessed 
(February 9, 2019)  
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World Health Organisation survey found that over 64% of Nigeria's antimalarial drugs 
are fake or counterfeit368. 
 
4.2 An Introductory Overview of Nigeria 
 
A booming economy, diverse people, and immense economic potential sum up the 
country called Nigeria. It is known as the giant of Africa for its strength and might in 
the economic, technological, educational, cultural and industrial prowess in the 
continent of Africa. To discuss Africa without mentioning Nigeria is tantamount to 
considering global issues without the United States of America. Therefore, to analyse 
the viability of TRIPs in relation to counterfeit in Nigeria, it is pertinent to look at the 
institutional, geographical, legal and economic framework of Nigeria to ascertain if the 
rules formulated by TRIPS undermines the surge of counterfeit drugs in Nigeria.  
Geographically, Nigeria is in Western Africa, bordering the Gulf of Guinea, between 
Benin, Ghana, Togo and Cameroon, with a total mass of land measuring around 
910,768 sq. km and water estimated around 13,000 sq. km as delimited by 
international boundaries and coastlines. Nigeria is endowed with abundant natural 
resources such as natural gas, tin, coal, iron ore, lead, zinc, limestone, niobium, arable 
land and most importantly, petroleum369. The oil and gas sector is the primary source 
of export, with over 83% of total export revenue and 10% of the country’s gross 
domestic product370. Nigeria’s oil reserve is estimated to be around 23 billion barrels, 
and the gas reserves are estimated to be 160 Trillion cubic meters. Regardless of such 
 
368 The Economist, fake medicine bad medicine 
available https://www.economist.com/international/2012/10/13/bad-medicine accessed (February 9, 
2019) 
369Central Intelligence agency, (CIA)world Fact book : Nigeria , Available 
https://www.cia.gov/library/publications/the-world-factbook/geos/ni.html Accessed (15  January 2019) 
370 Organisation of Petroleum Exporting Countries (OPEC) Nigeria Fact sand Figures , Available 
https://www.opec.org/opec_web/en/about_us/167.htm Accessed( 10 April 2019) 
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vast natural resources, Nigeria is classified as a developing country, with over 70% of 
its population living in abject poverty.  
Despite the abundant resource highlighted above, it can be argued that these 
resources can be referred to as a curse rather than a blessing. For instance, Obaje 
addresses the notion of a resource curse, indicating that the term emerged in the 
1980s. They assert that states with vast natural resources are beleaguered with 
undesirable economic output371 as a consequence of inflation, high unemployment 
level, terrorism, kidnapping, protests and negative political turmoil. These factors have 
invariably been affecting the utilization of natural resources. This is a typical example 
of Nigeria’s situation whose natural resources is perceived as a curse in disguise, as 
they are a constant source of hardship, death, pain and conflict in Nigeria although it 
is a limited perception to classify a country based on a single variable rather than other 
determinant factors. 
 
4.2.1 History of Nigeria  
 
Historically, Nigeria is a former protectorate of the British Empire, and most of its laws 
and policies emanate from the British Empire and influence. Scholars like Toyin Falola 
believe Nigeria's British occupation in early 1900 created enabling conditions for force, 
undue nationalism, political instability, corruption, and power tussle amongst the ruling 
elite. Maybe it was a way to resist colonialism or might be a precondition for the country 
called Nigeria372. These issues have eaten deep into the fabric of Nigeria, with Nigeria 
 
371 Nuhu George Obaje, Geology and Mineral Resources of Nigeria Vol. 120 (Springer, 2009) 
372 Toyin Falola, Colonialism, and Violence in Nigeria, (Indianan University Press, 2009)  
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rated as one of the most corrupt countries in the world373. An apple does not fall far 
from a tree; corruption is an integral part of colonialism, with the colonial masters 
bribing chiefs and elders with gifts to oppress Nigerians. Steven traced the current 
corrupt practices in Nigeria to the British colonial regime374. The leaders have failed 
Nigerians right from the beginning with the help of colonialism. 
Nigeria finally gained its independence from Britain in 1960, hoping that the country 
will be the giant of Africa. Unfortunately, the country experienced various military 
coups and countercoups, with different regimes struggling to rule the country. From 
1960 till 1999, Nigeria had long spells of military rule, precisely between 1966 to 1979 
and between 1984 and 1999. The Nigerian government continues to face the daunting 
task of institutionalizing democratic principles of good governance in a system 
encumbered with corruption. However, this thesis will not dwell too much on the 
historical issues of Nigeria.  
 
    
4.2.3 Population 
 
Modernization and technological advancement enabled people to live longer and 
healthy, resulting in the world population's unprecedented growth. Nigeria is one of 
such countries regarded as the fastest and most populated African country. Its last 
census in 2006 projected the population to be around 140 million people375. By 2013, 
the estimated population projection for Nigeria was 169.7 million, and by 2019 it was 
 
373 Transparency international –Nigeria is regarded as 144 least corrupt nation out of 180 countries, 
according to the 2018 Corruption Perceptions Index reported by Transparency International. With the 
Corruption Rank in Nigeria averaged to be around 121.48 from 1996 until 2018, reaching an all-time 
high of 152 in 2005 and a record low of 52 in 
1999.Available https://www.transparency.org/country/NGA Accessed (3 February 2019) 
374 Steven Pierce,' Looking like a State: Colonialism and the Discourse of Corruption in Northern 
Nigeria.' (2006) 48.4 Comparative Studies in Society and History 887. 




over 200 million people making it the 7th largest country in the world376. The United 
Nations projects that by 2050, the Nigerian population will surpass that of the United 
States and maybe the third most populous country in the world behind India and China 
377. The consequence of population growth is multidimensional economically378. It has 
led to an increase in the labour force and per capita income of a state. Pikett supports 
this view that population growth is a contributing factor for economic growth in per 
capita GDP379. The consequence of unregulated population growth transcends 
economic problems such as inflation and debt. It reduces development in low-income 
countries. 
4.2.4 Nigeria Trade Alliances  
 
No country is an island; every country has trade ties with other counties, coupled with 
trade liberalization policies. This has made trade easy and efficient, for trade is an 
engineer of growth, development, and a means of integration. Theoretically, two 
benefits of trade have been identified by international trade scholars. Firstly, trade 
allows specialized gains from trading activities, and the overflow from trade is profit380. 
However, the benefits of free trade to developing countries are multifaceted. According 
to the International Monetary Fund (IMF), liberalization has increased the wealth of 
 
376Eli H Tartiyus, Mohammed Inuwa Dauda, and Peter Amade,' Impact of population growth on 
economic growth in Nigeria, (2015)20.4: IOSR Journal of Humanities and Social Science (IOSR-
JHSS) 115.  
377 The Guardian Newspaper Nigeria expected to have a larger population than the US by 2050 
UN predicts that Africa – and Nigeria in particular – will be at the forefront of substantial global population 
rise over the next century Available, https://www.theguardian.com/global-
development/2013/jun/13/nigeria-larger-population-us-2050  Accessed (15 January 2019) 
378 Derek D Heady and Andrew Hodge' The Effect of Population Growth on Economic Growth: A Meta-
Regression Analysis of the Macroeconomic Literature' (2009) 35, Population and Development Review, 
221 
379 Thomas Piketty, Capital in the Twenty-First Century (Cambridge, MA: Belknap Press of Harvard 
University Press, 2014) 
380 Andrés Rodríguez-Pose and Javier Sánchez-Reaza ’Economic Polarization through Trade: Trade 
Liberalization and’ (2005) Spatial Inequality and development. 237 
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nations, leading to enhanced export and import, increased income, manufacturing381, 
and technological Proficiency amongst nations, particularly in developing countries. 
Nigeria is a member of various international, regional, and national trade 
organizations. For this research, a few of these organizations will be discussed briefly. 
Starting from International organizations, Nigeria has been a member of the WTO 
since 1990 and a GATT member since 1960. Nigeria has actively participated in the 
activities of the WTO. It has ratified most of the WTO trade rules which cover goods, 
services, and IP into its legal system, in addition to WTO permitted exceptions. 
Recently, Nigeria signed the trade facilitation agreement, which is expected to reduce 
the cost of trade by an average of 14.3%, with developing countries like Nigeria having 
the most gain. This agreement will ensure that import time is reduced, with an 
estimated average reduction time of 47% and 91% and the capacity to increase global 
merchandise export by over $1 trillion382. The WTO revised its implementation 
mechanism to reflect each member country's ability to achieve a desirable outcome. 
The benefit of being a member of the WTO is remarkable. Adejuwon, Nigeria 
Ambassador to the WTO. Has commented that Nigeria's economy has a lot to gain 
from its membership of the WTO, such as increased technical support for its 
developmental and infrastructural growth, easy flow of FDI, improved foreign 
exchange and earnings, elimination of technical and non-technical barriers to trade. It 
ensures free market access for local manufacturers in the international trade forum383. 
However, some scholars believe that WTO rules on trade liberalization favoured 
 
381 International Monetary Fund IMF, Global Trade Liberalization and Developing Countries, 
Available https://www.imf.org/external/np/exr/ib/2001/110801.htm  
Accessed (29 April 2019) 
382WTO Nigeria Ratifies the Trade Facilitation Agreement 
Available  https://www.wto.org/english/news_e/news17_e/fac_20jan17_e.htm Accessed (06 May 
2019) 
383The Nations, What Nigeria Stands To Gain From the WTO, 
availablehttps://thenationonlineng.net/what-nigeria-stands-to-gain-from-wto/ Accessed (06 May 2019) 
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developed countries, which had established a trading system rather than developing 
countries and LDCs, and its policies have increased the poverty and inequality ratio384. 
Since the WTO is a rule-based organization founded on negotiations (all-inclusive 
principal rule), it would seem plausible to suggest that developing countries may not 
have adequate negotiating skills to obtain agreement favourable to their national 
interest, which appears defensive rather than offensive. Developing countries tend to 
accept most conditions offered in the negotiating table instead of picking and choosing. 
Developed countries, have cutting-edge negotiators for every agreement ratified by 
their government and negotiate as a Bloc rather than individual member countries. 
Nigeria is a member of the Africa Union (AU)385, formerly the Organisation of African 
Unity (OAU)386. It was established based on the existing legal and institutional 
framework, with the sole objective of ensuring unity amongst African nations, defence 
of its sovereignty, political and economic integration to guarantee free trade amongst 
African states. Also, included in its objectives is that it provides for International 
corporations to promote sustainable development and harmonize regional economic 
policies to increase the living standard of all Africans387. The AU has endorsed different 
health initiatives during the HIV crisis, on peacekeeping from regional conflicts in 
states like Libya, Mali, Congo, Sudan, and Somali war. It can be said that the AU is a 
 
384Andrew K Rose.' Do WTO Members have more Liberal trade Policy' 2004 Vol 63 Issue2: Journal of 
International Economics 209 The notion of free trade, liberalization championed by the WTO has not 
been measured to check if its policies favour other developing countries. However, she proposed that 
liberalization can be measured under the following heading firstly Openness (e.g., the ratio of trade or 
imports to GDP), 2. Trade flows adjusted for country-characteristics (outcome-based), 3. Tariffs. 4. 
Non-tariff barriers 5. Informal or qualitative measures, 6 Measures based on price outcomes  
385 Konstantinos D Magliveras, and Gino J. Naldi' The African Union—A New Dawn for Africa?' (2002) 
Vol 51, Issue 2: International & Comparative Law Quarterly, 415. 
After a meeting by the head of states of African countries, the AU is created to establish a body solely 
for Africans called the African Union on 26 May 2006. With the sole responsibility of ensuring a legal 
and institutional framework for economic integration, military might, social and cultural integration 
amongst African states. 
386Colin Legum, 'The Organisation of African Unity-Success or Failure' (1975) Vol 51, issue 2, 
International Affairs (Royal Institute of International Affairs: PP 208-. 
387African Union, AU in a Nutshell, Available https://au.int/en/au-nutshel Accessed (27 May 2019) 
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true testament to cooperation amongst African nations. One would wonder if AU’s 
stated objectives can be achieved given the peculiar circumstance in Africa. The 
competence of AU can be compared to the likes of the European Union (EU), can AU 
deliver more for Africa like the EU is doing for Europe. Okhonmina highlights the 
importance of regional hegemony, linking it to regional power with significant influence 
on regional subjects for which the AU ought to be, to effectively deal with rapidly 
changing global issues388.  
Some issues have been identified that could potentially inhibit the success of AU. For 
instance, the AU is structurally incompetent in its operation due to the poverty ratio in 
Africa. The AU lacks a concise administrative capability to run the organization's 
activities and ideology to fulfil its stated objectives, so it can be said to be structural 
inadequate even though this argument is said to be speculative. Nevertheless, it is 
pragmatic in the way AU has handled issues. For example, one of its objectives is the 
free movement of people and goods. However, actualizing this objective is marred by 
unending corruption and a lack of cooperation amongst African states. 
In West Africa, Nigeria is a founding member of the Economic Community of West 
African States (ECOWAS) 389 and has championed this organization's cause over the 
years for the harmonization of trade, finance, and investment amongst the 16 member 
nations of ECOWAS. Nigeria has actively participated in many negotiations. One such 
agreement entered into force in 2017 is the negotiation of the Continental Free Trade 
 
388 Stephen Okhonmina, ’The African Union: Pan-Africanist aspirations and the challenge of African 
Unity' (2009) Vol3, Issue 4 The Journal of Pan African Studies PP 85. 
389 The Economic Community of West African States (ECOWAS) 
Available https://www.ecowas.int/ecowas-law/treaties/ Accessed (15 May 2019) is a multilateral 
agreement signed by the member states that made up the Economic Community of West African States. 
16 member states signed the first agreement in 1975 in Lagos, Nigeria, and a revised treaty was signed 
in 1993 in Cotonou, Benin Republic in July 1993 by the heads of states and government of West African 
countries, some of the countries include Nigeria, Ghana, Mali, Niger, Senegal, Serra Leone, Benin, 
Togo, Cape Verde Cameroon, and Gambia ETC. 
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Area (CFTA) under the African union free trade area for preferential trade access390. 
Article 3 of ECOWAS provides for "the removal, between the Member States, of 
obstacles to the free movement of persons, goods, services, and capital, and to the 
right of residence and establishment" 391. 
 ECOWAS guarantees a regional economic corporation and integration amongst West 
African states. Removing any impediment to trade promotes trade liberalization and 
the total removal of customs duties amongst member states. On the other hand, free 
movement has contributed to the surge of counterfeit, even though it is meant to transit 
original products. Furthermore, the essence of being a part of an international and 
local trade organization is to strengthen trade bonds, but with a negative turnout such 
as counterfeit, it is impossible to reconcile the positive objective of partaking in this 
organization, thus defeating the theoretical standpoint for the association.  
 
4.2. 5 Economic Viewpoint  
 
Nigeria's economy was known to be viable after independence with the per capita 
income in 1960- 1970 estimated to be around US$1,113 up until US$1,084 in 2000. 
However, recent figures show that Nigeria's economy and currency are among the 
world's 15 most impoverished nations 392. Despite this, Nigeria is not classified as a 
Least Develop Country (LDC) but a developing Country. Nigeria's economy facilitates 
integration and increased productivity supported by a viable service sector. The most 
enormous contribution to Nigeria's economy is from its natural resources, mostly from 
 
390 WTO summary, WT/TPR/S/356 • Nigeria 
Availablehttps://www.wto.org/english/tratop_e/tpr_e/s356_sum_e.pdf Access (04 May 2019) 
391 ECOWAS Revised Treaty Available http://www.ecowas.int/wp-content/uploads/2015/01/Revised-
treaty.pdf Accessed (15 May 201 
392 Xavier Sala-i-Martin and Arvin Subramanian 'Addressing the natural resource curse: An illustration 
from Nigeria,' 2013 Vol.22 issue 4 Journal of African Economies PP 570 
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crude oil exportation. As of 2018, Nigeria produced around 2.16 million barrels per 
day393 of petroleum. The sale of Oil and gas production is the backbone of Nigeria's 
economy, and it has greatly benefitted the country. It accounts for 70% of the total 
government revenue394. 
Nonetheless, oil production's negative impact led to environmental degradation and 
social deprivation of economic welfare in oil-producing communities395. Aside from the 
ecological and humanitarian effects of oil production, Nigeria has witnessed a steady 
decline in its foreign reserve due to its persistent deterioration in global oil prices. For 
instance, the Nigerian foreign reserve as of 2008 is estimated to be around $53.6 
billion, but by 2016 it dropped to $24.74 billion, which has weakened the naira's value 
against other currencies less dependent on petroleum. Nigeria inflation rate in 2016 is 
estimated to be 17.69% 396. It is predicted that the inflation rate will increase in 2019 
to around 13.5% for goods and services. According to the latest data obtained from 
the central bank of Nigeria (CBN), Nigeria's foreign exchange reserves now stand at 
$36.57 billion, having increased sharply from $33.42 billion as of April 29, 2020, which 
shows a gain of $3.15 billion in 33 days, the naira is still weak in comparison other 
non-oil dependent currencies.  
 
 
393 Femi Asun, 'Nigeria Daily Oil Production Rises to 2.16 Million Barrel'   
Available https://punchng.com/nigerias-daily-oil-production-rises-to-2-16-million-barrels/ Punch 
Newspaper, October 2018 Accessed (February 3, 2019) 
394 Augustine Ikelegbe, 'The Economy of Conflict in the Oil Rich Niger Delta Region of Nigeria.' 2005 
14.2 Nordic Journal of African Studies 208 
395 Gbadebo Olusegun Odularu, 'Crude oil and the Nigerian Economic Performance' Oil and 
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The fall of global oil prices has significantly affected the Nigerian economy due to over-
reliance on petroleum397. The government has overlooked other key non-oil tradable 
revenue sources398, such as agriculture, textile etc. Nigeria used to be heavily 
dependent on agriculture as its primary source of export, with products such as cocoa, 
palm oil and cotton before the advent of petroleum. However, farmers had fewer 
incentives or contributions from the government, and competitiveness towards 
agriculture is reduced. Neither were farmers willing to take advantage of new farming 
techniques after the oil boom. The passion for going into agriculture further declined 
with the mass emigration of potential labourers to the cities seeking white-collar jobs 
resulting in reduced labour availability399. Pinto has criticized government policies on 
agriculture for failing to provide adequate finance mechanisms for farmers, and neither 
is there any support system for training nor educating farmers on new farming 
techniques400. Overall, oil discovery is one of the most significant problems for the 
non-oil tradable sector's fundamental growth in Nigeria. 
The steady decline in the rate of production is another major issue affecting Nigeria's 
economy. Production is linked to human capital and a significant determinant of 
economic growth 401if harnessed. Nigeria is known to have a large population to 
sustain increased output. Despite being rich in human capital, the Nigerian 
government has not harnessed this resource but depends on foreign goods and 
services. Ojo suggests Nigeria ought to be a developed country if it maximizes its 
 
397 Nigeria is the 6th largest producer of petroleum in the world and a member of OPEC  
398 Brian Pinto, 'Nigeria During and After the Oil Boom: A Policy Comparison with Indonesia, (1987) Vol 
1, No 3 The World Bank Economic Review, Pg. 419. The comparison illustrates the setback witnessed 
in the agricultural sector in Nigeria after the discovery of Oil. The government withdrew all the subsidies 
and special assistance to farmers, failing to provide long term effect of weak oil prices. 
399 Sara J Scherr, 'Agriculture in an Export Boom Economy: Comparative Analysis of Policy and 
Performance in Indonesia, Mexico, and Nigeria." 1989 Vol 17, Issue 4, World Development 543.  
400 IBID 
401 Robert E Lucas Jr. 'On the Mechanics of Economic Development.' 1988 Vol 22. Issue 1 Journal of 
Monetary Economics,) pp 3  
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human and natural resources towards production instead of being a consumer-centred 
economy402. In broad terms, investing in human capital sustains economic growth and 
ensures long term returns for any country. The Nigerian economy is persistently 
deteriorating403, coupled with risky government expenditure on infrastructures and 
development. The situation requires a broad institutional and economic transformation 
different from the deformed structural adjustment program 404. The factors that are 
militating against the Nigerian economy's growth include growing government 
expenditure, a decrease in export, a rise in unemployment, an inadequate taxation 
system, lack of infrastructure, and corruption. 
I. Increased Government Expenditure is a viable tool used to influence 
economic growth and national income405. However, Nurudeen and Usman think 
that the government's primary function is to provide security and public services 
such as infrastructures, education, health, power, and defence. It will stimulate 
economic growth. However, a different view proposed by some scholars 
believes that increased expenditure weakens the performance of an economy 
and subsequently leads to higher borrowing406, high cost of production, reduced 
market access, break-in trade relationships, and will increase the value of 
goods and services. Another scholar, Wagner, posited in the law of increasing 
 
402 Johnson Ojo Adelakun, "Human Capital Development and Economic Growth in Nigeria" (2011): 3.9 
European Journal of Business and Management 29. 
 Developing human capital is a means of economic growth, for it turns economic surplus into 
investment. Nigeria should empower its people to achieve a desirable outcome economically. It can be 
attained by maintaining a high level of education and training in various fields, especially technology. 
403 Michael Watts, 'State, Oil, and agriculture in Nigeria,' Institute of International Studies, (University 
of California, 1987) also in  1988 Volume 70, Issue 1American Journal of Agricultural Economics, 
Pages 215 https://doi.org/10.2307/1242009 
404 Oluremi Ogun, ‘Real Exchange Rate Movements and Export Growth' Nigeria, 1960-1990.' Africa 
Portal (1998). 




406 Abu Nurudeen and Abdullahi Usman, 'Government Expenditure and Economic Growth in Nigeria, 
1970-2008: A Disaggregated Analysis,’, (2010) Volume 4 Business and Economic Journal, 237 
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state activity that increasing state spending and activity inadvertently leads to 
economic and state development. Although the new function of government will 
be capital intensive, in the long run, it will stimulate economic productivity407. 
The provision of infrastructure increases business prospects, and the lack of it 
is a significant drawback to Nigeria's economic development. Compared with 
other developed countries, for instance, the UK, which invested £19.7 billion in 
2017 on infrastructural development, it is a determinant for productivity, 
reducing the barrier to trade and open markets408 in  Nigeria. Consequently, 
Okoro recommends that to improve Nigeria's economic situation, the 
government ought to invest in infrastructures such as roads and electricity, for 
it increases productivity and employment, which will advance the economy409 
II.  A decrease in export-Indeed, the issues articulated above on the state of 
Nigeria's economy is worrisome. However, the World Trade Organisation 
(WTO) trade liberalization policies guarantee the reduction of any restriction to 
trade and advocates for the free exchange of goods and services with moderate 
tariffs. Nigeria is a WTO member state; thus, it is entitled to reduce surcharges 
and duty charges for all imports and export. Nigeria is known to export mainly 
crude oil, petroleum gas, cocoa beans, and sugar to India, Spain, the United 
States of America, the Netherlands, etc. It is estimated that in 2017, Nigeria 
exported over $46.8 billion worth of goods, which is a sharp contrast from 
previous export figures with a deficit of -17% reduction410, due to a decline in 
 
407 Ram Rati. 'Wagner's Hypothesis in Time-Series and Cross-Section Perspectives' (1987) vol. 
69(2) The Review of Economics and Statistics 194 
408 The Office of National Statistics, Developing new Statistics of infrastructure: August 2018, 
Available http://www.ons.gov.uk Accessed (18 April 2019)  
409 A .S Okoro, "Government spending and economic growth in Nigeria (1980-2011)." (2013). Global 
Journal of Management And Business Research PP 15 
410 OEC, Nigeria Available https://atlas.media.mit.edu/en/profile/country/nga/ Accessed ( 19 April 2019) 
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oil prices after the global financial crisis 411which accounts for 90% of Nigeria 
export. Unlike in the 1960s, Nigeria exported mainly agricultural products such 
as cocoa, palm oil, nuts. This sector was neglected after the discovery of crude 
oil. Neither did the government provide an incentive to farmers nor stimulate 
farming inputs, thus reducing potential yield412. Another issue highlighted for 
the fall of the agricultural sector in Nigeria is the negative influence of 
liberalization. Global change in agricultural policies creates unfair competition, 
an increase in farm products, protectionism, and unfavourable institutional 
policies, which limit the final output. 
III.  Inadequate taxation system- Taxation is the live wire of every country; its 
effect is so significant that without taxation, state expansion is impossible. The 
revenue accrued from tax is used for security and infrastructural development. 
States have developed effective structures supported by binding rules to collect 
and generate income used to improve the economy. For example, tax in the UK 
is the largest government revenue source with a functioning decentralized 
system of collection at national and local levels. Although every tax collected is 
supported by formal legislation of government in Nigeria, the taxation system is 
flawed from uneven data, ineffective tax administration, regulatory challenges, 
the difficulty of tax laws, and the multiplicity of tax413, and corruption414. Nigeria 
 
411 The financial crisis first started in the USA in 2007, from the sub-prime mortgage market to a global 
banking crisis due to excessive risk taken by banks resulting in a massive bailout to prevent the collapse 
of financial institutions 
412Nahanga Verter N., and Vera. Bečvářová "Analysis of Some drivers of Cocoa Export in Nigeria in the 
era of Trade Liberalization" Agris on-line Papers in Economics and Informatics 6.665-2016-45040 
(2014): 208 
413Micah, and others' Tax system in Nigeria–challenges and the way forward' (2012) 3.5Research 
Journal of Finance and Accounting): 9 Solutions proposed to tackle these problems in the administration 
of tax in Nigeria includes tax education, the public needs to be educated on the importance of paying 
taxes and the right form of payment. Equally, the tax policy should be modified in simple terms to ensure 
ease of payment and fairness. 
414 Adeleke Salami. 'Taxation, Revenue Allocation, and Fiscal Federalism in Nigeria: Issues, 
Challenges, and Policy Options.' (2011) 56189. Economic Annals 27 
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is still plagued by persistent tax issues even after various policy change, 
introduced to ease the tax system, including the e-payment system415. Okoye 
and Ezejiofor propose the following recommendation: the re-organization of the 
tax structure, modification of outdated rules, policies, and strict sanctions for 
failure to pay tax416. Moreover, if these recommendations are adopted, they will 
reduce over-reliance on crude oil to run the country's affairs. 
 
IV.  Unemployment- Unemployment is a significant problem in Nigeria. It is estimated 
by the Nigerian Bureau of Statistics (NBS) that over 23.10% 417of Nigerians are 
unemployed, i.e., people who have no job compared to the labour force418. 
Unemployment is so pervasive that it is challenging to tackle at the moment. 
Nigeria is endowed with human resources, but unemployment undermines the 
growth of industries/economic growth in Nigeria. With over 18 million people 
without a job, this suggests that 1 in every five youth is unemployed. According to 
Okafor, despite the large turnout of graduates, the street of Nigeria is littered with 
unemployed youth seeking employment, which can lead to a hostile environment 
and socioeconomic problems in the country419. There seems to be a correlation 
between unemployment, poverty, and criminal actions, combined with the fact that 
nearly 80% of the 180 million people live on less than 2 dollars a day420. The zeal 
 
415 Kingsley N. Ashibogwu and Kayode. O. Bankole 'Comparative Study of Nigeria and the United 
Kingdom Tax System,' (2018) Vol 5, No6 International Journal of Research in Business and Social 
studies and Management, pp31 
416 Pius VC Okoye, and Raymond Ezejiofor' The impact of e-taxation on revenue generation in Enugu, 
Nigeria' (2014): 2.2 International of Advanced Research 449 
417 Nigeria Bureau of statistic available  https://www.nigerianstat.gov.ng/ Accessed (27 April 2019) 
418 Trade and Economics. Nigeria Unemployment rate, 
Available https://tradingeconomics.com/nigeria/unemployment-rate accessed (27 April 2019) 
419 Emeka Emmanuel Okafor. 'Youth Unemployment and Implications for Stability of Democracy in 
Nigeria' (2011) 13.1 Journal of sustainable development in Africa: 35 
420 Punch newspaper, Available https://punchng.com/152-million-nigerians-live-on-less-than-2day-




to make money through other means will be on the increase, including crime. What 
exacerbates the situation is that the few employed people are underemployed, 
impacting the general output or work ethics. Having looked at the challenges 
restricting economic and social growth in Nigeria, it is worth noting that Nigerians' 
problem is burdensome. Practically, all the sectors from health, education, legal, 
developmental needs reform to increase the country's growth level. 
4.3 Introduction to Nigerian Legal system 
 
As noted above, Nigeria is a former British colony421 , and by legal transplant, it has 
adopted the British legal system which includes the British common law, doctrine of 
equity and statute of general application along with its customary law which is not 
repugnant to natural justice422. This is provided for in "Section 45 (1) of the 
Interpretation Act which provides among other things that, the common law of England 
and the doctrines of equity and the statutes of general application which were in force 
in England on 1 January 1900 are applicable in Nigeria, only in so far as local 
jurisdiction and circumstances shall permit"423 . This provision explicitly stipulates that 
the English legal system will be operative in Nigeria as it pertains to any legal issues 
without consultation or legislation from Nigeria houses of parliament. 
 British law was not necessarily welcomed by the ethnic groups that came to constitute 
Nigeria. Instead, acceptance was at the point of the sword with Nigeria accepting 
British rule and its laws on account of Britain’s military might. It is quite understated 
that the colonized state assimilated the legal system of its oppressors for fear of 
 
421 Emmanuel Okonkwo. 'An Appraisal of Nigerian Legal System in the Light of Savigny's Philosophy 
of Law.' (2014) 1.9 International Journal of Research 371. 
422 Alan Cuthbert Burns, History of Nigeria, (George Allen and Unwin Limited, London, 1929). 
423 Derek Asiedu-Akrofi, 'Judicial Recognition and Adoption of Customary Law in Nigeria' 1989 vol. 37, 
no. 3, The American Journal of Comparative Law, pp. 571–JSTOR, www.jstor.org/stable/840092 
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prosecution (British colonial system), and in the words of Gower, ' English law was 
applied without consideration of its suitability to local conditions 424. Colonial rule in 
Nigeria used intimidation, threat, infiltration, and treaty protection to ensure the 
occupation of territory without regard for the people's existing customs and traditions. 
Okeke suggests that international law was used as an instrument of intimidation to 
enhance Nigeria's colonial subjugation 425. Notwithstanding these arguments on 
colonialism, its merit shaped a structured legal system in Nigeria irrespective of its 
source. 
 
Source of Nigerian Law-The constitution contains the fundamental law of any 
country. The rules, provisions, and policies in the Constitution are supreme over any 
law. All laws must be compatible with the provisions contained in the Constitution. 
Section 1(1) of the 1999 constitution of Nigeria provides that "this Constitution and its 
provisions shall have binding force on all authorities and persons throughout the 
Federal Republic of Nigeria."426 In addition to this, Section 1(3) states that "if any other 
law is inconsistent with the provisions of this Constitution, the constitution shall prevail 
and that other law shall to the extent of the inconsistency be void427. This provision 
solidifies the Constitution's supremacy and renders any other law inconsistent except 
that which is provided for in the Constitution. The Nigerian Constitution's preamble 
essentially promotes good governance and the welfare of all persons in Nigeria under 
 
424 Gower, Laurence Cecil Bartlett. Independent Africa: The Challenge to the Legal Profession. 
(Cambridge, Mass.: Harvard University Press, 19670.  
425 Christian N. Okeke' International Law in the Nigerian Legal System' (1996) 27, California Western 
International Law Journal 311 
426 The 1999 Constitution of the Federal Republic of Nigeria , Section 1(1) 
Availablehttps://publicofficialsfinancialdisclosure.worldbank.org/sites/fdl/files/assets/law-library-
files/Nigeria_Constitution_1999_en.pdf Accessed (29 May 2019) 
427 The 1999 Constitution of the Federal Republic of Nigeria , Section 1(3) 
Availablehttps://publicofficialsfinancialdisclosure.worldbank.org/sites/fdl/files/assets/law-library-
files/Nigeria_Constitution_1999_en.pdf Accessed (29 May 2019) 
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the principle of equity and justice. The next source of law is statutory law; under the 
provisions of the 1999 constitution in section 4(2),' The National Assembly shall have 
the power to make laws for the peace, order and good government of the Federation 
or any part thereof ". It constitutes a body of law enacted by the legislature's express 
will as a binding legal order such as decrees and edits428. 
 
Customary law- Apart from the common law and statutory law, there is the 
established law and indigenous legal system binding and accepted by a particular 
group of people to regulate its daily activity. It must not be repugnant to natural justice, 
equity, and good conscience nor incompatible directly or by implication with any written 
law in force at that time429. This provision is otherwise known as the repugnancy 
doctrine. Different scholars have debated the rationale behind this doctrine. While 
some scholars perceive it as a form of the statute of limitations 430, others view it as a 
prerequisite for customary law recognition431, in order words. The different meanings 
attributed to the repugnancy doctrine are superficial, and it does not affect the court's 
use and recognition. Hence, a country's legal system determines if the rule of law is 
effective or undermined in the resolution of a dispute, managing contractual rights, 
protection of public goods, and policies put forward before it432. Moreover, the Nigerian 
legal system's efficacy will be tested against the pervasiveness of counterfeit 
pharmaceuticals to determine if the rule of law is operational in tackling counterfeit 
drugs.  
 
428 Charles Mwalimu, 'The Nigerian legal System': 2005 Vol. 1. Public law.  
429 Derek Asiedu-Akrofi, 'Judicial Recognition and Adoption of Customary Law in Nigeria' 1989. vol. 37, 
no. 3, The American Journal of Comparative Law, pp. 571–593. JSTOR, www.jstor.org/stable/840092 
430 Benjamin Obi Nwabueze, The Machinery of Justice in Nigeria (No.8, Butterworth, 1963) 
431 Onyeka Igwe, 'Repugnancy Test and Customary Criminal Law in Nigeria: A Time for Re-Assessing 
Content and Relevance.' Available at SSRN 2528497 (2014) 
432 Stephen Knack, and Philip Keefer's Institutions and economic performance: cross‐country tests 




4.4 Nigeria Intellectual Property Model  
 
It is pertinent to examine the intellectual property framework in Nigeria for IP is the 
bedrock of human welfare433. Broadly speaking, it is paramount to harness and 
regulate this newfound sphere's economic benefit within viable legal parlance for the 
actual value of IP is strategic to growth and increased revenue of states. This is 
particularly important as counterfeit drugs fall within the patent law of states. 
Therefore, it is essential to study the IP history, laws, rules, policy operating in Nigeria 
as well as its limitation. Other aspects of assessment include its contractual 
management rights, and the protection of public goods, which is intricately related to 
counterfeit drugs.  
Historically, the national laws governing the protection of IPR in Nigeria is derived from 
its colonial past and modelled per the British IP regime. The IP system did not exist in 
Nigeria before the advent of colonialism. To assert British control over its colony, the 
colonial office, in a bid to maintain order and protect people and property, adopted the 
indirect rule system with the colonial masters delegating power to traditional rulers to 
act on its behalf 434still maintaining sole authority. Given this situation, the English 
statute of 1900 had both positive and negative outcomes435 in its colonies.  
  
 
433 Christopher M Kalanje, 'Role of intellectual property in innovation and new product 
development.' World Intellectual Property Organization (2006) The true value of the patent to small 
scale industries is strategic to growth, increased revenue   
434 Nigeria: History, Commonwealth, Available, http://thecommonwealth.org/our-member-
countries/nigeria/history Accessed (02 September 2019)   
435 Ogba Chidinma Onwuchekwa' Archiving in Nigeria: Relevance for Legal Education' (2017) Vol9 
Issue 2 International Journal of Library and Information Science PP 7 
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Historical evidence substantiates that around 1861, Britain annexed Lagos' colony; it 
introduced its patent law applicable in England through the patent proclamation 
ordinance No. 27 of 1900 to north and southern Nigeria. Nigeria repelled the 1900 
patent ordinance in 1916 and further amended it by the new patent ordinance No. 6 of 
1925. It had its limitations, such as obstruction of local innovation and research, 
cumbersome registration requirement for the indigenous patent, and little recognition 
in the UK436. "Yankey also affirms this position that the introduction of the patent 
administrative institution was "never meant to encourage either inventive indigenous 
activity, local research, and development, innovation or to accomplish an effective 
transfer of technology. Instead, it works towards protecting property rights in 
machinery technology relevant to the exploitation of gold and other mineral and human 
resources in the Colonies"437. 
 Although the British IP system is unique, it is deemed inadequate to meet Nigeria’s 
unstructured legal system, thus integrating the British IP rule proved rather 
cumbersome for a young state. Even at that, the IP structure operative in Nigeria is 
outdated, for example, the current patent and design act of 1971 has not been 
reviewed or amended to bring it in harmony with contemporary IP improvement neither 
is there an established administrative mechanism for IP to be fully operational in 
Nigeria. Instead, it is saddled with corrupt practices such as counterfeit, piracy, and 
ineffective legal tool. Therefore, the wholesome adoption of an established IP system 
undermines the developmental trajectory of IP in Nigeria. It needs to abolish the part 
 
436Shafiu Adamu Yauri, The Patent system in Nigeria' (2012) Vol 34, Issue 3 World Patent Information 
213 
437George M Sikoyo, Elvin Nyukuri, and Judi W. Wakhungu' Intellectual Property Protection in Africa 
Status of Laws, Research and Policy Analysis in Ghana, Kenya, Nigeria, South Africa, and Uganda' 
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of its rigid patent system to bring it in line with the modern IP system, and have a 
Nigerian patent system, which is unique to Nigeria circumstances. 
Another issue with the Nigerian IP model is the inconsistency in the definition of 
counterfeit pharmaceuticals. These conflicting definitions have opened a wide array of 
terminologies and definitions such as substandard, falsified, piracy, fake, spurious and 
counterfeit drugs. These terms are interconnected but have different connotations, 
however, if a unified definition is accepted, this will positively impact the prevalence of 
counterfeit drugs. Nigerian IP model ought to address the legal and institutional 
inconsistency in its IP Laws. If it remains unresolved proffering solutions to counterfeit 
will prove unattainable.  
Another issue is the administrative part of IP in Nigeria. It is grossly inefficient to the 
extent that the trademarks, patent, and designs registry operated a manual recording 
system until recently when an electronic filling platform 438created with a commitment 
to delivering prompt, excellent, and consistent services in the area of modern 
technology and innovation consistent with best practices obtained globally. Upon 
completion and verification of novelty, a certificate is issued but territorially limited to 
Nigeria. But  
Nwabueze thinks that patent and trademark protection should be subject to different 
legal regimes. For instance, Cameroon, Chad, Niger, and Benin are members of 
Organisation Africaine de la propriété Intellectuelle (OAPI), an African IP organization 
for the protection of IP in Francophone countries 439. However, its protection 
 
438 Trademark, patent and design registry commercial law Department 
Available  http://www.iponigeria.com/#/  
Accessed (01 September 2019)  
439 Caroline Nwabueze, 'Challenges of Transnational Trademark Law Practice: The Case of Nigerian 
Companies' (2015) 45.1, Brands in the OAPI States." Revue générale de Droit 321. 
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supersedes patent and trademark matters in Nigeria, explaining the importance of 
joining a regional IP organization. 
 
4.4.1 The Nigerian Patent Act and Design Act of 1970  
 
The legal and institutional mechanism for the regulation and enforcement of IP in 
Nigeria falls under these acts, but for the sake of clarity, only the patent and design 
act and the copyright act will be examined in detail.  
Copyright Act (as amended), Cap. C28, Laws of the Federation of Nigeria 2004  
Nigerian copyright act is the primary legislation for the regulation of copyright in 
Nigeria. Part 1, section 1, provides literary work, musical work440, artistic work, 
cinematography, and sound recording is eligible for protection under the act. The 
Nigerian copyright-based industry is estimated to be worth around $7.5 Billion. 
However, the accruing potential of this industry is underutilized due to widespread 
piracy and copyright infringement. There is no viable enforcement mechanism or 
effective sanctions to deter the problems associated with piracy. Many issues have 
militated against the growth of copyright in Nigeria. For example, improved technology 
allowed rampant digital knowledge theft, which is against the Nigerian copyright act. 
The act guarantees protection for copyright owners to benefit from their inventive steps 
following the TRIPS agreement provision. 
To ensure clarity, in the fight against piracy and infringement, extrajudicial measures 
ought to be utilized, such as social, judicial, and technological approaches as judicial 
measures have proved inadequate considering their magnitude, especially in 
developing countries. Similarly, Lemley and Reese suggest that the issue of 
 




infringement should not solely be on infringers but equally on third parties aiding and 
abetting the work of digital infringers for indirect liability can eradicate the entire 
network of infringers441. 
The courts hardly recognize an indirect liability, but under the doctrine of vicarious 
liability (holding someone in authority accountable for the actions of another) and 
contributory negligence, a third party can be judicially liable for infringement. However, 
the court's interpretation of these provisions is a restrictive approach442. Copyright is 
from creative knowledge; it is intangible; it is a special right, worthy of protection by 
the law to reward originality and imagination. Furthermore, in Adenuga V. Ilesanmi 
press and sons Ltd443, the court held that copyright is the right exclusively restricted 
to the creator of the copyright444. The law ought to be effective in protecting copyright 
as the impact of piracy on any state's economy can deter creativity and inventive steps. 
  
4.4.2 The Patent Registry System  
 
The need for a reliable system to regulate, protect, and guarantee the efficient 
utilization of the rights accrued to the owner of an inventive step falls within the scope 
of an operational patent registry. To an economist, innovators can be rewarded in two 
ways. Firstly, by allocating IP rights (monopoly) to the invention, and secondly by 
 
441 Mark A Lemley & R Anthony Reese, 'Reducing Digital Copyright Infringement Without Restricting 
Innovation,' (2003) Vol 56  
Stan Law Review pp. 1345 Prosecuting third-party infringers has its unique advantages, for it can 
discourage illegal trading of digital materials. Another solution to deter infringement is taxation, making 
the infringers pay tax towards the stolen digital content. 
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outright ownership by the state, otherwise known as compulsory license 445. However, 
how do we determine how much reward should be given, and what rubric should be 
used to resolve it? A competent patent registry can only determine this. The patent 
and design act of 1970 regulates patent registration and other ancillary matters. 
In Nigeria, the patent and design registry under the federal ministry of trade and 
commerce administers the protection of patents, trademarks, and designs to ensure 
consistent delivery and registration of modern innovation consistent with the best 
practices across the globe446. The patent registry primarily protects ideas. It begs the 
question: What idea can be registered since not all ideas are valuable or patentable. 
In Jonson's words, ideas are necessary elements of thought that can either be visual, 
concrete, or abstract447. The idea is free and unique but must be backed up by 
manifestation or methodology to warrant legal protection. According to the Nigerian 
patent registry, only a statutory inventor has the legal right to claim patent protection 
even if he is neither the true inventor nor the first to apply, but as far as there is 
sufficient proof to establish that he is the statutory inventor448 right will be issued. 
The patent and design act provided the conditions needed for the registration of a 
patent in Nigeria's patent registry. This act determines patentable ideas, qualification, 
prohibition, exception, right accorded, timeline, and protection type. The following 
essential conditions must be met to be eligible for patent protection: 
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Qualification- To qualify for registration, a prospective patent application must 
meet the following conditions. 
1. Patentable inventions (1) Subject to this section, an invention is patentable 
(a) If it is new, results from inventive activity and is capable of industrial application; or 
(b) if it constitutes an improvement upon a patented invention and is new, results from 
inventive activity and capable of industrial application.  
 (2) For subsection (1) of this section— (a) an invention is new if it does not form part 
of state of the art;  (b) an invention results from an inventive activity if it does not follow 
from state of the art, either as to the method, the application, the combination of 
methods, or the product it concerns or the industrial result it produces; and (c) an 
invention is capable of industrial application if it can be manufactured or used in any 
industry, including agriculture. (3) In subsection (2) of this section, "the art" means the 
art or field of knowledge to which an invention relates, and "state of the art" means 
everything concerning that art or field of knowledge which has been made available to 
the public.   
Prohibition-The Nigerian patent and design act prohibits the registration of 
Patents for the following. 
(4) Patents cannot be obtained in respect of- (a) plant or animal varieties, or essentially 
biological processes for the production of plants or animals (other than microbiological 
processes and their products); or (b) inventions the publication or exploitation of which 
would be contrary to public order or morality (for this paragraph that the exploitation of 
an invention is not contrary to public order or morality merely because its exploitation 
is prohibited by law) (5) Principles and discoveries of a scientific nature are not 
inventions for this Act.  
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A right accorded- after fulfilling the requirement, this section provides for the 
right specified to a prospective applicant. 
Right to patent (l) Subject to this section, the right to a patent in respect of an invention 
is vested in the statutory inventor, that is to say, the person who, whether or not he is 
the true inventor, is the first to file, or validly to claim a foreign priority for, a patent 
application in respect of the invention. (2) The true inventor is entitled to be named in 
the patent, whether he is also the statutory inventor, and the entitlement in question 
shall not be modifiable by contract.  
Prohibition –once the right is conferred, a patentee can do the following 
according to section 6 of the patent and design act. 
(1) A patent confers upon the patentee the right to preclude any other person from  
doing any of the following acts---(a) where the patent is granted in respect of a product, 
the Act of making, importing, selling or using the product, or stocking it for sale or use; 
and (b) The patent has been granted in respect of a process, the Act of applying or 
the process of doing, in respect of a product obtained directly through the process, 
any other acts mentioned in paragraph (a) of this subsection.  
Lapse of patent -A patent will be nullified where the description of the invention 
does not conform to the provision of the law 
Duration and lapse of the patent (1) Subject to this Act; a patent shall expire at the end 
of the twentieth year from the date of the filing of the relevant patent application.  
(2) A patent shall lapse if the prescribed annual fees are not paid in respect of it: 
Provided that- (a) a period of grace of six months shall be allowed for the payment of 
the fees; and (b) if the fees and any prescribed surcharge are paid within that period, 
the patent shall continue as if the fees had been duly paid. (3) The expiration or lapse 




Figure 3 patent application by region  
Source WIPO449 
 
Following the review, the Nigerian patent registry mandated the requirement for the 
grant of patent. A patent is a viable tool for economic growth, and it ought to be utilized 
in full capacity. Nigerians ought to be enlightening on the benefits the law provides to 
inventions in all fields of technology. It appears to be underutilized. For example, WIPO 
indicators show over 3 million patent applications were submitted globally, with China 
leading with over 236,600 applications, 98% of global applications, followed by the 
USA with 16, 200 addition filling while the rest of the world accounted for 0.2%. This 
statistic shows that there has been a gradual decrease in filing for a patent in 
 
449 WIPO Indicator , Available https://www.wipo.int/edocs/pubdocs/en/wipo_pub_941_2017-chapter2.pdf 
Accessed (12 October 2019) 
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developing countries, which limits growth and may have allowed counterfeit to exist in 
a bid to evade the law. 
4.5 National Agency for Food and Drug Control-NAFDAC  
 
During the pre-colonial period, Nigeria rarely had issues with counterfeit drugs, but the 
drug problem escalated in the 80s and 90s when "briefcase importers" 450 of drugs 
and the influx of unregulated pharmaceutical imported by indigenous and foreign firms 
saturated the local market with counterfeit drugs causing devastating health problems, 
increased morbidity, drug resistance and subsequently death. Economically, the influx 
of unregulated medicines is associated with economic globalization and free trade. 
Although the government heavily promotes domestic manufacturing of 
pharmaceuticals to ensure sustainable economic growth, it is yet to attain its full 
potential of producing affordable drugs, neither is there any incentive to make high-
quality drugs. The gap created from the absence of genuine pharmaceuticals and the 
need for the establishment of a viable industry to regulate the production of 
pharmaceuticals resulted in the surge of counterfeit pharmaceuticals. One of the 
initiatives to curb the surge of counterfeit by the Nigerian government is the 
establishment of the National Agency for Food and Drug Administration and Control 
(NAFDAC) created by Law from the NAFDAC ACT cap N.1 LFN 2004, Counterfeit and 
fake drugs and unwholesome processed food (miscellaneous provision) Act Cap 
 
450NAFDAC the 21st Annual National Conference of Association of Industrial Pharmacists of Nigeria 
(NAIP)held on 18 April 2018 at Kwara hotels, Ilorin, Kwara state 




34LFN 2004451, the food and drug Act Cap F 32 LFN452 and the food drug and related 
Product (Registration) Act453. NAFDAC's vision is to safeguard public 
health, complemented with a mission statement to ensure that only the right quality 
drugs, food, and other regulated products manufactured, imported, distributed sold, 
and used in Nigeria. The vision and mission statement summarises the purpose and 
goal of the agency. NAFDAC objective is to prohibit the sale and distribution of fake, 
banned, substandard or expired drugs. It is recognised as a global pacesetter in 
diligence, innovation, and a subsistent interdisciplinary organisation, an excellent case 
study for Africa's growth. Therefore, it is pertinent to examine the stated vision of 
NAFDAC for any variation. 
The first line of the NAFDAC vision statement, the phrase "safeguarding public 
health," is not specific neither does it provide a degree of flexibility to literarily interpret 
the meaning of public health protection. For instance, the term public health is not well 
specified. It could mean the quality of health, quality of life, preventing diseases, 
physical and mental health conditions and contrasting it with the US Food and Drug 
 




C.34.pdf Accessed (16 October 2019) Section 1 and 2 of this act prohibits the sale of any fake 
substandard pharmaceutical product and specified penalties ranging from N500,000 or imprisonment 
for a term of not less than five years or more than fifteen years. It also made provision for penalties for 
corporations by holding defaulting companies accountable for actions of members of the company and 
actions can be instituted in the federal high court.   
452 The food and drug Act Cap F 32 LFN Available https://www.nafdac.gov.ng/wp-
content/uploads/Files/Resources/Regulations/NAFDAC_Acts/FOOD-AND-DRUGS-ACT.pdf Accessed 
(16 October 2019) This act prohibition the sale of certain food , drug and cosmetics that contains 
harmful substances that is against stipulated safety requirement  
453 Food, Drugs And Related Product (REGISTRATION, Etc) ACT Cap F.33 LFN 
2004,Available https://www.nafdac.gov.ng/wp-
content/uploads/Files/Resources/Regulations/NAFDAC_Acts/FOOD-DRUGS-AND-RELATED-
PRODUCTS-REGISTRATION-ACT-Cap.F.33.pdf Accessed (16 October 2019) Relates to prohibits 
the manufacture of unregistered drugs and food production in Nigeria. Unless it is duly registered 
before any drug or food can be imported, exported, advertised, sold or distributed in Nigeria. However 
a sample of the food or drug clinically tested to ensure it meets the required standard provided by 
Law. When the agency is satisfied that all the required standards have been established, a certificate 
of registration is issued to show compliance. 
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Admiration (FDA) mission statement which seeks to ensure the safety, efficacy and 
security of human and veterinary drug and national food supply454. It is glaring that 
there is a clear delimitation of objective; it is specific, not vague.  
Secondly, NAFDAC seeks to regulate the manufacture and import of drugs and food 
into the country. However, Akinyandenu careful observed that achieving this criterion 
by NAFDAC, means the placement of health inspectors at airports and seaports, but 
how practicable is this vision in tackling counterfeit (lack of funding/manpower). He 
suggests that local manufacturing should be encouraged with added incentives by the 
government. Instead, local manufacturers have less favourable conditions for the 
production of drugs. For instance, obtaining registration is cumbersome, starting with 
initial analysis, drug testing and safety requirement, which can take months to get 
registration455. In addition, the Law that created NAFDAC has not been reviewed since 
its formation like other similar organisations with the same mandate to bring it to 
conformity with modern standards acceptable standards. 
Despite NAFDAC's best efforts to tackle counterfeit drugs, the problem seems 
unabated. Statistics from the National Agency for Food and Drug Administration and 
Control revealed that 70% of drugs sold in Nigeria are fake. That means 7 in  10 drugs 
sold are counterfeit. Recently, NAFDAC raided 5 locations in Nigeria (Abuja, 
Shagamu, Ogun, Kaduna and Gombe) and destroyed counterfeit drugs worth over 
#4.7million456. It is also reported that NAFDAC seized 80 truckloads of counterfeit 
medicines457  during the same raid? Be that as it may, counterfeit drugs are 
 
454 US food and drug Administration Available https://www.fda.gov/home Accessed (21 October 2019) 
455 Olusegun Akinyandenu, 'Counterfeit drugs in Nigeria: A Threat to Public Health.' (2013): 
7.36 African Journal of Pharmacy and Pharmacology 2571. 
456 Leadership, Curbing incidence of fake drug in Nigeria 
Available  https://leadership.ng/2019/07/29/curbing-incidences-of-fake-drugs-in-nigeria/ Accessed (21 
October 2019) 
457 John Spink, Douglas C. Moyer, and Michael Rip, 'Addressing the risk of product fraud: a case study 
of the Nigerian Combating Counterfeiting and Sub-standard Medicines Initiatives' (2016): 4.2 Journal 
of Forensic Science & Criminology 1 
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responsible for nearly 450,000 preventable deaths from fake anti-malarial drugs taken 
by unsuspecting victims, making Nigeria one of the highest countries with the most 
counterfeit drug incidence. As such, Counterfeit is still a threat to global public health, 
and it undermines the whole system of drug regulation and control458. 
 
4.5.1 NAFDAC Securing Nigeria’s Medicine Security 
 
Life without health is unattainable as health is necessary to fulfil life. In recognition of 
this stated importance, the 1948 Universal Declaration of Human Right guaranteed 
the right to health for all people found in Article 25 and read as follows that everyone 
has a right to a standard of living adequate for the health and well-being of himself and 
family which includes food, clothing, housing, and medical care''459 . Also, the World 
Health Organisation made a similar provision for the right to health. Its preamble states 
that "the enjoyment of the highest attainable standard of health is one of the 
fundamental rights of every human being, without distinction of race, religion, political 
belief, economic or social condition.  It is an inclusive right that encompasses freedom, 
entitlement, good quality healthcare, and access to essential medicine460.  
 
 
458Kaliyaperumal Karunamoorthi. 'The Counterfeit Anti-Malarial is a Crime Against Humanity: A 
Systematic Review of the Scientific Evidence; 2014, 13 Malar Journal, 13:20910.1186/1475-2875-13-
209. PMID: 24888370; PMCID: PMC4064812. 
459 Universal Declaration of human right, Available httpwww.un.org/en/universal-declaration-human-
rights/ Accessed (22 October 2019Article 25 Right to health, (1) Everyone has the right to a standard 
of living adequate for the health and well-being of himself and his family, including food, clothing, 
housing, and medical care and necessary social services, and the right to security in the event of 
unemployment, sickness, disability, widowhood, old age or other lack of livelihood in the circumstances 
beyond his control. This declaration was reached after the traumatic events of the 2nd world war, which 
created a need to safeguard human existence and foster international peace amongst conflicting 
nations. It resulted in the establishment of the United Nations in 1945 with 50 initial member states. To 
engrave this unity, a list containing human rights necessary for peaceful coexistence was devised and 
accepted by the UN General assembly and enshrined in the ratifying state constitution. 
460 World Health Organisation Right to Health, Factsheet No 31, 




Ratifying states to the World Health Organisation (WHO) made significant efforts by 
making health care a paramount concern, especially in developing countries like 
Nigeria. Remarkably, Nigeria's constitution affirms that the government must uphold 
the standards of social justice, equity, welfare, and human right to quality healthcare 
and develop and implement a national policy for controlling medicine. However, 
various setbacks ranging from lack of coordination, resources, adequate human 
resources, decaying infrastructures, bias resource distribution461, and essential 
medicine have delayed the attainment of the standard mandated by the WHO. 
Sustainable healthcare seems unattainable even though the WHO identifies the 
importance of medicine by stating that the "Lack of access to medicines is one of the 
most complex and disturbing problems that stand in the way of better health' 462' If 
there is no adequate medicine, life cannot be sustained. On this premise, the Nigerian 
government developed a series of initiatives and proposals to attain the best possible 
health care for its people, and one of such initiatives is the creation of NAFDAC. 
NAFDAC's sole objective is the safety, security, and equitable provision of medicine 
to all. Adeyeye recently noted that the problems facing drugs are non-availability, 
which negatively compromises drug security. In his words, drug security is the 
standard '' medicines produced in facilities must meet the right standards and that the 
integrity of such medicines should not compromise stated rules and regulations, during 
its production and distribution along the supply chain from the manufacturers down to 
the consumers." Therefore, if a drug standard is compromised, it will undermine 
medicine's effectiveness on an unsuspecting consumer. It is imperative to have a 
 
461 Menizibeya Osain. 'The Nigerian Health Care System: Need for Integrating Adequate Medical 
intelligence and surveillance systems.' (2011) Vol. 3, 4 Journal of Pharmacy & Bio Allied Sciences 
4708doi:10.4103/0975-7406.90100 
462 WHO, Availablehttps://www.who.int/publications/10-year-review/chapter-
medicines.pdf?ua=1 Accessed(22 October 2019) 
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significant national drug security policy that is sustainable and covers essential 
medicine access. For example, recently, the statehouse medical centre in Aso Rock 
recorded an incident of non –availability of drugs. If the presidency lacks essential 
drugs, what happens to other vulnerable Nigerians in rural areas. Cooperation is 
needed amongst stakeholders to establish a structure or network backed by strict legal 
sanctions. 
 
4.6 Infringement and enforcement of IP under Nigerian Laws 
 
This section aims to discuss the place of IP enforcement in Nigeria’s legal system by 
examining some reported cases on IP violation and the attitude of the Nigerian court 
to ascertain if it meets the international standard required by local, regional and 
international law. The court plays a vital role in the interpretation and development of 
IP laws in Nigeria. It is undoubtedly significant in the current dynamics of IP practice 
and application. IP protection creates commercial value for ideas and innovative steps 
in all fields of technology. It is therefore paramount to protect IP, especially in this era 
of globalisation, which has integrated different economies463. IP is a contemporary 
issue in the emergent knowledge economy464. It is interesting to note that intellectual 
property laws in Nigeria present a pattern and shortcoming in the law from which it 
may be possible to highlight some discernible attributes or characteristics in the 
development of some aspects of the law.  
 
 
463 Eswar Prasad and others. ’Effects of Financial Globalisation on Developing Countries: Some 
Empirical Evidence.’ (2003) Vol. 38, No. 41 Economic and Political Weekly, pp.4319-4330. 
464 Michael W Carrol. ‘One for All: The Problem of Uniformity Cost in Intellectual Property Law’ (2006) 
Vol 55 No 4 American University Law Review, pp.845-900. 
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Laws for the protection of IP is an exclusive right that excludes a 3rd party from 
exercising the right to IP without the express authorization of the right owner. This right 
is transposed into Nigeria’s legal system from the English legal system. It forms the 
bedrock to bring actions against infringement of IP rights. However, despite the 
international development of IP and Nigeria’s membership of the WTO-TRIPS 
agreement, IP is relatively an obscure issue of contention in the Nigerian courts: the 
case law is rare, and litigation is slow-paced, neither has there been any law reform 
or revision, all of which have considerably impacted the judicial trend of IPR. Until now, 
only the Federal high courts have exclusive jurisdiction to hear and determine disputes 
about the infringement of IP. The provision is found in Section 251(1) of the constitution 
of the Federal Republic of Nigeria which states as follows ‘’Notwithstanding anything 
contained in this Constitution and in addition to such other jurisdiction as may be 
conferred upon it by an Act of the National Assembly, the Federal High Court shall 
have and exercise jurisdiction to the exclusion of any other court in civil causes and 
matters subsection.’’ 
 (f) any Federal enactment relating to copyright, patent, designs, trademarks and 
passing-off, industrial designs and merchandise marks, business names, commercial 
and industrial monopolies, combines and trusts, standards of goods and commodities 
and industrial standards’465’ 
The provision of the section above shows that in respect to patents and any form of IP 
in Nigeria, jurisdiction lies only with the federal high court. As seen in Arewa Textile 
Industries. V.Finetex Limited (2003) 466, the court held that on the issue of jurisdiction, 
it is fundamental for the adjudicating court and it is crucial to determine the issue of 
 
465 Section 251(1)(F) Constitution of the Federal Republic of Nigeria 1999.1. 
466 Arewa Textile Industries. V.Finetex Limited (2003) 7 Nigerian Weekly Law Report. 
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jurisdiction in order not to waste the time of the court. The position of the court is 
similar, in the case of Dyketrade Ltd. v. Omina (Nig.) Ltd467. One of the issues 
submitted before the judge was that of jurisdiction. The Federal High Court is said to 
lack jurisdiction to entertain claims of unregistered trademark. To support the 
argument on competency, the appellant relied upon the case of Madukolu v. 
Nkemdilim (1962) 468. The court held that under section 251, the Federal High Court 
is conferred with jurisdiction to hear and determine not only on matters stipulated in 
subsection (f) but other jurisdictions as may be conferred upon it by an Act of the 
National Assembly. Given this, in Nigeria, it is accepted legal practice to bring all IP 
related matters to the Federal High Court, or else the issue would not be resolved. 
This requirement may be cumbersome for IP litigants. This exclusivity of the Federal 
High court has not significantly helped to shift the frontiers of scientific and 
technological development such that it is difficult to assert the accuracy of the 
adjudicating system in Nigeria. 
Similarly, the role of the Nigerian court is questioned in terms of the quality of 
adjudication required for the advancement of IP. The standards set by the court will 
determine protection. For instance, if a penalty meted out for infringement of IP is stiff, 
infringement will decrease. However, if infringement gains surpass, the penalty IP 
violation will surge. This is the typical situation of Nigeria as seen in the following 
cases, Barewa Pharmaceutical Limited. v. The Federal Republic of Nigeria469. This is 
the famous case of ‘My Pikin’ teething powder, which made over 111 children sick, 
three-quarters of whom have died. The mixture is believed to have been tainted with 
a high concentration of diethylene glycol, which is linked to poisoning cases. At the 
 
467 Dyketrade Ltd. v. Omina (Nig.) Ltd 43 NIPJD (SC 2000) 57/1995. 
468 Madukolu v. Nkemdilim (1962) 2 NWLR.  




end of the trial, the court found the appellant and the two other accused persons guilty 
of the offence, and they were convicted accordingly. The appellant, being a company, 
was ordered to be wound up, with its assets forfeited to the Nigerian government while 
the two other convicts were each sentenced to seven years imprisonment, for which 
the sentences were ordered to run concurrently. On the other remaining counts, the 
accused persons were discharged and acquitted. This case is a typical example of 
how the Nigerian court has missed the opportunity to advance the jurisdiction of the 
court about matters of IP infringement. Adequate enforcement of IP will deter 
infringement. The approach of the Nigerian courts in respect to IP matters is 
unconstitutional, IP is as much a right as the right to tangible property. Although IP is 
an intangible right, infringement of this intangible right can be resolved in both civil and 
judicial Courts. Also, right holders should be allowed to bring IP matters to any court 
in Nigeria. The provision that restricts IP matters to just the Federal High Court in 
Nigeria should be declared null and void. To this end, IP rights holders should be given 
the means to get redress in any court in Nigeria, by so doing reduce infringement.  
Conclusion  
This chapter examined the Nigerian situation using historical evidence to demonstrate 
that Nigeria is a country with immense wealth both in human and natural resources. 
Nigeria, from its inception, was a British colony, and it adopts the English legal system. 
Its laws modelled the law existing in England, including Nigeria IP Law. Nigeria is a 
member of the WTO, AU, ECOWAS to increase trade and development, but the 
promised benefit from membership to these organizations negatively impacted trade 
in Nigeria, which can be attributed to the increase of counterfeit. To reduce the 
incidence of counterfeit pharmaceuticals, Nigeria, created NAFDAC. Although it has 
been relatively successful in tackling counterfeit, counterfeit pharmaceuticals is still on 
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the increase. It is, therefore, imperative to develop an overarching framework with 
specific objectives, which tally with the need to have affordable medicine and an 
























Chapter 5 Balancing TRIPS Standard against Nigeria Counterfeit Regulatory 
Efforts: A Critique   
5.1 Introduction  
 
'The tremendous increase in IP application in recent years reflects the growing 
importance of technology and innovation in the global economy and our daily lives." 470 
Today's relevance of innovation or novelty is so essential that a complementary right 
is created to protect its advancement. It is a way of thinking outside the present; 
instead, it is a future based insight. Innovation compares past and future ideas to solve 
a future problem471. Innovation is linked to creativity. In Tienken's words, creativity is 
new, unique and creates innovations in countries'472.Many innovations can only be 
protected by intellectual property to generate economic value with an established 
competitive advantage to guarantee commercial control and use. IP is reward-based; 
the reward is an incentive for creativity. It established the fact that IP is a unique value-
adding creation,473 which generates a legal right when the due process of registration 
and grant of according right is established. It creates an entitlement to creativity.  
However, intellectual protection granted by a state is limited in scope as there is a 
delimitation between international and national intellectual protection. The first part will 
attempt to rectify this issue by examining the meaning of property supported by 
scholarly evidence advocating clarity in interpreting what a right to property means. 
Secondly, it is right to understand the nature of TRIPS protection and the strategy 
 
470 WIPO, Harnessing the Benefit of IP for Development Keynote Address by Ambassador Amina C. 
Mohamed, Cabinet Secretary of the Ministry of Sports, Culture and Heritage of the Republic of Kenya, 
Availablehttps://www.wipo.int/wipo_magazine/en/2019/03/article_0002.html Accessed (27 December 
2019)  
471 Anneli Stenberg, 'What does Innovation mean – a Term Without a Clear Definition' Available 
https://www.diva-portal.org/smash/get/diva2:1064843/FULLTEXT01.pdf 
472 Christopher H. Tienken' International Comparisons of Innovation and Creativity' (2013), Vol 49 No 
4 Kappa Delta Pi Record, PP 153 
473 Christopher M. Kalanje, 'Role of Intellectual Property in Innovation and New Product Development.' 
2006, World Intellectual Property Organization 
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preferred for the utilization of this protection, especially in developing countries such 
as Nigeria, for if the protection authorized by TRIPS is established, any discrepancy 
in its application will be underlined and questioned in resolving Nigeria counterfeit drug 
problem.  
   
5.2 The nature of Intellectual Protection  
 
The subject of Intellectual property was unknown and mostly overlooked in the 1960s. 
Recently, it has gained widespread acceptance as a viable instrument for economic 
growth and development. States have come to recognize and see IP as a new form of 
'resource' which can foster innovation, development and shape economic relations. 
An intellectual resource is an intangible right to a creative outcome in today's 
conditions, be it scientific, industrial, or any inventive step new to humankind; it is 
deemed a resource worthy of protection. Because of this, any unauthorized use of IP 
resources is tantamount to stealing a creator's legal authority over his goods. States 
approve legal protection on IP to safeguard against unauthorized use and to 
encourage new technological inventions, artistic expression, and creativity with the 
sole objective of preventing others from benefiting from the creativity of another. It 
promotes fair trading. With this authority, a right holder can bring actions in a civil or 
criminal proceeding to enforce IP rights.  
Given the peculiar nature of intellectual property rights, two key issues need further 
clarification. These include: 
• Understanding what delineates IP from other forms of property that ensure 
global recognition and protection 
• Secondly, what is the nature of TRIP protection and how is TRIP's strategy 
integral for innovative growth in developing countries. 
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On the first issue, it is established that IP is a form of property protection granted by 
the national law of a state and governed within that state's exclusive jurisdiction. The 
law in that jurisdiction determines the time frame, limitation, minimum requirement, 
and usage of such rights 474. However, Lemley thinks it is absurd to associate IP with 
real property (propertization)475, especially in terms of its economic importance and 
profitability. With this noted association, the IP regime appears to be modelled around 
property laws even though both regimes are different. It will inevitably affect the 
balance of both paradigms. 
Therefore, it may seem appropriate to adopt a utilitarian approach to delineate both 
regimes because it does not attempt to strike a balance between a right and the type 
of property; instead, it looks at the ordinary meaning of terms476. Given this argument, 
IP is a recognized right that is knowledge-based given to a private individual or party 
to control information accruing from the creative ability or outcome477. It is also quite 
clear that intellectual property right is territorial and is different from physical property. 
Following the idea established earlier, on delineating IP from the 
property, Easterbrook equated both regimes and concluded that inventive property is 
similar. For example, the invention framework improves with time, resulting in new and 
better products, which inadvertently means more financial gains. It is similar to 
developing a property to secure more profit. Another connection is the issue of 
 
474Jonathan M W. Chu, 'When Property Does Not Mean Property: An Analysis of the Existence of 
International Intellectual Property' (2011) 39 International law Journal of  
Legal Info, 328 
475 Michael A. Carrier "Cabining intellectual property through a property paradigm. (2004), 54 Duke Law 
Journal 1. Over the years, the context of IP has been revolutionized to fit into the discourse of real 
property as such, narrowing its essence as an intangible right worthy of protection. Although using this 
context has limited IP expression, the unlimited duration and scope of the previous IP right resemble 
the unlimited duration and scope of property rather than the finite regime of protection that the creators 
proposed 
476 Mark A Lemley' Property, Intellectual Property, and Free Riding. (2004) 83, Texas Law. 
Review, 1031 
477 Harry Surden, 'Technological Cost as Law in Intellectual Property' (2013) 27, No 1 Harvard Journal 
of Law & Technology 135-202 
202 
 
monopoly. A patent or copyright entitles a right holder to control its output to the 
exclusion of all others. The IP rights holder has rights of exclusion, the same as the 
property rights holder478. Importantly, finding proves that IP and property rights are 
intricately connected, but this relationship's true nature needs clarification to 
contextualize IP correctly. IP pertains to the right to abstract ideas479, so it is justifiable 
to suggest the establishment of a distinct theory to meet its peculiar needs. 
 
 
Secondly, what is the nature of TRIP protection, and how is the strategy adopted 
by TRIP integral for innovative growth in developing countries. 
To determine the principle of an agreement is tedious and can cause ambiguity in its 
interpretation. If a common approach is adopted, then the philosophical question on 
its nature might seem unanswered because the more abstract it is, the more difficult it 
will be to analyse 480. However, without dissipating ambiguity, the existing principle 
cannot be disputed or probed, which is the case of the WTO-TRIPs agreement. The 
nature and purpose of TRIPS can only be understood within a broader context of the 
WTO agreement. The WTO agreement is all-encompassing and unique in all facets. 
However, scholars have argued that the WTO IP rules in developing countries are 
detrimental to fundamental health and life and, if possible, an absolute nightmare for 
developing countries,481 prompting various debates on the suitability of having a 
 
478 Frank H. Easterbrook, "Intellectual Property Is Still Property' (1990) 13, Harvard Journal of Law 
and Public Policy 108. 
479 Milkhalien Du Bois, 'Justification Theories for Intellectual Property Viewed Through the 
Constitutional Prism, (2018), No 1, Potchefstroom Electronic Law Journal/Potchefstroomse 
Elektroniese Regsblad 21 
480 John P. Humphrey, ‘On the Definition and Nature of Laws, (1945) Vol 8, issue 4 The Modern Law 
Review 194 
481 Peter K. Yu, ‘The Objectives and Principles of the TRIPS Agreement’ (2009), 46Houston Law Review 
.979. Available, https://scholarship.law.tamu.edu/facscholar/457 To developing and least developing 
countries, the implementation of TRIPS minimum standards demands more protection than can be 
provided by these countries. TRIPs is perceived to have ignored the local needs of the people, such as 
medical, legal, and technological needs, and it may have stifled the development of IP. 
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uniform standard diverse world. 482It begs the same question of the nature, and what 
TRIPS aims to protect in the first instance; is it health or wealth?  
In the context of TRIPS, it is designed to protect all forms of IP collectively483, and it is 
regarded as the most comprehensive international treaty for the protection of IP rights, 
with mandatory minimum standards for the protection and enforcement of IP provided 
by each member with specified terms of protection, for a given subject matter within a 
definite period covered by permissible exceptions of those rights484. It is a standard-
setting agreement intended to be a rational process for intending members to boost 
efficiency and economic growth. This standard ought to be voluntarily accepted 
without questioning the authority of TRIPs. However, this is not the case with TRIPS. 
It is an annexe of the WTO, i.e., a de jure standard; thus, a legal requirement is created 
under the WTO485.TRIPS requires all members to adapt their laws to fit into the 
minimum required standard of IPR protection, even though it will significantly impact 
access to medicine and the pharmaceutical sector486. These standards or obligations 
are mandatory for all members concerning their development position. 
No proof that increasing standards increases economic welfare. On the contrary, 
excessive standards can stifle economic development. In the case of pharmaceuticals, 
TRIPS Standard mandates patent protection for a minimum term of 20 years for 
product and process487 even though the time was shorter in most developing 
 
482Thomas Cottier ’The Doha Waiver and its effects on the nature of the TRIPS system and on 
competition law: the impact of human rights’ (2006) NCCR Trade working papers, Available www.nccr-
trade.org Accessed (29 December 2019) 
483Peter K. Yu, ‘The Objectives and Principles of the TRIPS Agreement’(2009), 46 Houston Law Review 
979. Available, https://scholarship.law.tamu.edu/facscholar/457 
484 WTO-TRIPS, Overview: The TRIPS Agreement 
485 Steven M. Spivak, Standardization Essentials: Principles and Practice (CRC Press, New 
York.2001) 
486 WHO-Essential Medicine and Health Product, the WTO and TRIPS Agreement, Available 
https://www.who.int/medicines/areas/policy/wto_trips/en/ Accessed (30 December 2019) 
487 WHO-Essential Medicine and Health Product, the WTO and TRIPS Agreement, TRIPS also 
mandates members to adhere to some listed provisions such as the 1967 Paris convention to protect 
industrial property, the 1971 Berne Convention for the protection of literary and artistic work.  
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countries, resulting in counterfeit rise pharmaceuticals. Essentially, TRIPS ought to 
set applicable standards, not a one size fits all approach but permit various 
measures488 which the state can efficiently utilize.   
 
5.2.1- Compulsory license right on pharmaceuticals in Nigeria and the   
'generics.'  
 
This section will look at the provision and operation of the phase 'other use without 
authorization of the right holder' otherwise known as a compulsory license. It is not 
found in the TRIPS Agreement489. It is inferred into the agreement under the guise of 
its purposed use, in a bid to strike a balance between R&D in drugs and to promote 
unlimited access to drugs. To developing countries, it is a welcomed idea, but it still 
illustrates the existing inequality operating within the WTO's multilateral trade regime. 
Therefore, a detailed analysis of how compulsory licenses can be interpreted and 
utilized will be examined to demonstrate the salient problems associated with its 
application, mainly in the aspect of Nigerian counterfeit drug problems. 
A compulsory license is a legal flexibility permissible within the WTO but granted to a 
state to permit the production of a patented product or process without the right 
owner490. Regardless of the foregoing, compulsory license is deemed an exception to 
the bold expression of the right to intellectual property, as the right owner's consent 
was not sorted. In order words, it takes away the right conferred on the right owner, 
 
488 Steve Charnovitz, ‘International Standards and the WTO’ (2005)George Washington University Law 
School, Legal Studies Research Paper 394, http://scholarshiplaw.gwu.edu/faculty_publications/394 
489 WT0- Factsheet: TRIPS and Pharmaceutical Patent, Obligations and Exceptions, 
Available http://www.wto.org/english/tratop_e/trips_e/factsheet_p Article 31 provides for other use. This 
means or includes the use of any patent right by the government for their purposes without getting 
formal authorization from the right owner, mostly if voluntary license application has failed but if 
compulsory licenses are granted the right holder is adequately remunerated. 
490 WTO-compulsory Licencing of Pharmaceuticals and TRIPS 




which is the right of acceptance or refusal, which is an infringement of ownership. 
Nevertheless, the compulsory license is valuable as a means of saving lives, for a 
government can authorize the use of the pharmaceutical patent to address public 
health problems.  
The idea behind compulsory license originates from the lack of access to essential 
medicine, particularly in developed and LDC, often because these pharmaceuticals 
are unaffordable491. This concern further intensified during TRIPS negotiation, 
particularly the patent provision within TRIPS. In response to this foreseeable problem, 
the World Trade Organisation (WTO) Doha Ministerial conference of 2001 adopted 
the TRIPS agreement492. This declaration affirmed that the TRIPS agreement should 
be implemented, and it should not be detrimental to Public Health as per its scope, 
implication, implementation, and application, while still recognizing the importance of 
intellectual property to the advancement of new drugs493.  
Article 31 of the TRIPS Agreement provides for a compulsory license, which can be 
summarized as follows (section A-F) 'That authorization can only be granted based on 
the individual merit of each application, however, permission is granted based on the 
previous refusal from the right holder within a period, but this requirement can be 
waived in the event of a national emergency, public non-commercial use after due 
notification to the right holder'494.  In retrospect, the Doha Declaration further simplified 
 
491 Ellen F.M Hoen and others, 'Medicine procurement and the use of flexibilities in the Agreement on 
Trade-Related Aspects of Intellectual Property Rights,' (2018), Vol 96, Issue 3, Bulletin of the World 
Health Organization, 2001–2016 DOI:10.2471/BLT.17.199364  
492 Carlos M. Correa, 'Implications of the Doha Declaration on the TRIPS Agreement and Public 
Health,' 2002 Geneva: World Health Organization, No. WHO/EDM/PAR/2002.3. 
493 IBID Correa 
494 TRIPS Agreement- Article 31 
Available https://www.wto.org/english/res_e/publications_e/ai17_e/trips_art31_oth.pdf Accessed(2 
January 2020)( A.)authorization of such use shall be considered on its merits; 
 (b) such use may only be permitted if, before such use, the proposed user has made efforts to obtain 
authorization from the right holder on reasonable commercial terms and conditions and that such 
efforts have not been successful within a reasonable period. This requirement may be waived by a 
Member in the case of a national emergency or other circumstance of extreme urgency or in cases of 
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Article 31 of the TRIPS agreement, to Gathii the "Doha Declaration captures the 
middle ground between the positions adopted by developing and developed countries. 
It embodies the commitment to protect patent for the development of new drugs and 
the availability of these drugs, in addition, it can be interpreted and implemented in a 
manner supportive of WTO Members' right to protect public health and, in particular, 
to promote access to medicines for all495. Ultimately, it is a freely granted right decided 
on merit, otherwise known as government use. This right given can be assigned to a 
government entity or non-government entities as an alternative measure in market 
failure (patented pharmaceuticals)496. Article 31 clearly instructs that a compulsory 
license must be issued principally for the supply and utilization by the TRIPS member's 
domestic market granting the license. However, countries without a substantial 
 
public non-commercial use. In situations of national emergency or other circumstances of extreme 
urgency, the right holder shall, nevertheless, be notified as soon as reasonably practicable.  
In the case of public non-commercial use, where the government or contractor, without making a patent 
research, knows or has demonstrable grounds to know that a valid patent is or will be used by or for 
the government, the right holder shall be informed promptly;  
 (c) the scope and duration of such use shall be limited to the purpose for which it was authorized, and 
in the case of semi-conductor technology shall only be for public non-commercial use or to remedy a 
practice determined after the judicial or administrative process to be anti-competitive;  
(d) such use shall be non-exclusive.  
 (e) such use shall be non-assignable, except with that part of the enterprise or goodwill which enjoys 
such use.  
 (f) any such use shall be authorized predominantly for the supply of the domestic market of the Member 
authorizing such use.  
 (g) Authorization for such use shall be liable, subject to adequate protection of the persons' legitimate 
interests so authorized, to be terminated if and when the circumstances that led to it cease to exist and 
are unlikely to recur. The competent authority shall have the authority to review, upon motivated 
request, the continued existence of these circumstances.  
 (h) the right holder shall be paid adequate remuneration in the circumstances of each case, considering 
the economic value of the authorization. 
 (i) the legal validity of any decision relating to the authorization of such use shall be subject to judicial 
review or another independent review by a distinct higher authority in that Member 
495 James Thuo Gathii, 'The Legal Status of the Doha Declaration on TRIPS and Public Health under 
the Vienna Convention on the Law of Treaties' (2002) Vol 15, No2 Harvard Journal of Law and 
Technology PP 301 
496 Kyung-Bok Son, 'Importance of the Intellectual Property System in Attempting Compulsory Licensing 




pharmaceutical sector have not utilized the compulsory licensing provisions of 
TRIPS497. 
In practice, it can be argued that compulsory license is inconsistent with the statutory 
right accruing to a patent holder to recoup the cost and benefit of research and 
development. Neither will the patent holder oppose the production and distribution of 
the generic version of the pharmaceutical. It can stifle the incentive to innovate new 
essential medicines. A typical example of this highlighted point is the case of 
sofosbuvir used in the treatment of hepatitis C, and in the USA, it cost $64 per 
treatment. In contrast, in developing countries such as India, it cost $539, this is 
exceedingly expensive; the Malaysian government issued a compulsory license for 
this drug498, thus reducing the earning powers of the patent holder. 
To developing countries,  compulsory licencing is a welcome development to solving 
public health crisis such as tuberculosis, malaria, Ebola and HIV Aids 
problems499 needing extreme urgency as seen in the case when Brazil issued a 
compulsory license for the patented drug efavirenz (patented HIV Medicine) after 
negotiation with the patent holder Merck failed. However, the emergency is not limited 
to just these diseases, but it covers any public health concern to health advocates. A 
compulsory license can lead to low priced drugs in cases of national crisis500. 
Consequently, compulsory license repels the standards of intellectual protection 
 
497 Alexandra G. Watson' International Intellectual Property Rights: Do Trips' Flexibilities Permit 
Sufficient Access to Affordable HIV/AIDS Medicines in Developing Countries (2009), Vol 32, Issue 
1, Boston College International law & Comparative law review (2009): 143 
498Gorik Ooms and others Could International Compulsory Licensing Reconcile Tiered Pricing of 
Pharmaceuticals with the Right to Health? (2014),14 BMC International Health and Human Rights, 37 
499 Holger Hestermeyer, Human Rights, and the WTO: The Case of Patents and Access to Medicines. 
(Oxford: Oxford University Press, 2007) 
500 James Thuo Gathii, 'The Legal Status of the Doha Declaration on TRIPS and Public Health under 




dictated by TRIPS, and guarantees access to essential medicine, making it a legal 
exception to the TRIPS directive.  
Regarding Nigeria, the compulsory license is enshrined in the Nigerian patent and 
design act, particularly in section 11, which states as follows. That the provisions of 
the First Schedule to this Act shall affect compulsory licenses and the use of patents 
for the service of government agencies, the first schedule explicitly explains 
compulsory license provision, specifying that Section 13 of the first schedule permits 
a state minister by order in the Federal Gazette to authorize, certain patented products 
and processes (or for specific categories thereof) declared by the order to be of vital 
importance for the defence or the economy of Nigeria or public health, compulsory 
licenses may be granted before the expiration of the period mentioned in paragraph 1 
above and may permit importation501. The provision of this Act allows a government 
agent or minister to adopt compulsory license on any ancillary matter concerning 
access to patented medicine, although it is not automatic. Only the court can authorize 
the grant if the following conditions have been met. 
 (I) Inability to obtain a patented license 
 (ii) Parties cannot agree on terms 
(iii) The patentee will be adequately remunerated (royalty or otherwise) considering 
the relevant invention to be worked 
(iv) It will be contrary to the public interest if not granted. 
 Once all these conditions are established, a compulsory license will be authorized. 
However, these conditions can be waived in the case of extreme emergency, or 
 
501 Eric Bond and Kamal Saggi, 'Compulsory Licensing, Price Controls, and Access to Patented Foreign 
Products, (2014)109, Journal of Development Economics 217-228. After Brazil triggered the first 
compulsory license to make Merck reduce efavirenz's price, even after the price reduction (30%). The 
government issued a 5-year compulsory license; still, the local company for efavirenz production did 
not have the workforce or technology. Patents and Designs Act, Chapter 344 Laws of the Federation 
of Nigeria 1999, Cap C23 Laws of Federation of Nigeria 
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national emergency termed government to use502. In principle, the compulsory license 
is a welcomed development given that in the past, most developing countries and 
developed countries did not permit patents on pharmaceutical products503. It is a vital 
government tool for exemption of liability, especially in the context of pharmaceuticals. 
Even if the rights of a patent holder is undermined, the zeal to save the public comes 
first. 
For a country like Nigeria, compulsory license seems to be a viable option for its failing 
public health. Winslow suggests that' Public health is the science and art of preventing 
disease, prolonging life, and promoting physical health and efficacy through organized 
community efforts for the environment's sanitation. The control of communicable 
infections, the education of the individual in personal hygiene, the organization of 
medical and nursing services for the early diagnosis and preventive treatment of 
disease, and the development of social machinery which will ensure every individual 
in the community a standard of living adequate for the maintenance of health; so 
organizing these benefits in such a fashion as to enable every citizen to realize his 
birth right and longevity504.” Similarly, Rosen emphasized that the scope of public 
health has evolved as society developed to not only include prevention and control of 
diseases as earlier stated but now include new emerging communicable diseases, for 
example, HIV, AIDS, Anthrax, and Ebola, which are relatively new diseases.505 Faced 
 
502Jerome H. Reichman' Comment: compulsory licensing of patented pharmaceutical inventions: 
evaluating the options." (2009) Vol 37.2 The Journal of Law, Medicine & Ethics PP 247. This comment 
traced the history of TRIPS in a bid to discover the legality of the all-encompassing compulsory license 
provision and its relative effect on developing countries' essential medicine problems without 
undermining the right guaranteed as a member of the WTO or face unilateral sanctions from patent 
right holders. It wouldn't be the case if the WTO did not increase its minimum patent protection standard 
without an underpinning effect on developing countries. 
503 IBID Reichman 
504 Jeffrey Koplan and others, 'Towards a common definition of global health' (2009) no. 9679 The 
Lancet 373: 1993-1995 citing Winslow Charles-Edward. "The untilled field of public health" Mod Med 2 
(1920).183-91 
505 George Rosen, A History of Public Health, (John Hopkins University Press: New York, 2015) 
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with this growing threat, a state must ensure the best possible health care. Given this, 
the Nigerian government is expected to seek the best viable option available 
(compulsory license), especially regarding the increasing cost of producing drugs and 
the new problem of pharmaceuticals counterfeit. 
The Nigerian government is facing challenging issues underpinning its pharmaceutical 
sector. Amongst the problems is the scourge of counterfeit and substandard drugs, 
which is contrary to ensuring safe and cost-efficient pharmaceuticals that meet the 
national health needs. The capacity to meet this stated need seems unrealistic in 
Nigeria's failing developmental and medical agenda. It has been observed that not 
until the early 1970s, Nigeria was solely dependent on finished drugs such as syrups, 
tablet suspensions imported from developed countries such as the USA and UK. The 
country lacks a viable local industry to produce drugs (process or product) neither was 
patent rule acceptable nor practised; therefore, having a TRIPS standard on drugs 
seems unlikely. 
  
Although compulsory license is an all-encompassing solution to TRIP Agreement, the 
stringent patent is defective in developing countries. Specific concerns have been 
raised on compulsory license, which seems to encourage the increase of counterfeit 
pharmaceuticals. For example, it allows unapproved generic drugs to be produced 
and distributed. It raises a safety concern506that counterfeit drugs can be possibly 
manufactured instead of the original drugs. Moreover, developing countries with a 
large population like Nigeria (with lax immigration laws) can be used as dumping 
ground for unwanted generic irrespective of its source or dangerous impurities utilized 
 
506 Muhammad Zaheer Abbas, 'Pros and Cons of Compulsory Licensing: An Analysis of Arguments' 
(2013) Vol 3, No3 International Journal of Social Science and Humanity PP254 
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in making it. In conclusion, compulsory license is an all-important administrative right 
bestowed on the government to protect public health. Still, developing countries, 
effective utilization seems to affect the use of this right. Communal harmony amongst 
stakeholders of developing countries can effectively reduce the price of medicine, 
without actively relying on the compulsory license. It should be a last resort to 
unforeseen emergencies.    
5.2.2 The Impact of Parallel importation on counterfeit on Nigeria national drug 
plan 
 
The need to have a sustainable drug plan is the foremost goal of any government, 
especially the Nigerian government, particularly in the face of its current health care 
situation with life expectancy at birth estimated to be 54 years and the infant mortality 
ratio around 86 per 100 births. The death toll from preventable diseases such as 
tuberculosis, HIV, malaria, asthma, and sickle cell507 is alarming; still, the gap between 
the health care value and the current pharmaceutical reality is changing given the 
perversity of counterfeit drugs production, trafficking, and use which subsequently 
could result to death. Therefore, existing strategies ought to be critically examined in 
a bid to draw a contrast with current IP rules authorized by TRIPS. This is intending to 
find out if the rules stifle the availability of pharmaceuticals in Nigeria. One such 
adopted option available to developing countries is the parallel import option. 
The Nigerian National Drug Control Master Plan (NDCMP) offers an integrated and 
comprehensive approach towards tackling pharmaceuticals from 2015-2019. The plan 
includes counterfeit drug supply and distribution following international regulatory 
 
507 Muhammad, Faisal, Jamil Hassan Abdulkareem, and ABM Alauddin Chowdhury ‘Major Public Health 




authority on drug control and use. It is established that a viable drug plan does exist 
that recognizes international authority for pharmaceutical regulation. However, this 
drug plan's paramount goal is the eradication and reduction of counterfeit to the barest 
minimum. The plan is strategic, for it links the rule of law to public health while 
canvassing for a viable criminal justice system in place to prohibit the surge and usage 
of counterfeit drugs. Essentially it is a rule-based system that upholds criminalizing the 
production and distribution of counterfeit or illicit drugs. To sustain this approach, 
Nigeria ratified regional and international agreements on anti-drug initiatives and 
programs to control the counterfeit drug surge.  
To implement this initiative, stakeholders consulted local authorities, ministers, and 
heads of ministries to formulate plans and find ambiguities in existing rules. One such 
gap identified is the inefficiency of Nigerian Law Enforcement agencies in tackling the 
surge of counterfeit drugs or illicit drugs. The law enforcement agency is considered 
obsolete and not proactive in intelligence collection and analysis. It lacks 
professionalism, unlike other recognized law enforcement agencies. Also, unethical 
practices within the agency and the adverse effect of inadequate policy and a non-
operative legal framework inhibit how it is dealing with counterfeit Issues.  Similarly, 
the most obvious gap is the lack of synergy between law enforcement agencies' 
operations at the federal and state level for both levels lacked corporation in strategic 
drug issues508. Perhaps the shortcoming of this plan is that it is keen on curtailing drug 
trafficking and the use of narcotic substances for medical and scientific 
purposes509 instead of solving the problems of counterfeit pharmaceuticals. 
 
508Nigerian National Drug Control Master Plan (2015-2019) Available 
file:///C:/Users/ugo/AppData/Local/Packages/Microsoft.MicrosoftEdge_8wekyb3d8bbwe/TempState/D
ownloads/ndcmp-2015-2019%20(1).pdf   
Accessed (25 January 2020) 
509United Nation Office on Drug and Crime (UNODC) Nigeria takes the lead, rolls out policy documents 
to improve availability and access to controlled medicines and improve drug treatment standards 
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Counterfeit is a core problem affecting both public health and the economy. If up till 
now, no adequate drug plan has been proposed, then how will this new drug plan be 
effective. 
 Nigeria needs to develop a viable drug policy. For example, in Malawi, interested 
parties in the supply and distribution of drugs came together to form a proficient drug 
policy from collaboration510. The latter issue is relevant and ought to be taken seriously 
by the Nigerian government policy formation to control the increasing pharmaceutical 
counterfeit rate. Another relevant narrative on drugs is that the Nigerian National Drug 
plan is supported and promoted by the World Health Organisation (WHO). It is worth 
pointing out that as far back as 2003, a drug plan has been in existence for Nigeria. 
Though obscure, it serves as a precedent to develop a useful, efficient strategy to 
tackle the counterfeit problem. The drug plan background states that" no matter how 
vibrant a health policy is, without the availability of good quality and affordable 
medicines, that policy will be sterile." Therefore, affordable and safe medicine is an 
important goal for an innovative drug plan. The national drug policy's goal is to ensure 
the availability of good quality safe medicine in Nigeria and the expansion of local 
production of medicine. Amongst the objective provided by the drug policy includes 




(25 January 2020) 
The initiative and development of a National Policy for Controlled Medicines is anchored on recognizing 
individual needs and the best interest of human development. The National policy elaborates and 
presents a practical approach to ensure the availability and accessibility of medicines. It addresses a 
barrier to essential medicine to prevent abuse and overdose. The government hopes to provide the 
best health care based on internally accepted practice to ensure safe ace, to quality and affordable 
medicine. 
510 Ransome O. Kuti, 'National Drug Policy in Nigeria' (1992), Vol 13, No 3 Journal of Public Health 
Policy, pp. 367 
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system, promoting rational use of drugs, regulation of the import, distribution sale of 
medicines and increasing research on alternative medicine511.  
Having established the potential existence of a national drug plan in Nigeria, the next 
step is to examine this section's core issue, which is the applicability of parallel import 
on the Nigerian national drug plan. Parallel import, otherwise known as (PI), is a 
controversial topic amongst IP scholars and commentators who have diverse views 
on its significance in the global trading regime. Strong IP advocates support banning 
PI, arguing that it reduces profit incentives in the pharmaceutical industry and can 
undermine the growth capacity of the research in pharmaceuticals. Conversely, this 
school of thought contravenes the interest of developing /underdeveloped countries, 
which places a high value on medicine's affordability rather than supporting a robust 
IP regime512. Thus, strong patent invariably leads to high drug prices, which is at 
variance with access to affordable medicine513.  
The concept of PI is essential in a discussion of access to medicine. It is pertinent to 
examine what parallel import means, for without meaning. Elucidation is pointless. 
Price is money worth for the right to exchange an article, or it is a measure of value 
placed on a commodity. To Fetter, value is deemed more subtle than the word money; 
it is all-encompassing and can reflect the energy utilized in creating a valuable 
 
511 WHO Nigerian National Drug Policy 2003 
Available  https://apps.who.int/medicinedocs/documents/s16450e/s16450e.pdf Accessed ( 25 
January 2020) 
512Keith E Maskus, 'Parallel imports in pharmaceuticals: implications for competition and prices in 
developing countries.' Final Report to World Intellectual Property Organization 13 (2001), 
Availablehttps://www.wipo.int/export/sites/www/about-ip/en/studies/pdf/ssa_maskus_pi.pdf  Accessed 
(27 January 2020) Most developing countries do not have research capacity to develop their own 
medicine, so reliance on cheaper medicine is essential for the treatment of disease. To demonstrate 
how important price is, South Africa resorted to using PI after exhausting other remedies to reduce 
the excessive price of HIV drugs protected by patent.  
513 Patricia M Danzon and Adrian Towse, 'Differential Pricing for pharmaceuticals: Reconciling access, 




commodity514. In contemporary society, much value is placed on pharmaceuticals 
because it is essential to public health and economic development. It is like a double-
edged sword. On the one hand, there is the impact of price on access and affordability, 
and on the other hand, there is the incentive to create new drugs. Monopolistic profit 
is a driving factor in the pharmaceutical industry due to the high investments required 
to start-up and run a pharmaceutical company515. 
The pharmaceutical industry is one of the most booming sectors accounting for the 
high-profit margin necessary for its rapid growth. To Kyle, the price of pharmaceuticals 
is paramount in terms of the quantity and quality of drugs. For instance, the United 
States has the largest single market on pharmaceuticals estimated annually, 
generating revenue of around $97 Billion, followed by Europe, making over $51 billion 
annual revenue516. With much revenue generated, it can be implied that these 
companies may exploit the need of consumers, particularly the most vulnerable in 
society, for higher returns on investments. Although monopoly stimulates innovation, 
the dire consequences of this on middle-income countries cannot be determined due 
to inaccurate recording systems. Thus, price undermines the total utilization of drugs 
prompting the rise of generic medicine.  
The global sale of generic pharmaceuticals has increased, although it is a controversy 
amongst its brand pharmaceuticals, thus altering the competitive dynamics in the 
pharmaceutical market. Grabowski and Vernon observed a price correlation between 
generic and branded pharmaceuticals. As generic medicine prices reduced, branded 
 
514 Frank A. Fetter, 'The Definition of Price,' (1912) Vol. 2, No. 4, The American Economic Review pp. 
783-813  
515 Dos Santos and others' Factors Influencing Pharmaceutical Pricing- A Scoping Review of Academic 
Literature in Health Science'. (2019) Vol 12, No 1 Journal of Pharmaceutical Policy and Practice pp 1-
12 
516Margaret K Kyle, 'Pharmaceutical Price Controls and Entry strategies.' (2007), Vol 89 Issue 1 The 
Review of Economics and Statistics 89.1 (2007): pp. 88.  
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medicine's price increased, leading to a substantial shift in the pharmaceutical 
market517. Gibson, Ozminkowski, and Ron Goetzel believe that generic is a form of 
cost-sharing but holds reservations on its therapeutic value518. Hence, it can be 
summarized that generic rivalry has reduced pharmaceuticals' prices, but the 
contradictory effect in less-regulated regimes can be challenging and result in a 
different option. 
One such option available to developing countries and endorsed by TRIPS Agreement 
is parallel import (PI). The significance of permitting PI is a contentious issue amongst 
IP scholars and advocates. For instance, Maskus and Chen speculate, "those welfare 
implications of allowing parallel imports is ambiguous" 519. However, parallel imports 
are genuinely patented, and trademarked goods that still have existing intellectual 
property protection, placed into circulation in one market but imported into a second 
market without due authorization from the license holder. This product is not different 
from the original product, although it may be packaged differently without the original 
license owner warrant. It is important to note that the product is presumed to be 
genuine, not counterfeit. However, PI is legal (international exhaustion), but it 
contravenes the intellectual property's principle standpoint 520.  
 
 
517 Richard G Frank and David S. Salkever' Generic entry and the pricing of pharmaceuticals' (1997) 
Vol 6 issue 1 Journal of Economics & Management Strategy PP 75-90. 
518 Teresa B Gibson, Ronald J. Ozminkowski and Ron Z. Goetzel, 'The effects of prescription drug cost-
sharing: a review of the evidence.' (2005) , Vol.11 Issue11 American Journal Management Care PP 
730-740. 
519 Keith E. Maskus and Yongmin Chen. 'Vertical price control and parallel imports: theory and 
evidence.' (2004) Vol 12, Issue 4Review of International Economics pp551 
520 Keith E. Maskus, 'Parallel Imports in Pharmaceuticals: Implications for Competition and Prices in 
Developing Countries' (2000) Vol 23, Issue 9 The World Economy pp1269. PI of pharmaceuticals can 
be observed to restrict the incentive to produce new pharmaceuticals. IP supporters have argued for 
states to desist from using PI, for it slows down innovation and creativity. However, developing countries 
and public health advocates have argues that pharmaceuticals' availability is far more vital than the 
source of the pharmaceutical. 
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Developing countries are keen on availability rather than the source. Therefore, PI is 
a vital territorial tool used in the regulation of the price of pharmaceuticals. It is rather 
disturbing that price stands in the way of good health, but this is the reality most 
developing countries like Nigeria encounter daily. PI is an individual prerogative state 
can exercise, though states can choose any form of 'exhaustion.' The policy on 
exhaustion comprises three distinct concepts. The first is national exhaustion. Here, 
the holder of IP right to a product is exhausted when the product is sold in the national 
territory, while regional exhaustion is when the IP holder product is sold in a regional 
province, for instance, the African Union regional market. In this case. "Parallel 
imports" will only be permitted, but only regarding goods initially placed on the market 
within a regional territory. Whereas the "international" exhaustion policy makes the 
IPR holder's right extinguished when a protected product is sold in any global market. 
States can pick and choose what form of PI to adopt based on the condition that it 
pertains to goods or services lawfully first placed on the market anywhere in the 
world521. 
Nevertheless, to WIPO, exhaustion is a limitation to IP rights, as the name implies, it 
merely means the exhaustion of IP right in a product after the sale. This means the 
product can be resold in a different jurisdiction without the authority of the IP owner. 
This product can be parallel imported outside the distribution channel contractually 
negotiated by the right owner522. The doctrine of exhaustion provides a legal base for 
PI. Certain factors can influence PI, such as price. Price plays a vital role in the parallel 
 
521 Frederick M Abbott, 'Parallel Importation: Economic and Social Welfare Dimensions.' International 
Institute for slowing Development (IISD), Swiss Agency for Development and Cooperation (SDC) 
(2007), Countries tend to pick and choose exhaustion policy to adapt to fit its peculiar circumstance. 
For instance, a country may adopt a regional exhaustion policy for goods protected by patent and adopt 
a national exhaustion policy for copyright-protected products. 
522 WIPO, International Exhaustion and Parallel Importation, Available 




trade of pharmaceuticals: high prices can prompt competition between the original 
producer and parallel importers523. It may be possible that excess price competition in 
the pharmaceutical sector can potentially result in over-investment in research and 
development or excessive duplication ideal, and it may reduce the incentive to produce 
new pharmaceuticals524.   
 The salient idea on PI from a developing country perspective is thus: PI ensures 
expensive patented drugs from another country can be sold at a lower price, 
inadvertently competing with a similar product having similar IP protection in that 
region. If PI is implemented in Nigeria, drugs can be sold at cheaper or subsidized 
rates. This can set a standard for negotiations amongst pharmaceutical importers to 
dictate the basis of sales with multinational pharmaceutical companies. However, for 
PI to be applicable in Nigeria, it can only be under international exhaustion of rights, 
for regional exhaustion will not be applicable for being a member of the Economic 
Commission of West African States (ECOWAS).  
ECOWAS rules do not support regional exhaustion; neither did it allow competition 
rules to be domesticated in its regional states. In practice, national exhaustion ought 
to be applicable, but the supreme court in Nigeria deliberated on consent and 
protection in the case of Dyktrade v. Omnia, on IP protection. The court contended 
that the registered owner of a product could institute actions against trademark 
infringement. The court went further to clarify who is entitled to protection to include 
the owner, importer, and exporter525. Whereas on the subject matter of consent, the 
supreme court in Ferodo Ltd v. Ibeto Ind. Ltd held that "A proprietor has the exclusive 
 
523 Brekke R. Kurt, Tor Helge Holmås, and Odd Rune Straume' Price Regulation and Parallel Imports 
of Pharmaceuticals (2015) Vol 129, Journal of Public Economics pp. 92-105 
524 Barfield, Claude E., and Mark A. Groom Bridge. 'Parallel Trade in the Pharmaceutical Industry: 
Implications for Innovation, Consumer Welfare, and Health policy.' Fordham Intellectual. Property 
Media & Entertainment. 1999 Vol 10, Law Journal 185 
525DYKTrade Limited(Appellant).V.Omnia Nigeria Limited (Respondent)(2000)AllN.L.R.591 
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right to use, market and sell goods, without the express consent and use or sale the 
proprietor can sue for infringement or sue for passing off of goods526.   
The status of parallel import and exhaustion in Nigeria can be deduced from the court's 
findings in the case of Honda Place Limited V. Globe Motors(2005)14 NWLR 527 Limited, 
the federal high court upheld that defendant should cease importing cars from the 
United States for the plaintiff had the sole right, and that right cannot be contravened 
by way of parallel import. The Nigerian Court of Appeal in the case of Pfizer Specialties 
Limited Vs. Chyzob Pharmacy Limited 528held that parallel importation is a foreign 
doctrine, which is not actionable under Nigerian Law529. For PI to be applicable in 
Nigeria, it is international exhaustion, but no rule suggests that all international law 
must be implemented in the national legal system of states. In this instance, by the 
WTO legal order, states have ratified a single undertaken to apply the WTO binding 
rules in its domestic legal system530.  
Perhaps in Nigeria, the PI institution may serve as a myriad or a perfect solution in its 
struggle with the high cost of pharmaceuticals. Nonetheless, an IP owner's exclusive 
right is not exhausted; consequently, legal options may seem laudable in some 
instances to assert ownership especially where international exhaustion supersedes 
an individual right to IP. The underlying principle interpreted on PI is the availability 
 
526Olasupo Shasore , 'Parallel import –How to Manage the Problem,' 
Availablehttp://www.ajumogobiaokeke.com/wp-
content/uploads/2018/01/c930665fe00db0095450d9d46b3e39d6.pdf  Accessed (18 February 2020) 
527 (2005)14 NWLR 
528 (LER [2006] CA/L/282/2001) 
529 Banwo and Ighodalo, 'Fair Trade, Monopoly and Competitiveness: Appraising the Legal Rights of 
Franchisees Against Parallel Imports in Nigeria' Date? Available https://www.banwo-
ighodalo.com/assets/grey-matter/0d297c0b10ddcd02b610149391ac60f3.pdf Accessed (18 February 
2020)  
530 Pascal Lamy, 'The Place of the WTO and its Law in the International Legal Order, (2006) Vol17, 
No.5 European Journal of International Law pp. 969 The WTO upholds a principle of equality by making 
fair rules applicable in all states in respect of the state of development; its rules have developed for over 




and accessibility of essential pharmaceuticals, but PI may significantly impact the 
surge of counterfeit drugs. A gap is created when the price of medicine varies in 
different jurisdictions because of PI. The outcome is the introduction of counterfeit in 
the supply chain. Equally, the right owner may have lost the IP right to sue for 
infringement or detect low quality or counterfeit products for PI erodes the legal right 
to IP.  
Liang posits that it is perceived to be a global phenomenon, stating that price 
differentiation creates an incentive to move medicine from one jurisdiction. 
Unfortunately, legitimate medicine may be replaced with fake, tainted, expired, or 
diluted medicine or medicine with ineffective material or counterfeit drug, which can 
create harm in circulation 531without arousing suspicion because there is no emphasis 
on IP nor the existence of a binding legal obligation from the IP owner. Essentially, the 
distribution of finished medicine is complex and difficult to trace for medicine and might 
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counterfeit market." Journal of pharmaceutical and biomedical analysis 87 (2014): 167.  
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very low price. The countries in EU have so developed and adopted PI to the point that PI is the largest 
import market for pharmaceutical, with Britain estimated to have parallel imported 70% of its 
pharmaceutical supply. But the drawback of PI is in the redistribution network here, drugs can be 





 Fig.4. Shows the Intricacy of the parallel pharmaceutical trade enabling the introduction of 
counterfeit pharmaceutical533 
 
This diagram shows the intricacy of PI that creates an enabling environment for 
counterfeit pharmaceuticals to thrive. Medicine manufacturers supply wholesalers' 
medical products directly who, in turn, distribute to hospitals and pharmacies. These 
drugs come from authorized licensees who have existing IP rights to sell and 
distribute. However, if PI is invoked, it may create a break in the chain of distribution 
and regulation. It can be suggested that PI on genuine patented or trademarked 
pharmaceuticals in circulation in one jurisdiction can be repackaged and exchanged 
with counterfeit pharmaceuticals to be supplied to an unsuspecting market, making it 
difficult to trace the originality of the drug.  Thus far, there is little doubt on PI's 
sustainable objective on pharmaceuticals: it has legal validity under the WTO Legal 
order. However, its shortcoming outweighs its benefits. PI seems plausible in the 
Nigerian situation, but its implementation and utilization might be encumbered by the 
 
533 Jonathan Harper, ‘European Alliance for Access to Safe Medicines (EAASM), European Patient 
Safety and Parallel Pharmaceutical Trade–A Potential Public Health Disaster’ Medicom Group Ltd., 




weak operating system534. In my view, PI ought to be further improved in a bid to close 
the lacuna caused by PI. However, PI has informed this research by demonstrating 
how the WTO policy can encourage the surge of counterfeit medicine.  
 
5.2.3 TRIP plus Rules on Counterfeit Pharmaceutical  
 
The TRIPS Agreement reaffirmed its commitment to promote access to essential 
medicine. This can be perceived from the standard set during the implementation of 
the Doha declaration. States had the right to utilize any of TRIPS available safeguards 
such as compulsory license, use exception, and parallel import discussed above to 
meet its medical needs. Although it is regarded as a breakthrough, the state is 
obligated by the policy of one size fits all approach undertaken by the WTO. To adopt 
more stringent patent protection known as TRIPs-Plus, which targets explicitly 
developing countries to encourage the implementation of stricter patent laws even 
through it.   
It can be inferred from the USA and EU countries' trade deals with developing 
countries such as the Dominican Republic-Central America FTA (DR-CAFTA), the US-
Jordan Free Trade Agreement, and the Trans-Pacific Partnership Agreement (TPP). 
A typical example of TRIP-Plus provision includes patent linkage, data exclusivity, 
increased enforcement mechanism, and patent term extension longer than 20 
years535. TRIP Plus obligation intends to ameliorate the problems of access to 
medicine in developing countries. However, it has compounded the issue by limiting 
access to a free alternative source to much-needed medicine. Nigeria and other 
 
534 Mary Shepherd, 'Beef up International Cooperation on Counterfeits." (2010) Vol16 issue 4 Nature 
Medicine pp. 366 
 
535 Jennifer Reid, 'InforJustice.org, The Effect of TRIPS –Plus IP provision on access to affordable 
Medicine, Available http://infojustice.org/archives/34601Accessed (14 March 2020) 
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developing countries such as China have modelled their existing IP rules following 
TRIPs' equivalent obligation536. Therefore, this section seeks to examine the influence 
of TRIP-Plus rules in the surge of counterfeit pharmaceuticals and its relative influence 
in the developing IP regime.  
The use of TRIPs safeguards and flexibility has improved access to medicine and 
made the IP regime seemly workable in developing countries and LDCs. For instance, 
the Ecuador IP office used one of TRIPs' flexibility, which is compulsory license in the 
manufacture of Antiretroviral (ARV) medicine, which is a combination of Lopinavir and 
Ritonavir. This action informed the reduction of the existing patented HIV medicines. 
Equally, the Ghana IP authority applied to the government to use the exception to 
purchase antiretroviral medicine from India, and this reduced the cost of ARV medicine 
by over 50% in the country. No doubt, TRIPs safeguards have ameliorated the plight 
of developing countries and remedied the impact of patent protection.  
 It is useful when implemented into the legal framework of member states. However, 
developed countries consistently canvassed for more stringent and restrictive IP rules 
that go beyond TRIPs for developing countries because of the notion that having a 
higher level of protection outside the framework of TRIPs mandate would increase 
profit. Developed countries possess the technology, invention, and patent in 
pharmaceuticals needed by other state members to the WTO. This gave rise to the 
development of TRIP-Plus. It is a non-technical term, which does not demand an 
obligation for acceptance by WTO member states. Acceptance of TRIP Plus rules 
would be considered part of a Free Trade Agreement (FTA)537 due to fear of trade 
 
536 Qingjiang Kong, 'A Rising Tide Lifts All Boats, IPR Provision In China's Free Trade Agreement 
Regional Cooperation and Free Trade Agreements in Asia Edited by Jiaxiang Hu and Matthias 
Vanhullebusch 
537 Lawrence R. Helfer and Regime Shifting: 'The TRIPs Agreement and New Dynamics of International 
Intellectual Property Law-Making' (2004) 29 YALE Journal of International Law PP 1 
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repercussions from developing countries, such as the United States or the European 
Union. Critics speculate that TRIP-Plus will inhibit the perception of TRIPS flexibilities 
and safeguards, thus limiting its applicability. It can be suggested that both TRIPS and 
TRIP Plus create a conflict of relationship. Both forms are valid and applicable but 
incompatible and left to states to decide which norm should supersede the other538. 
TRIP Plus required states to implement provisions to limit the use of compulsory 
licenses. Secondly, it supports extending the patent protection term to be increased 
by more than 20 years. It also includes restrictions for generic competition. However, 
the most peculiar is data exclusivity. Developed countries knew that the 
pharmaceutical market is regulated by two laws, IP and laws on drug regulation. If 
both laws are restricted, for instance, patent, a patent right holder can withhold the 
right to sell or produce patented medicine if TRIP Plus is applied. Although the drug 
regulatory system ensures the information on the registration of drug safety, efficacy, 
and quality submitted by companies for market authorization, this prevents competition 
and generate high profit. TRIP plus demands that this information should be kept 
confidential539. Therefore, if TRIP Plus rules are affected, the overall impact on access 
to medicine would be dreadful because the safeguards and minimum standard ought 
to increase access, not limit access to medicine. This section discussed the 
 
538 Henning Grosse Ruse-Khan' The International Law Relation between TRIPS and Subsequent 
TRIPS-Plus Free Trade Agreements: Towards Safeguarding TRIPS Flexibilities' (2010) Vol 18 Journal 
of Intellectual Property Law 18 (2010)PP 325 To resolve any issue between two international law rules, 
the Vienna rule of interpretation is the last resort to resolve this issue.  Article 31 (3)(c) state that 
"relevant" rules of TRIPS "shall be taken into account "because all TRIPS provisions amount to "rules 
of international law applicable in relations between the parties" therefore, the rule of treaty interpretation 
is essential in resolving conflicts but does resolving the conflict supersede the aim of the rules for if 
attention is paid more to conflict than their stated obligation, then both norms are unreliable. 
539World Trade Organisation (WTO), Data exclusivity, and other "trips-plus" measures Available 
file:///C:/Users/ugo/AppData/Local/Packages/Microsoft.MicrosoftEdge_8wekyb3d8bbwe/TempState/D
ownloads/Data-exclusivity%20(1).pdf Accessed (01 April 2020) The context of data exclusivity prevents 
competition. It gives pharmaceutical companies a monopoly for 5-10 years before the information is 
made public. Drugs ought to show its therapeutic effect and safety instead of repeating clinical trials. 
The pharmaceutical patent owner holds this information until data exclusivity has passed, thus 
generating higher revenue.    
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importance of TRIP safeguards concerning access to medicine in both developing and 
LDCs. The highlighted safeguards have been utilized efficiently and it has a relative 
impact on the pharmaceutical industry. TRIPS safeguards have ameliorated access 
to medicine, although complicated in its application and utilization. However, to make 
progress, proponents called for more robust protection TRIP-Plus, but the adverse 
effects of TRIP plus rules impede what it intends to protect, resulting in another issue 
beyond the scope of the WTO-TRIPs Agreement 
 
5.3 Linkages between access to medicine and counterfeit medicine: A critical 
evaluation  
In sections [ 2.2, 2.2.1], this study discussed the notion of access and counterfeit 
drugs. However, this part will seek to establish an interaction between these two norms 
to show a concise analytical summary using identifiable tools to determine the 
significance of counterfeit pharmaceuticals from a Nigerian perspective. Medicine is a 
substance administered to treat disease to improve quality of life and be regarded as 
one of humankind's most important discoveries because it is a preventive and curable 
measure.540 This point is rightly observed by Philip Abelson that 'pharmaceutical is 
responsible for improved health care in this century 541 and attributed to the increase 
in life expectancy 542 due to its therapeutic effect and safety. However, over time there 
is a new threat to human health and safety known as counterfeit or substandard 
medicine ‘’the WHO defines substandard medicine as any approved medical product 
that fails to meet quality standards and specifications. At the same time, counterfeit or 
 
540John P Bunker, 'The Role of Medical Care in Contributing to Health Improvements within Societies 
(2001) Vol 30, Issue 6 International Journal of Epidemiology PP 1260 
541 Philip H. Abelson, 'Improvement in Health Care' (1993) Vol,260 No 5104 'Science, PP11 
542Sharyl J Nass, Laura A. Levit, and Lawrence O Gostin, 'The Value, Importance, and Oversight of 
Health Research" in Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health through 
Research (National Academies Press (US), 2009)  
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falsified medical products are drugs deliberately/fraudulently misrepresented by its 
identity, composition, or source’’. However, up till now, there has been no uniform or 
concise acceptable definition of counterfeit 543neither does counterfeit and 
substandard drug have the same meaning. They have different inferences; for 
instance, substandard means (low-quality medicine)544 and counterfeit means 
(outrightly fake in quality and composition), both terms are used interchangeably. [For 
a detailed discussion on the definitions of counterfeit and substandard 
pharmaceuticals, see 2.2, 2.4 above] 
Although counterfeit is deemed a global problem even in developed countries, the 
percentage of counterfeit in the American drug market is on the rise through unlawful 
online sales545, but there is a presumption that developed countries have smaller 
incidents of counterfeit compared to developing countries. Correspondingly, many 
factors have been recognized to cause counterfeit. One example is the technological, 
economic, social, and financial disparity between the developed and developing 
/LDCs. Similarly, some of the standards and flexibility required by the WTO-TRIPS 
agreement have been known to stimulate counterfeit pharmaceuticals, whether 
directly or indirectly. The flexibilities include trade liberalization policy, compulsory 
license, parallel import, Doha declaration, TRIP –Plus. The issue that needs to be 
resolved goes beyond the WTO-TRIPS scope, for the negative impact that arises from 
using TRIPS flexibilities outweighs its overall utilization. Thus, the issue is the 
 
543WHO Substandard and Falsified Medical product, Available https://www.who.int/news-room/fact-
sheets/detail/substandard-and-falsified-medical-products Accessed (03 April 2020) 
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158 
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provision of adequate pharmaceuticals for the treatment of disease away from politics, 
IP, economic considerations to meet the people's needs. 
5.3.1 WTO-TRIPS 'Quick fix' Approach  
 
A multilateral trading system is a progressive approach cheered by the WTO, for it 
encourages openness and fairness in the trading system of the world. More so, it has 
resulted in the breakdown of barriers between countries, government, and people 
based on the principles of non –discrimination, national treatment, equality/MFM, and 
free trade within the well-organized structure of the WTO. The scope of WTO 
membership encompasses over 164 member states. This serves as proof of WTO's 
credibility in regulating the growth and development of the world's trading system 546. 
Despite the WTO's remarkable success, the organization continued to reform and 
revise its trade policies, considering changing circumstances around the world. 
 By this singular mega-regional endeavour, commentators and academics have 
applauded it as a breakthrough in creating global success in the international Trade 
system. However, a contrary view to the WTO success maintains that the WTO failing 
restructuring rounds has resulted in establishing various trade policies to resolve new 
trade dimensions such as solving protectionism, trade barriers, and violation of IP. 
Instead of dealing with one issue before another, the WTO adopts a quick fix approach 
(i.e., utilizing the fastest solution to solve reoccurring problems), leading to the 
increase of other subsequent unforeseeable issues such as counterfeit. This problem 
may have been created as a domino effect from the problem of access to medicine. 
 
546WTO, Golden Jubilee of the Multilateral-trading system, 
Available https://www.wto.org/english/news_e/pres98_e/pr88_e.htm Accessed(April 13 2020) 
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Without being resolved, the WTO prioritizes other salient issues. An example of this is 
the collapse547 of the Doha trade negotiation round548. 
The failure of the WTO as a global trade organization is predictable for its agenda is 
not explicitly favourable to developing countries, although it arranged some initiatives 
such as ‘’certain special and differential treatment rights." These provisions are 
perceived to be inadequate. Even the Ministers at the 4th Doha ministerial conference 
the Committee on Trade and Development is authorized to examine these special and 
differential treatment provisions549to strengthen and create a more effective and 
operational system. However, Wallach and James have expressed concern about the 
text of the Doha development round, stating that the underlying agenda of the round 
is the expansion of the current scope of the WTO. This expansion will further 
undermine economic growth in developing countries even though, since its ratification, 
economic developments have deteriorated with a large percentage of people living on 
less than $1 a day550.  
Adequate measures have been put in place to shift attention from WTO performance 
to future gains achievable only from strict adherence to WTO rules and mandates. 
Using the case study of the WTO-TRIP, the agreement can be considered as the most 
significant protectionism agreement in the world, which is a direct extension of the 
 
547 Popa Diana. 'The Collapse of the Doha Round and a Possible Completion of Negotiations' (2012) 
Vol 15 Issue 43 Romanian Economic Journal PP 44 
548 Peter Halewood, 'Trade Liberalization and Obstacles to Food Security: Toward a Sustainable Food 
Sovereignty" (2011), Vol 43 Issue 1, The University of Miami Inter-American Law Review 115-136 
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549World Trade Organisation(WTO) Special and Differential treatment right provision 
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essed(April 14, 2020) The special provisions include: Extension of time for adopting and implementing 
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and resolve dispute, and implement technical standards, and provisions related to least-developed 
country (LDC).  
550 Wallach Lori, Deborah James and Public Citizen, 'Why the WTO Doha Round Talks Have 
Collapsed–and a Path Forward." Global Policy Forum August 14, 2006 
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WTO monopolistic mandate of controlling trade while still advocating for trade 
liberalization. It also demands states to provide stiff intellectual property protection for 
drugs without considering the relative impact on drug availability. The WTO ought to 
fix the multilateral trading system's ills rather than standing back with a quick fix offer. 
It should be proactive, reflective551, and deliberate on potential solutions to make it 
stand out as a world-leading trade organization. 
The one size fits all or single undertaken approach utilized by the WTO can be said to 
be ill-suited in the evolving global trading system, partly as a result of the complex 
policy obligations such as facilitation of trade-in service552 and the Trade-related 
aspect of intellectual property rights (TRIPS). The implication of strengthened 
protection may have negatively affected developing countries such as high price, 
product imitation, copying, and drug counterfeit. Besides, most developing countries 
have changed their legal regime to conform to WTO compatibility standards. Given 
this situation, it will be unlikely for states to push for more trade rounds or ministerial 
conferences within the WTO. Instead, states advocate for more plurilateral trade 
agreements to protect the weak institution. 
In conclusion, for the WTO to retain its status as a leading trade organization, it needs 
to be more proactive towards the issues affecting member states by supporting, 
encouraging a broad spectrum of plurilateral agreements and extend terms in IP for 
developing/LDCs. Other steps will be to support non-restrictive measures for the sake 
of protecting public health553, reprimand aggressive trade policies offered by 
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developed member states, permit transparency in WTO rules and safeguards and 
adopt stiff penalties for members flouting WTO rules. Thus, it can be presumed that 
the WTO, failing rounds, and policy recommendations have influenced the surge of 
counterfeit in developing countries like Nigeria. Getting solutions will start from the 
WTO amending and reflecting on proper measures to tackle its discrepancy before 
member states can implement it. Except there is a rethink in the way the WTO handles 


























Chapter 6 Conclusion and Policy Recommendations 
 
I return to this thesis's original question: How does the WTO-TRIPs agreement 
comport with the regulation of counterfeit pharmaceuticals in Nigeria? The introductory 
part set out the context to test the viability of the WTO-TRIPs agreement. This thesis 
demonstrated the importance of protecting IP in a modern economy, for it can 
encourage innovation and the promotion of technological advancement. IP is a 
valuable economic and developmental tool both to developing and developed 
countries. IP can be said to be interrelated to the rise and protection of new medicines 
and vaccines needed to safeguard public health. This research has shown why 
protecting IP within the WTO's multilateral trading system is vital for world growth. It 
started by tracing the WTO's historical development, its ascension over the GATT 
agreement and negotiations, amendments, reports, and trade rounds till the WTO 
became the principal legal instrument for the regulation of trade and IP.  
Nigeria is a member of the WTO since its inception in 1994. The WTO membership 
has its benefits such as free trade, liberalization, reduction of tariffs, economic growth, 
fair trade, fair competition, support for local industry, and movement of technology. All 
this is promised as a single package deal to members. As a single package deal, 
members are obliged to bring their laws in conformity with the WTO standards and 
abide by the rules. Before the negotiation of the TRIPs agreement, IP matters were 
solely within the jurisdiction of WIPO. However, due to perceived gaps and 
inconsistencies from developing and developed countries, especially in the area of 
technology transfer, enforcement, and adequate protection of IP rights, this created 
the need to incorporate IP within the WTO's scope to provide stringent standards 
backed up by sanctions.  
232 
 
 The WTO-TRIPS agreement is a comprehensive agreement, which allows members 
to provide extensive protection for IP. It protects all forms of IP rights, including patent, 
copyright, trademark, geographical indications. However, the TRIP standard is all-
encompassing and unique for encouraging IP growth for developing countries such as 
Nigeria. However, WIPO's low standard may have reduced the burden of tackling 
counterfeit products due to tough TRIPs IP rules. The perspective that stringent IP 
laws can enhance IP development in developing countries is vague, for developing 
countries find it hard to rely on WTO-TRIPS to solve its public health problems, which 
includes counterfeit pharmaceuticals. The WTO-TRIPS is supportive of developing 
countries, not the issues that arise from the interpretation of WTO rule in its members' 
legal system. One such outcome is counterfeit pharmaceuticals.  
Stringent IP protection has the potential to lead to the economic exploitation of 
pharmaceuticals. This thesis has established a link between counterfeit and IP 
protection, stating that IP is an important economic tool needed to uphold creativity 
and economic development, nevertheless counterfeit is a product of pharmaceutical 
patent in terms of pricing and access. Pharmaceutical patent protection can directly 
limit medicine availability, and subsequently, lead to counterfeit medicine 
preponderance. Counterfeit is derived from the infringement of IP. It is a targeted 
threat to the growth of IP and innovative steps.  
Proffering a definition of counterfeit seems far-fetched; it is a relative term with a wide 
array of interpretations. Counterfeit means deceit: a portrayal of goods as what it ought 
to be instead of what it is, which can undermine its applicability. Till now there is still 
no concise or uniform definition of counterfeit pharmaceuticals. Reliance on existing 
definition can lead to different means, attributed to the problem, the definitional 
question should be resolved as a step towards combating the surge of Counterfeit 
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pharmaceuticals. The multilateral trade framework of the WTO-TRIPS advocates 
implementing TRIPS policies and safeguards, which would contribute to eradicating 
counterfeit pharmaceuticals in Nigeria. Having implemented the slated objectives of 
WTO-TRIPS, hoping that counterfeit pharmaceutical will reduce, it still on the increase. 
It proves that TRIPS standards, safeguards, objectives, and all existing legal rules 
(national and international) proffered for regulating international trade, cannot tackle 
counterfeit pharmaceuticals.   
 
6.1. Reforms on WTO-TRIPs IP Regulation to Tackle Counterfeit 
 
The WTO-TRIPS Agreement is a legal recognition of the significant link between IP 
and Trade. It is essential for setting a standard for the regulation and interpretation of 
IP rights. It has succeeded in harmonizing trade and utilization of creativity, which has 
enhanced international trade amongst nations. TRIPS is commended for being a 
catalyst in forcing state members to the WTO to re-evaluate outdated IP laws to bring 
them in line with modern trade reality and value inventive endeavours. However, 
TRIPS, in a bid to safeguard creativity, modified the terms of IP, implemented more 
stringent measures on IP trade, members were not allowed to tailor their approach to 
IP enforcement and protection outside TRIP set standards. All this extension is to 
prevent the infringement or abuse of IP; instead, it intensified the problem. TRIPS 
agreement is pragmatic for achieving some of its stated objectives while still 
considering alternatives to prevent restrictive IP issues that will negate the maximum 
utilization of IP standards.   
Analysis of the TRIPS agreement revealed that TRIPS' objective supports the 
development of principles, rules, and discipline dealing in trade in counterfeit goods, 
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including pharmaceuticals. If the TRIPS standard can regulate Nigeria's counterfeit 
drug surge, different suggestions and areas for further research have been mentioned. 
For example, linking the WTO-TRIPS to EU-Acquis is the law of communication for 
intending member states to examine the pros and cons of membership, especially the 
provision of special consideration for the transition of intending members legal system. 
However, the TRIPS agreement allows for a single undertaking that prevents member 
states from deciding on the favourable aspect of its circumstance. Developing 
countries must accept the conditions and exceptions without having time to determine 
what provision in the agreement is useful as picking and choosing is not allowed.  
If TRIPS were to be a plurilateral system like GATT, member states would not be stuck 
to rigid WTO-TRIPS policies. Even with TRIPS safeguards, the period for developing 
countries to bring their laws in conformity to the TRIPs agreement is too short. It might 
seem right to suggest that developing countries might succeed in tackling the scourge 
of counterfeit if they operate outside the WTO framework, but instead, use guidance 
from the TRIP agreement or revisit the plurilateral system to lead to development. If 
the last position is adopted, the WTO-TRIPS agreement will still be operating, but from 
a distance. It will allow developing countries to build a structure that is capable of 
transitioning into the WTO system smoothly. 
Finding from this research so far indicates that the WTO- TRIPS agreement may need 
to evolve to prioritize developing countries' needs, or its rules will be inadequate to 
tackle counterfeit pharmaceuticals. The fact stated above indicates that WTO-TRIPS 
laws and policies do not target Africa's needs in general bearing in mind that it is only 
when a law is deeply rooted in a country experience can it be workable. So far, the 
WTO-TRIPS Agreement is not deeply rooted in the counterfeit experience. Although 
different measures have been proposed, such as parallel import and TRIP plus rules 
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implemented, it has failed to close the existing gap. The WTO laws ought to be 
applicable without conformity with existing legislation neither has Nigeria developed a 
unique framework that can tackle its counterfeit pharmaceutical issues; it solely relies 
on the WTO-TRIPS. 
 
6.2 Legal Reforms on Nigeria counterfeit Pharmaceutical regulation 
 
Nigeria has witnessed the emergence and proliferation of counterfeit pharmaceuticals 
since the 1980s, and there is an urgent need to reform the counterfeit drug laws and 
policy to ensure the swift eradication of counterfeit drugs from Nigeria's 
pharmaceutical system. The first point of call will be to change the existing laws to 
reflect new realities to achieve rectification. It is a core value of the rule of law, for law 
protects, respects, and favours every citizen's rights and liberties during new 
uncertainties. The quality of laws made and upheld needs to be useful, simplified, 
modified, and effective. Reforming a law is very important, for it allows a country to 
keep abreast of current situations by effecting changes to its legal system to become 
more efficient. 
 Hence the framework for a good law/policy reform should be clear, positive, inclusive, 
ratified, and publicized. The overall outcome of law reform should not be perceived as 
a tool of domination imposed from the outside or the top but provides valuable tools to 
live everyday life. Therefore, it is essential to revise the counterfeit drug laws and policy 
in Nigeria, for reformation will be perceived as an attempt by the government to take 
definite steps toward controlling the preponderance of counterfeit drugs.  
On this note, the first known decree promulgated by the Nigerian military government 
to control counterfeit drugs in 1988 is decree No. 21, a miscellaneous provision 
banning the distribution and sale of counterfeit, fake, and adulterated drugs. This 
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decree was welcomed as a positive act of the Nigerian government to prevent the 
surge of counterfeit, but the perversity of counterfeit drugs undermined this degree's 
capability. Other laws have been implemented, such as the Poisons and Pharmacy 
Act, Cap 366 of 1990, Food and Drugs Act Cap 150 of 1990, Counterfeit and Fake 
Drugs (miscellaneous provisions) Act, Cap 73 of 1990, Drugs and related products 
(registration) Decree No. 19 of 1993. Invariably, these laws have been futile in 
rectifying the counterfeit pharmaceutical problems. 
Counterfeit drugs' invisible perversity is more insidious than projected; it created the 
need to re-evaluate the mediocre laws on counterfeit drugs. One of such significant 
changes in Nigeria reformation policy came with the enactment of the National Agency 
for Food and Drug Administration and Control (NAFDAC), established by Decree 15 
of 1993, amended by Decree 19 of 1999, Act Cap N1 Laws of the Federation of 
Nigeria, 2004. It is welcomed as an alternative to the failed counterfeit drug laws and 
decrees. NAFDAC laws are all-encompassing; its provision is substantive, regulatory, 
procedural, and specifically designed to criminalize acts connected to the sale and 
distribution of counterfeit, fake, and substandard pharmaceuticals. 
 NAFDAC is revered as a regulatory organization, but there seem to be legal gaps in 
the NAFDAC laws from the previous analysis. The first observation is with NAFDAC's 
mission statement; it appears vague and needs reform because using the 
catchphrase' safe guiding public health," undermines its stated purpose. Neither does 
it provide room to interpret the importance of protecting public health literally. For 
example, the term public health is not explained in the Nigerian context. It is a relative 
term: it can mean the quality of health, quality of life, preventing diseases, physical 
and mental health conditions. Thus, what NAFDAC aims to protect is ambiguous.  
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Secondly, NAFDAC seeks to regulate the manufacture and import of drugs and food 
into the country, but this vision is not practicable due to a lack of adequate funding and 
human resources. Even so, Akinyandenu observed that this criterion makes NAFDAC 
incompetent in tackling Nigeria's counterfeit pharmaceutical needs. Worse still, the law 
that created NAFDAC is obsolete, for it has not been reviewed since its formation to 
bring it in line with current situations and problems, especially the challenges 
presented from falsified, substandard, and counterfeit drugs threat. This law needs to 
be reformed so it can be more efficient, accessible and can create a fair system of 
tackling counterfeit drugs within the purview of the law and sustaining public health at 
the same time. 
Recognizing NAFDAC's flaws is necessary, for this is a direct threat to realizing its 
aims and objective, it is reasonable to suggest possible ways NAFDAC can reform 
starting from its goal. NAFDAC must review its goal to be broad or all-encompassing 
and clear. The agency function is the "regulation, control and investigation of the 
importation, exportation, manufacture, advertisement, distribution, sale and use of 
food, drugs, cosmetics, medical devices, bottled water, and chemicals." It is not 
explicit; it looks like a one-size fit- law for everything, which creates doubt on 
NAFDAC's protection. Is it food, drug, cosmetics, or water? If the function of the 
agency were specific, the surge in counterfeit drug cases would have subsided. 
 
The pharmaceutical sector's importance to public health cannot be overemphasized; 
it can make or break nations, but scholars have stressed the need for more regulation 
and good governance practice to protect this vulnerable sector. In Nigeria, NAFDAC 
is known to have a culture of transparency in the registration, selection, licensing, and 
procurement of pharmaceutical products. This task is one of the core functions of 
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NAFDAC. However, issues have been raised about this function. NAFDAC needs to 
have a transparent system built on integrity, values, and ethical principles to 
incorporate institutional confidence in its activities and seek stricter rules when issuing 
medicine permits and registration in Nigeria.  
Another recommendation will be to advise the Nigerian government to reform and 
review the drug laws to enable the judiciary to apply penalties commensurate to the 
offences. The issue of interpretation hinders the application of existing laws. The 
punishment for counterfeit drug offences is not specific, so it tends to encourage 
counterfeiting. If the penalty is stiff (magnitude of the crime and the intention to commit 
a crime), the fear of the consequences will reduce counterfeit prevalence. The drug 
laws conflict concerning scope and application in different counterfeit situations. The 
government should call for a judicial reform constituting a well-structured approach 
that brings all the partners and leaders in the pharmaceutical, legal, and economic 
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